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Parkinson’s disease (PD) is the most common neurodegenerative movement disorder of the 
basal ganglia and is characterized by a progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc). The glial cell line-derived neurotrophic factor 
(GDNF) has been identified in preclinical experiments as an important differentiation and 
survival factor for dopaminergic neurons of the midbrain, yet its application in clinical trials 
has shown inconsistent efficacy. Current gene therapies delivering neurotrophic factors via 
neuronal expression may not fulfil essential safety criteria for more elaborate strategies with 
higher dosages or younger patients. Given that neurotrophic factors are potent modulators of 
neuronal physiology and thus may potentially provoke unwanted side effects if present in 
brain areas not affected by PD, it seems preferable to restrict their impact to the immediate 
vicinity of the site of lesion. In this study it was investigated, whether adeno-associated virus 
(AAV)-5 vectors injected in low and high titre concentrations into the striatum of C57Bl/6-J 
mice leading to either neuronal or astrocytic production of GDNF have different effects on 
protective and neuroregenerative efficacy in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) mouse model of PD. Unilateral striatal vector application resulted in delivery of bio-
functional GDNF to the striatum and SN of both brain hemispheres if GDNF was expressed 
in neurons, indicating distribution to sites far remote from the vector application. In contrast, 
effects of GDNF were restricted to the injected hemisphere by expression in astrocytes. 
Astrocytic GDNF expression was neuroprotective at low vector dosage thus representing a 
safe alternative to current gene therapeutic strategies for PD. 
It has been claimed that higher concentrations of GDNF may also signal through receptors 
other than the prototypical rearranged during transfection (RET) and glycosyl 
phosphatidylinositol–linked GDNF family (GFR)α receptors. However, using mice with a 
tissue-selective ablation of the gene encoding Ret (DAT-Retlx/lx mice) no alternative to an 
intact GDNF-RET-mediated signalling in the nigrostriatal system to awaken the protective 
potential of GDNF after MPTP lesion was found. 
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1 Summary 
1.1 Astrocytic versus neuronal expression of GDNF: implications for gene therapy 
PD is the most common neurodegenerative movement disorder of the basal ganglia, 
affecting about 2% of the population over the age of 60. Progressive loss of dopaminergic 
neurons in the SNpc is the main characteristic of PD and leads to the major clinical 
abnormalities. GDNF has been identified in preclinical experiments as an important 
differentiation and survival factor for dopaminergic neurons of the midbrain. The encouraging 
data from these experiments and the potential for therapeutic applications led to clinical 
trials, which, however, have shown inconsistent efficacy; possibly related to insufficient 
putamenal distribution of GDNF. Following another hypothesis, the patients participating in 
these clinical studies likely had too little of their nigrostriatal dopaminergic tract intact to 
induce therapeutic effects of GDNF. Effective GDNF delivery to the nigrostriatal system 
combined with restriction of its impact to the immediate vicinity of the site of lesion would be 
indeed an attractive clinical option and reduce safety concerns, especially if future Phase II 
trials might be performed in patients at an earlier stage of PD.  
Therefore it will be analyzed if cell-specific GDNF expression, with either selective astrocytic 
or neuronal production of GDNF, delivers a safe and efficient supply of the nigrostriatal 
system in an experimental mouse model of PD. MPTP induces a syndrome in humans 
almost indistinguishable from PD, thus making it ideal to study PD in animal models. 
In a first step different systems were characterized, which allowed to distinguish between 
GDNF produced in astrocytes or neurons by unilateral injection of the cell-specific viral 
constructs AAV-5 glial fibrillary acidic protein (GFAP) GDNF (transducing astrocytes) and 
AAV-5 synapsin (SYN) GDNF (transducing neurons) in the striatum of C57Bl/6-J mice. 
Neuronal and astrocytic production of GDNF mediated by AAV-5 resulted in broad long-term 
expression of GDNF in the striatum, but transport of GDNF to the SN was much more 
efficient if GDNF was produced by neurons.  
As confirmed by multiple parameters like immunohistochemistry, nigral dopaminergic neuron 
numbers, striatal fibre density and dopamine (DA) content it was found that unilateral striatal 
vector application resulted in the delivery of bio-functional GDNF to the striatum and 
substantia nigra of both brain hemispheres if GDNF was expressed in neurons, indicating 
distribution to sites far remote from the vector application. In contrast, GDNF delivery was 
restricted to the injected hemisphere by expression in astrocytes. Astrocytic GDNF 
expression was bio-active at low vector dosage and thus represents a safe alternative to 
current gene therapeutic strategies to treat PD. 
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1.2 Ret signalling: the basic requirement for GDNF-mediated protection against MPTP 
toxicity 
GDNF classically signals through a two-component receptor complex consisting of RET and 
GFRα. It has already been observed in our laboratory that endogenous GDNF-mediated RET 
signalling has no influence on the survival of dopaminergic neurons in the MPTP model of 
PD, but rather facilitates the regeneration of dopaminergic axon terminals in the striatum in 
longitudinal studies. The predictive value of these previous results is limited by their 
dependence on physiological GDNF concentrations, whereas under treatment conditions 
several times higher concentrations may be achieved. 
It has been claimed that GDNF at higher concentrations may also signal through other than 
the prototypical RET and GFRα receptors. Neural cell adhesion molecule (NCAM) has been 
proposed as an alternative signalling receptor for GDNF and also other RET-independent 
GDNF signalling pathways have been described.  
Tyrosine kinases like RET signal through the mitogen-activated protein kinase (MAPK) 
and/or the phosphatidylinositol 3-kinase (PI3K) pathway. For the activation of PI3K higher 
concentrations are necessary than for the activation of the MAPK, and only higher 
concentrations provide protection against MPTP toxicity. GDNF may thus have qualitatively 
different effects on RET-induced signalling at different concentrations. 
To address these possibilities mice with a tissue-selective ablation of the gene encoding Ret 
(DAT-Retlx/lx mice) as well as DAT-Cre, Ret lx control mice were used. By 2x108 AAV-5 
GFAP-mediated GDNF overexpression in the striatum, the effects of high amounts of GDNF 
in a MPTP mouse model that is independent of RET-mediated signalling were investigated. 
It was found that astrocytic GDNF expression only mediates short- and long-term protection 
of the nigrostriatal system from MPTP toxicity if the RET receptor is expressed. Furthermore, 
without the RET receptor no striatal recovery of catecholamine concentrations from MPTP 
toxicity could be observed. 
In conclusion, there may be no alternative to an intact GDNF-RET mediated signalling in the 
nigrostriatal sytem, this being a prerequisite for the protective potential of GDNF and the 
natural regenerative capacity of the striatum after MPTP lesion in mice. 
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2 Introduction 
2.1 Neurodegenerative disorders  
The major causes of disability in the western society are spontaneous or traumatic lesions in 
the central or peripheral nervous system; the resulting disorders strongly impair quality of life 
in a degree rarely comparably with other diseases. Neurodegenerative diseases (NDD) are 
often associated with atrophy of the affected central or peripheral structures of the nervous 
system. Alzheimer’s disease (AD), PD, multiple sclerosis (MS), Amyotrophic lateral sclerosis 
(ALS), prion diseases, Huntington’s disease (HD) and spinocerebellar ataxias are examples 
of these diseases. The majority of NDDs are characterized as having multifactorial 
pathology, not being related to inherited mutations of specific proteins and as having 
advancing age as the major risk factor. 
Typical features of the pathology of NDDs are e.g. oxidative stress, axonal degeneration, 
demyelination, protein aggregation with consequent impairment in cellular physiological 
function, excitotoxicity and inflammation; in many cases of NDDs the cause has not yet been 
identified and there exist merely symptomatic treatments rather than a cure. In order to 
identify the possible causative disease mechanism various experimental animal models of 
NDDs have been developed. Although any one animal model reflects only certain aspects of 
the human disease it models, animal models lead to a better understanding of specific 
disease mechanisms and may serve as preclinical evaluation to develop therapies in 
humans (Jellinger 2009; Dauer and Przedborski 2003). 
 
2.2 Parkinson’s disease 
Parkinson’s disease is the second most common NDD after AD and affects more than 1% of 
55-year-old individuals and more than 3% of those over 75 years of age (de Rijk et al., 1997). 
The overall age- and gender-adjusted incidence rate is 13.4 per 100,000 with a higher 
prevalence among males (19.0 per 100,000) than females (9.9 per 100,000) (Van den Eeden 
et al., 2003). PD was initially described by James Parkinson in 1817. He defined the clinical 
picture for the first time in his monograph “An Essay on the Shaking Palsy” (Parkinson 2002). 
In his letters Wilhelm von Humboldt (1767–1835) precisely described the symptoms from a 
patient’s point of view. He interpreted the clinical signs as an accelerated aging process 
(Horowski et al., 1995). More than one century had to pass after his classic monograph 
before the central pathological feature of PD was found; the discovery of DA in the 
mammalian brain and the nigrostriatal dopaminergic pathway formed by the SNpc neurons 
(Fig. 2.1) provided the basis for the understanding that the loss of SNpc neurons leading to a 
striatal DA deficiency causes the major symptoms of PD (Dauer and Przedborski 2003). 
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Fig. 2.1: The nigrostriatal DA pathway in the rat brain. In the intact brain the DA 
producing cells reside in the SN, which is located in the ventral midbrain, and send 
projections (the nigrostriatal projection, NSP) to the striatum (CP), the input structure to the 
basal ganglia, which is situated beneath the cortex in the forebrain. The pre-terminal axons 
course in the medial forebrain bundle and pass through the globus pallidus (GP) before 
entering the target nuclei, where terminal arborizations and synaptic contacts with striatal 
neurons are seen. CP, caudate putamen (image taken from Kirik et al., 2004) 
 
2.2.1 Clinical aspects  
PD or the idiopathic Parkinson syndrome is a chronically progressive NDD, in which mainly 
voluntary and involuntary motor skills deteriorate (motor symptoms), but also speech and 
other functions including thinking, mood and sensation (non-motor symptoms) (Jankovic 
2008). A Parkinson syndrome is characterized by the four cardinal motor symptoms tremor, 
rigidity, brady-/akinesia and postural instability (Sian et al., 1999; Fahn et al., 2003).  
Tremor is usually unilateral at onset, reaches its maximum during rest and decreases with 
voluntary movement in PD. In most cases the upper extremities are more affected than the 
lower ones. The term rigidity means stiffness and a increased tone of the muscles. Muscle 
strength is sustained; flexibility of the ankles is decreased, while the resistance increases. 
Movements are slowed (bradykinesia), diminished (hypokinesia) or, in severe cases 
completely abrogated (akinesia). An impairment of postural reflexes leads to gait and 
balance instability and an increased fall susceptibility (Dauer and Przedborski 2003). 
Additional motor symptoms are impaired gait (decreased stride length during walking, 
shuffling, freezing: the inability to begin a voluntary movement such as walking, patients 
remain “stuck” to the ground as they attempt to begin moving), posture (camptocormia, 
dystonia) (Lepoutre et al., 2006), speech (hypophonia), swallowing and motor coordination 
performance, fatigue, reduced mimic (hypomimia) leading to a masked face (Deuschl and 
Goddemeier 1998) and decreased size (micrographia) and speed of handwriting. Typical 
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non-motor symptoms are disturbances in mood (Ishihara and Brayne 2006; Lieberman 
2006), cognition (slowed reaction time “bradyphrenia”, dementia, dilution) (Frank et al., 
2005), sleep (somnolence, insomnia), autonomic control (dermatitis (Gupta and Bluhm 
2004), incontinence, nocturia) sensation (reduction or loss of sense of smell, dizziness, pain, 
impaired proprioception), affect (patients become passive and withdrawn, with lack of 
initiative; they may sit quietly unless encouraged to participate in activities).  
Only about 75-80% of the Parkinsonian disorders corespond to PD and are referred to as 
primary (idiopathic) Parkinson syndromes of unknown etiology. The heredodegenerative 
Parkinsonism includes the rare inherited cases (~ 5%). The remaining cases are classified as 
symptomatic or secondary Parkinson syndromes of known etiology (including medicinally or 
drug abuse-induced intoxications, infarcts of the basal ganglia, encephalitis or traumatic 
brain injury, tumors, metabolic dysfunction and atypical or Parkinson-Plus syndromes as part 
of other neurodegenerative disorders including for example multiple system atrophy (MSA), 
cortico-basal ganglionic degeneration or progressive supranuclear gaze palsy. 
 
2.2.2 Pathology   
PD is the most common neurodegenerative movement disorder of the basal ganglia. The 
basal ganglia are a group of nuclei in the brain interconnected with the cerebral cortex, 
thalamus and brainstem that play an important role in motor control, cognition, emotions and 
learning. The human basal ganglia comprise the striatum, consisting of the putamen and 
nucleus caudatus, the globus pallidus (GP), which is divided into an external (GPe) and an 
internal (GPi) segment, the nucleus subthalamicus (STN), the SNpc and the pars reticulate 
(SNpr) (Blandini et al., 2000). The inhibitory output of the basal ganglia, via the GPi and the 
SNpr, is thought to be modulated by one direct pathway (striatal neurons with D1 receptors, 
facilitating transmission) and one indirect pathway (D2 receptors, reducing transmission) 
providing a positive and negative feedback in the circuit between the basal ganglia and the 
thalamus. Although their synaptic actions are different, the DA inputs to the two pathways 
lead to the same effect, namely a reduction of inhibition of the thalamococortical neurons and 
thus a facilitation of movements initiated in the cortex. In PD loss of DA input from the SNpc 
to the striatum leads to increased activity in the indirect pathway and decreased activity in 
the direct pathway. Both of these changes lead to increased activity in the GPi, which results 
in increased inhibition of thalamococortical and midbrain tegmental neurons and thus to the 
hypokinetic features (brady- and akinesia) of the disease (Fig. 2.2) (Kandel et al., 2000 
Principles of Neural Science 4th ed.). The inhibition of nuclei in the brainstem is believed to 
cause gait and posture disturbances (Wichmann and DeLong 1993). 
A diagnosis of PD can only be confirmed by the a post mortem identification of the 
pathological hallmarks of PD for example the loss of DA neurons in the SNpc. Approximately 
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60% of the SNpc DA neurons have been already lost at the onset of PD symptoms. Different 
modes of cell death, e.g. apoptotic, necrotic and autophagic, have been described to 
contribute to the neuronal loss occurring in PD (von Bohlen Und Halbach et al., 2004; Blum 
et al., 2001). Furthermore, the axonal projections of the SNpc dopaminergic neurons to the 
striatum are reduced, leading to depletion in DA of approximately 80% in the putamen. Thus, 
the degree of terminal loss in the striatum appears to be more pronounced than the 
magnitude of SNpc DA neuron loss, suggesting that striatal DA nerve terminals are the 
primary target of the degenerative process and that neuronal death in PD may result from a 
“dying back” process (Dauer and Przedborski 2003). This theory is supported by results of 
studies with PD animal models showing that the destruction of striatal terminals precedes 
that of SNpc cell bodies (Herkenham et al., 1991) and protection of striatal nerve terminals 
prevents the loss of SNpc DA neurons (Wu et al., 2003). If the DA content drops below a 
threshold of about 20%, the increase in the glutamatergic innervation of the striatal 
cholinergic interneurons tips the balanced ratio between DA and acetylcholine (ACh) in 
favour of the latter. The resultant physiological alterations in the activity of the neural circuits 
within the basal ganglia induce PD symptoms (Muller et al., 1999; Bernheimer et al., 1973). 
“Lewy bodies” (LBs), another hallmark of PD are intracellular proteinaceous inclusions. LBs 
are spherical eosinophilic cytoplasmatic deposits with a diameter of more than 15 µm that 
consist of a dense granulovesicular core surrounded by a clear halo of 8-10 nm-wide 
radiating fibrils. Next to α-synuclein, which is their major component (Goldberg and 
Landsbury 2000; Spillantini et al., 1998; Spillantini et al., 1997; Pappolla 1986) the LBs 
contain a variety of other proteins including parkin (Shimura et al., 2001), ubiquitin (Lowe et 
al., 1988), ubiquitin carboxy-terminal hydrolase (UCH-L1) (Ardley et al., 2004), 2001) PINK1 
(Muqit et al., 2006), cytoskeletal proteins (Schmidt et al., 1991; Ihara et al., 2003), and 
synphilin-1 (Wakabayashi et al., 2000). 
The degenerative process of PD is not restricted to the SNpc. Mental, autonomic and 
endocrine dysfunctions are proposed to be caused by extranigral alterations (Braak and Del 
Tredici 2008). The locus coeruleus, the ventral tegmental area, the nuclues basalis Meynert, 
the thalamus, the hypothalamus and many cortical areas are other pigment-containing brain 
structures, which are affected to a different extent (Gibb 1997). An interesting hypothesis in 
this regard is the Braak theory, demonstrating that the major cellular pathology of PD, 
aggregate formation begins in the dorsal glossopharyngeal-vagus complex in the medulla as 
well as in the anterior olfactory nucleus and spreads up the brainstem, involving the SNc only 
later in its course (Braak et al., 2003; Del Tredici et al., 2002) but prior to the point that cell 
loss in these other structures generally reaches symptomatic thresholds; indeed olfactory 
dysfunction has been recognized as a very early feature of typical PD (Tissingh et al., 2001). 
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It is proposed that once the SNc is affected by the original pathobiological process, additional 
processes more specific to DA neurons are triggered (Lang 2007). 
 
    
 
Fig. 2.2: The basal ganglia-thalamocortical circuitry under normal conditions and in 
PD. Two types of DA receptors (D1 and D2) are located on different sets of output neurons in 
the striatum that give rise to the direct and indirect pathways. Inhibitory connections are 
shown as gray and black arrows; excitatory connections as pink. Degeneration of the 
nigrostriatal DA pathway in PD leads to differential changes in activity in the two 
striatopallidal projections, indicated by changes in the darkness of the connecting arrows 
(darker arrows indicate increased neuronal activity and lighter arrows, decreased activity). 
Basal ganglia output to the thalamus is increased in PD. GPe = external segment of the 
globus pallidus; Gpi = internal segment of the globus pallidus; SNc = substantia nigra pars 
compacta; STN = subthalamic nucleus (image taken from Kandel et al., 2000 Principles of 
Neural Science 4th ed.). 
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2.2.3 PD causative hypotheses  
Pathological processes, including oxidative and nitrosative stress, inflammation, 
mitochondrial defects, excitotoxicity, apoptosis and genetic predisposition have been 
implicated in the pathogenesis of PD (Moore et al., 2005; Larkin 1999). A multifactorial 
genesis is currently assumed, involving both genetic and environmental risk factors, since a 
clear toxic, environmental or genetic etiology can be identified only in the minority of PD 
cases (Lorincz 2006).  
DA cells of the SNc are more likely to be susceptible to oxidative stress in comparison to 
other brain structures due to highly oxidative intracellular environment (Lotharius and Brundin 
2002; Lotharius et al., 2002; Kuhn et al., 1999; Jenner and Olanow 1998; Berman and 
Hastings 1997). The DA metabolism leads to the formation of free radicals and other reactive 
oxygen species (ROS) (Aisen et al., 1990). Free radicals rapidly react with cellular 
macromolecules (Blandini et al. 2000) leading to a dysfunction of proteins (Bowling and Beal 
1995), DNA damages (Yoritaka et al., 1996), mitochondrial deficits via dysfunction of the 
electron transport chain (Allen et al., 1995) and finally cell death (Halliwell  1992).  
In SNc DA neurons of sporadic PD patients increased amounts of oxidative damaged lipids, 
proteins, DNA (Jenner 2003; Floor and Wetzel 1998) and changes in the ROS detoxification 
systems were found. In comparison to age-matched control subjects the enzymatic activity of 
catalase (CAT) and glutathione (GSH) peroxidase in pathological early PD patients are 
unaffected, while GSH levels are significantly decreased (Sian et al., 1994), suggesting that 
PD patients have a reduced H2O2 clearance capacity. DA is degraded to 3,4-
dihydroxybenzoic acid (DOPAC) and homovanillic acid (HVA) by monoamine oxidase B 
(MAO-B) and catechol-O-methyltransferase (COMT) leading to the production of one 
molecule H2O2 per molecule DA. Depletion of synaptic DA during the progression of PD 
leads to a compensatory increased DA turnover, which might exacerbate the oxidative stress 
by further increasing the production of H2O2 (Schulz and Falkenburger 2004). A decrease of 
the mitochondrial complex-I activity was observed in PD (Schapira et al., 1989).  
The second mechanism held to play a causative role in PD pathogenesis is protein 
misfolding and aggregation. Proteopathies, including PD (cytoplasmatic LBs), Alzheimer’s 
disease (extracellular senile plaques and intracellular tau) and HD (intranuclear huntingtin 
inclusions) are characterized by the presence of proteinaceous deposits, built up by 
aggregated proteins.  
The proteolytic ubiquitin-proteasome system (UPS) reduces the levels of these soluble 
abnormal proteins (Hanna and Finley 2007; Pickart 2001; Voges et al., 1999). Chaperones 
support folding, refolding or degradation of misfolded polypeptides, prevent protein 
aggregation and are involved in the formation of proteinaceous inclusions, called 
aggresomes (Opazo et al., 2008).  
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2.2.4 Genetic clues to the etiology of PD  
Since the late 1990s genetic analyses of PD patients have been able to identify a number of 
loci (PARK 1-13) and genes associated with either autosomal dominant (α-synuclein, UCH-
L1, LRRK2), autosomal recessive (Parkin, PINK-1, DJ-1, ATP13A2) or inherited forms of PD 
with incomplete penetration (synphillin-1, HtrA2/Omi) that play a causal role in PD. In support 
of the two PD causative hypotheses most of the proteins encoded by these genes are 
involved in the UPS or in mitochondrial function. Although, just a minority of PD cases (~5%) 
is due to genetic defects, the typical and extremely consistent phenotype of both idiopathic 
and familial PD suggests that they share a common molecular mechanism (Thomas and 
Beal 2007). Typical for familial PD is an early onset, a slowed progression of motor and 
cognitive symptoms and in some cases a lack of LB formation. 
 
2.3 Therapeutic approaches for PD treatment 
None of the currently available treatments have been proven to slow the progression of PD. 
However, medications or surgery can provide relief from the symptoms as palliative, rather 
than curative therapies for PD. Since the early days of experimental gene therapy for other 
disorders, PD was considered an ideal brain disease for this approach (Mouradian and 
Chase 1997), because of the relatively selective localization of the pathology, at least in the 
early stages of the disease, an understanding DA biosynthesis and basal ganglia circuitry, a 
knowledge of DA neurotrophic factors and the availability of animal models. Improvements in 
vector design have made it possible to deliver therapeutic genes directly into the brain with 
reasonable safety, thus having fueled the development of therapies to augment DA 
neurotransmission, modulate basal ganglia circuitry or even for neuroprotective approaches 
(Mochizuki et al., 2008).  
 
2.3.1 Current therapeutical strategies and limitations 
The pharmacological standard for the symptomatic treatment of PD is to substitute DA by: (i) 
administration of DA precursors or agonists and (ii) inhibition of DA degradation. This is 
typically accomplished with the dopamine precursor 1-3,4-dihydroxyphenylalanine (L-DOPA). 
The latter became clinical practice after being reported to improve akinesia in PD after initial 
studies in the 1960s (Hornykiewicz 2002; Cotzias et al., 1968). L-DOPA is administered in 
combination with DOPA-decarboxylase blockers such as carbidopa or benserazide, which 
reduce the peripheral conversion of L-DOPA to dopamine thus allowing a considerable 
amount of drug to cross the blood brain barrier and undergo decarboxylation to DA in the 
brain. As the disease progresses, up to 80% of patients experience motor fluctuations (the 
so-called “wearing off” and “on-off” phenomena) and dyskinesias within 5-10 years after 
disease onset. To delay these fluctuations DA agonists can be used as an initial and 
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adjunctive therapy in PD. Limits of this agonist therapy are cardiovascular and psychiatric 
complications (Jankovic and Stacy 2007; Lang and Lozano 1998). A further reduction of 
medication dosage-dependent fluctuations can be realized by novel drug delivery systems 
for constant administration of L-Dopa and dopamine agonists via intratestinal, 
transcutaneous or subcutaneous infusion (Schulz 2008). 
Other medications including anticholinergic agents, inhibitors of MAO-B or COMT provide 
only mild to moderate benefit (Olanow and Stocchi 2004; Hristova et al., 2000; Lang et al., 
1998). MAO-B inhibitors, such as rasagiline and selegiline, increase concentrations of 
dopamine in the brain by blocking its reuptake from the synaptic cleft. This can slow motor 
decline, prolong “on” time and improve symptoms of PD. Administration of COMT inhibitors 
in combination with L-DOPA decelerate the elimination half-life of L-DOPA, leading to 
decreased “off” time and increased “on” time and allow for a lower daily L-DOPA dosage, 
since DA and L-DOPA are metabolized by COMT. “Off” time refers to periods of the day 
when the medication is not working well for the patients; over the course of PD a substantial 
number of patients develop these fluctuations in response to medication. This process is 
related to the progression of PD and the reduction of a DA storage capacity. 
At later stages of the disease, when symptoms are no longer adequately controllable with 
medications, or if medications have severe side effects, patients may benefit from 
neurosurgical procedures. The common principle of these neurosurgical treatments is to 
mimic the inhibitory function of the SNpc on its target regions, which become overactive due 
to the degeneration of the SNpc by preventing them from firing either via electrothermal 
tissue ablation or chronic, high frequency deep brain stimulation (DBS) (Kringelbach et al., 
2007). The ventrointermediate thalamic nucleus, the GPi and the STN are the anatomic 
targets for that therapy.  
 
2.3.2 Neuroprotective PD therapy  
Different strategies with varying degrees of success have been employed to inhibit 
neurodegenerative processes; no sustained neuroprotection could be accomplished by early 
studies aimed at blocking the executioners of apoptotic cell death, cysteine proteases of the 
caspase family (Rideout and Stefanis 2001; Perrelet et al., 2000; Kermer et al., 1999). Most 
pro-apoptotic signals converge on breakdown of mitochondrial membrane potential, followed 
by release of pro-apoptotic factors and subsequent caspase activation (Chang et al., 2002). 
Thus several studies aimed to maintain mitochondrial integrity via the overexpression of anti-
apoptotic members of the bcl-2 family of proteins (Malik et al., 2005; Wong et al., 2005; 
Azzouz et al., 2000). Although this approach was reported to be significantly more efficient 
than caspase inhibition, in long-term studies substantial neuronal cell loss was still observed 
(Kim et al., 2005; Malik et al., 2005). Furthermore, the MAO-B inhibitor rasagiline (Sampaio 
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and Ferreira 2010; Naoi and Maruyama 2009) and the complex I mitochondrial fortifier 
coenzyme Q10 are under clinical investigation for neuroprotective effects (Spindler et al., 
2009). Neurotrophic factors in several paradigms could only shortly postpone neuronal 
degeneration (van Adel et al., 2003; Cheng et al., 2002). GDNF and neurturin (NRTN) 
appear to be an exception and remain promising candidates in the treatment of PD. 
 
2.3.3 AAVs in PD gene therapy  
Recombinant viral vectors such as lentivirus (LV), herpes simplex virus (HSV), adenovirus 
(AdV) and AAV have been developed to transfer genes of interest into target tissues of the 
central nervous system (CNS) (Mandel et al., 2008). However, since LVs integrate into the 
genome (Mitchell et al., 2004; Sinn et al., 2005) they are basically carrying the risk of tumor 
formation (Follenzi et al., 2007). Furthermore, in comparison to LVs, AAV vectors seem to be 
more efficient in transducing the brain, thereby requiring less vector to transduce a unit area 
(Manfredsson et al., 2009). In view of neuroprotective applications the advantage of AdVs 
being retrogradely transported to the SNpc following injection into the striatum (Peltekian et 
al., 2002; Soudais et al., 2000) also has to be relativised by safety concerns, because of 
immune responses to AdV infection (Lowenstein et al., 2007; Puntel et al. 2006; Muruve et 
al., 2004; Lowenstein and Castro 2003).  
Wild-type (wt) AAV is not known to be associated with any disease in humans or mammals 
and shows no inherent vector toxicity, which makes it an attractive tool for human gene 
therapy. A short viral production time, long-lasting transgene expression from the 
recombinant genome and in combination with cell specific promoters an expression 
exclusively in target cells are further benefits of AAV vector systems (Shevtsova et al., 2005; 
Kügler et al., 2003; Peel and Klein, 2000).  
To date, 10 different AAV serotypes have been identified (AAV1-9 and AAVRh10) of which 
AAV1-, AAV2-, AAV5-, AAV8- and AAV10-derived viral vectors have been used in the CNS 
(Mandel et al., 2008). Studies have demonstrated that AAV can infect lower motor neurons 
after injection into the sciatic nerve, followed by retrograde transport and transgene 
expression (Kaspar et al., 2003; Pirozzi et al., 2006). A comparison of the retrograde 
transport efficiency between serotypes revealed AAV-1 with greatest efficiency of retrograde 
transport after intramuscular injection. Serotypes 2-6 showed a low efficiency for retrograde 
transport (Hollis et al., 2008). The various serotypes differ in structure and bind unique 
membrane-associated receptors, resulting in differences in cell tropism and virus spread 
among the serotypes. The most extensively studied serotypes are AAV-2, the only AAV 
serotype in active clinical trials, and AAV-5 (Hildinger and Auricchio 2004). 
Recombinant AAV vectors are considered to have one of the highest biosafety ranking 
among the viral vectors (Mandel et al., 2008). Furthermore, deletion of the wt rep gene 
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impairs their propensity for the site-specific integration in the chromosomal DNA ending up 
mainly in an episomal form of the AAV DNA (Duan et al., 1998). Nevertheless, rAAV have 
been proven to mediate stable transgene expression for more than one year (Stieger et al., 
2006; Woo et al., 2005). Furthermore, AAVs are capable of infecting both dividing and non-
dividing cells (Flotte et al., 1994; Flotte et al., 1992).  
In a phase 1 trial of AAV-2-mediated expression of glutamic acid decarboxylase (GAD) in the 
STN, neither antibody responses to either the AAV vector or the expressed transgene 
occurred during the first 12 months, demonstrating that AAV gene therapy is safe and well 
tolerated by patients with advanced PD. Since GAD catalyses the synthesis of γ-
aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain and since in PD 
patients activity of the STN is increased mainly because of reduced GABAergic input from 
the GP, the GAD expression led to a balance of this increased STN activity in PD patients 
(Kaplitt et al., 2007). Additionally, another phase I clinical safety trial using bilateral 
intraputaminal infusion of an AAV-2 expressing the human aromatic l-amino acid 
decarboxylase (hAADC), which catalyses the conversion of L-DOPA to DA also declared 
AAV gene therapy as safe. In this study they detected after (non-blinded) analysis of a first 
small cohort a good tolerance of the viral vector infusion and (in the absence of controls) 
revealed an average 30% increase in striatal 6-[18F]-fluoro-L-dopa uptake capacity as a 
marker for DA synthesis in a low-dose group and 75% in a high-dose group (five patients 
each). Total and motor rating scales improved in both cohorts and motor diaries revealed 
increased on-time and reduced off-time dyskinesia (Christine et al., 2009). Preliminary, open 
label evidence in PD subjects offered support for CERE-120 (AAV-NRTN) as a novel PD 
therapy, possibly restoring function of degenerating DA neurons and preventing further 
degeneration (Marks et al., 2008; Bartus et al., 2007). However, latest results of a double-
blind phase 2 clinical trial showed no convincing clinical benefit (Bartus 2009, Scientific 
Symposium 113: Late stage industry clinical trials). 
 
2.4 Animal models of PD 
Modelling human neurological disorders in animals is common practice used for the study of 
underlying pathogenetic mechanisms and evaluation of novel therapeutic approaches. 
Various animal models currently in use can be subdivided into two groups: 1) genetic and 2) 
toxic models. The first group continuously enlarges due to the discovery of new mutations in 
PD-related genes as well as due to successful transgenic technologies, the use of different 
model systems (ranging from Drosophila, via mice to primates) and gene transfer 
approaches. The toxic models of PD remain a widely employed alternative, since they are 
easy to create and are able to reproduce the major etiopathologic features of PD induced by 
oxidative stress and inhibition of complex I. Several different neurotoxins, 6-
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hydroxydopamine (6-OHDA), MPTP, paraquat and rotenone are commonly used to this 
purpose (von Bohlen and Halbach et al., 2004; Blum et al., 2001).  
Since 6-OHDA cannot cross the blood brain barrier, it requires direct application into the 
brain. Its preferential uptake by DA and noradrenaline transporters causes the specific 
toxicity for catecholaminergic neurons after cytosolic accumulation and formation of ROS and 
toxic quinones (Terzioglu and Galter 2008; Bove et al., 2005). Moreover, 6-OHDA has been 
demonstrated to impair enzyme activity of cellular anti-oxidants like GSH and SOD, which 
can further enhance destructive effects of oxidative stress (Schober 2004).  
The herbizide paraquat has structural similarities to MPTP, but is not selectively taken-up by 
DAT and thus does not accumulate in DA neurons after systemic administration. It induces a 
modest, specific loss of DA neurons in the SNpc (Ossowska et al., 2006; McCormack et al., 
2002) by redox cycling with cellular diaphorase such as nitric oxide synthase producing ROS. 
Rotenone is produced in the roots and stems of tropical leguminosa plants, having been 
widely used around the world as insecticide, pesticide and piscicide. By inhibiting the transfer 
of electrons from complex I to ubiquinone in the mitochondrial electron transfer chain, it 
affects mitochondrial function at the same site as 1-Methyl-4-phenylpyridinium (MPP)+, but is 
only mildly toxic for humans.  
 
2.4.1 MPTP 
So far, none of the validated toxic models faithfully reproduce PD. However, among these, 
the MPTP model has several advantages over the others. MPTP induces a syndrome in 
humans and monkeys almost indistinguishable from PD with an irreversible lesion of the 
nigrostriatal DA pathway and even though safety measures are important for its use neither 
surgery nor particular equipment is required (Jackson-Lewis and Przedborski 2007; Langston 
et al., 1986), thus making it ideal to study PD in animal models. Responses in the MPTP 
animal model, as well as the complications to traditional anti-Parkinsonian therapies are 
virtually identical to those seen in PD (Dauer and Przedborski 2003). 
MPTP was recognized in 1982, when young drug addicts developed an irreversible, rapidly 
progressing Parkinsonian syndrome following the intravenous injection of an illicit preparation 
of 1-methyl-4-phenyl-4-propionpiperidine (MPPP), an analog of the narcotic meperidine 
(Demerol), contaminated with MPTP, which was inadvertently synthesized as a by-product of 
MPPP (Langston et al., 1983).  
From neuropathological data, we know that MPTP administration causes -as seen in PD-, 
the disruption of mitochondrial oxidative phosphorylation, oxidative stress, degeneration of 
DA neurons in the SNpc and depletion of striatal DA levels (Forno et al., 1993). Additionally, 
an increased expression of inflammatory markers colocalizing with microglia has been 
observed (Liberatore et al., 1999; Hunot et al., 1999). On the other hand, two typical 
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neuropathological features of PD have, until now, been lacking in the MPTP model. First, 
neurons are not consistently lost from other monaminergic nuclei, such as the locus 
coeruleus. Secondly, the eosinophilic intraneuronal inclusions called Lewy bodies, 
characteristic of PD, have not thus far been convincingly observed in MPTP-induced 
Parkinsonism (Forno et al., 1993). However, continuous MPTP infusion by osmotic 
minipumps triggered formation of ubiquitin and α-synuclein positive nigral inclusions in mice 
(Fornai et al., 2005). Due to its lipophilic character, MPTP can easily pass cell membranes 
and the blood brain barrier. In the brain, specifically in astrocytes, it is converted into the 
active toxic metabolite MPP+ by the enzyme MAO-B. MPP+ is selectively taken up into DA 
neurons by DAT and after transportation into mitochondria it inhibits complex I of the 
mitochondrial respiratory chain. This promotes ATP depletion and generation of ROS, finally 
activating apoptotic pathways (Przedborski et al., 2004; Ghahremani et al., 2002; Lei et al., 
2002). Inflammation, the activation of excitatory amino acid receptors, apoptosis, and 
autophagia as cell death mechanisms have been implicated in MPTP toxicity (Dawson 2000; 
Beal 2001). The susceptibility to MPTP seems to depend on MAO-B activity and on the 
capacity to sequester MPP+ into synaptic vesicles via the vesicular monoamine transporter 
(VMAT) as cellular protective mechanism, probably based on the ratio of DAT and VMAT 
(Miller et al., 1999; Takahashi et al., 1997). This can be an explanation for mouse strains 
reacting very differently to the toxin, whereas humans are sensitive to MPTP intoxication at 
quite low doses. The impact of systemic MPTP treatment in mice depends on the regimen of 
administration and induces either loss of DA-ergic neurons in the SNpc and striatal DA 
depletion alone, or in addition, motor symptoms including bradykinesia, rigidity and posture 
abnormalities (Sedelis et al., 2000). If neurons are estimated shortly after MPTP treatment 
the TH immunoreactivity loss may not reflect the actual DA cell death, since MPP+ down-
regulates TH gene expression (Xu et al., 2005). 
 
2.5 Potential of growth factors for PD treatment 
One treatment area that has gained significant momentum over the last several years has 
been the use of various growth factors aimed at halting or slowing the progressive loss of 
striatal DA innervation. Several candidate molecules have been proposed including GDNF, 
NRTN, brain-derived neurotrophic factor (BDNF), conserved DA neurotrophic factor (CDNF), 
mesencephalic astrocyte-derived neurotrophic factor (MANF), insuline-like growth factor 
(IGF) and basic fibroblast growth factor (bFGF). All these candidates offer protective 
potential but due to strong side effects (BDNF) or the lack of sufficient preclinical data 
(CDNF, MANF, IGF, bFGF) to date only GDNF and its relative NRTN have progressed to PD 
clinical trials (reviewed by Manfredsson et al., 2009). 
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2.5.1 Neurotrophic factors 
Endogenous neurotrophic factors regulate physiological cell death during neuronal 
development, facilitate target innervation, neurite branching and synaptogenesis, maintain 
the survival of neurons during postnatal life and regulate adult synaptic plasticity and 
maturation of electrophysiological properties. The neurotrophic theory postulates the function 
of neurotrophic factors primarily through a retrograde mechanism with the basic tenants of 1) 
limited quantities of a neurotrophic factor are produced in a specific target tissue; 2) 
responsive neurons projecting to these targets compete for this limited quantity of trophic 
factor and die if unable to access adequate amounts; 3) the factor is then bound to cell 
surface receptors; 4) receptors and trophic factor are internalized; and 5) retrogradly 
transported to the neuronal cell nucleus (Peterson and Nutt, 2008). Neurotrophic factors 
include neurotrophins (for example nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-
3)), neurokines and GDNF family ligands (GFLs). In addition to GDNF, artemin (ARTN), 
NRTN and persephin (PSPN) belong to the group of GFLs distantly related to the 
transforming growth factor-beta superfamily, containing seven cystein residues with the 
same relative spacing and acquiring similar conformation as the other members of this 
superfamily (Airaksinen and Saarma, 2002, Ibanez 1998). Possible actions by which trophic 
factors could provide important therapeutic effects in PD are 1) the promotion of DA SNpc 
neuron survival; 2) the restoration of neuronal function regarding their DA phenotype (the 
capacity to synthesize and release DA); and 3) the stimulation of the DA system since acute 
effects on ion channels causing changes in cell excitability occur with some trophic agents. 
Finally, it is possible that loss or disruption of specific trophic factors, their receptors or their 
signal cascades cause PD (Peterson and Nutt 2008).  
 
2.5.2 GDNF 
Although GDNF was originally purified from rat glioma cell line supernatant and thus termed 
glial cell line-derived derived (Lin et al., 1993), striatal GDNF expression in the developing 
brain is largely neuronal, as astroglial cells were not found to express detectable GDNF (Oo 
et al., 2005). However, upon injury, glial cells appear to become the predominant source of 
GDNF (Bresjanac and Antauer 2000; Nakagawa and Schwartz 2004; Chen et al., 2006). 
Astrocytes are key elements in the brain response to injury since upon activation they up-
regulate antioxidant molecules, membrane transporters, and trophic factors that support 
neuronal and glial survival and tissue repair (reviewed by Liberto et al., 2004). 
GDNF was first characterized as a trophic factor that supports differentiation and survival of 
midbrain dopaminergic neurons (Lin et al., 1993) but GDNF also supports motor neurons 
(Henderson et al., 1994), noradrenergic neurons (Arenas et al., 1995), sensory and 
autonomic neurons (Trupp et al., 1995). In the developing and adult rat nervous system, 
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GDNF is present in the thalamus, hippocampus, cerebellum, cortex, striatum and spinal cord 
(Trupp et al., 1997; Pochon et al., 1997; Choi-Lundberg and Bohn 1995; Stromberg et al., 
1993). In the developing rat nervous system GDNF levels in the SN are much lower 
compared to the striatum (Oo et al., 2005, Choi-Lundberg and Bohn 1995) suggesting a role 
for GDNF mainly as a target derived neurotrophic factor for DA neurons. This part of the 
neurotrophic theory for GDNF gets further support by the fact that GDNF is transported 
retrogradely from the striatum to the DA cell bodies in the SNpc and that there is no GDNF 
mRNA but rather only GDNF protein detectable in the SNpc (Barroso-Chinea et al., 2005; Oo 
et al., 2005; Choi-Lundberg and Bohn 1995; Tomac et al., 1995).  
GDNF is a glycosylated, disulfide-bonded homodimer, with a molecular weight of 33-45 kDa, 
while the monomer has a molecular weight of 16kDa after deglycosylation (Lin et al., 1994). 
Sequence data suggest that GDNF is synthesized as an active 211 amino acids/long pre-
proGDNF, and then processed to the mature protein with 134 amino acids (Lin et al., 1993). 
GDNF expression can be positively regulated by neurotransmitters (for example DA, 
serotonin, glutamate), pro-inflammatory molecules (for example lipopolysaccharide (LPS), 
interleukine (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and TNF-β), hormones  (for example 
melatonin, vitamin D3, Oestrogen), signalling pathways (for example mitogen-activated 
protein kinase (MAPK), protein kinase C (PKC), Ca2+) and transcription factors (for example 
NF-κB, cAMP response element-binding protein (CREB)); a negative regulation has been 
revealed for molecules reducing oxidative stress (NF-κB inactivators), IL-10 and type-2A 
protein phosphatases (PP) (Saavedra et al., 2008).  
Since the levels of other growth factors are decreased in PD brains, it was suggested that 
the unchanged levels of GDNF in PD might be due to compensatory production by glia cells 
(Mogi et al., 2001). However, large reductions in GDNF content are reported in surviving PD 
SN neurons (Chauhan et al., 2001) and increased levels of a GDNF isoform were found in 
the putamen of PD patients with marked neuronal loss (Backman et al., 2006). Interestingly, 
GDNF up-regulation can also be detected in the SN and striatum after MPTP intoxication. 
Whatever might be the endogenous changes of neurotrophic factors in PD, a therapy with 
GDNF might prevent the progression of the disease and restore function (Slevin et al., 2005; 
Gill et al., 2003).  
 
2.5.3 GDNF signalling 
Until recently, neither GDNF nor its receptors have been utilized in gene ablation analyses to 
study the effects of GDNF on DA neurons in vivo because all of the engineered mice were 
neonatally lethal (for review, (Baloh et al., 2000)). GDNF signals through a two-component 
receptor complex consisting of the RET receptor tyrosine kinase, which was initially 
discovered as protooncogene (Takahashi 2001) and the GPI-linked GDNF family receptor 
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alpha (GFRα)1. To date four members of this family have been identified (GFRα1-4). GFRα1 
and RET have been detected via Northern blot, PCR, and in situ hybridization analysis in DA 
neurons from the SN (Nosrat et al., 1997; Trupp et al., 1997, 1996; Treanor et al., 1996).   In 
addition to the known receptors GFRα1 and RET, GDNF signalling and the cellular response 
to GDNF requires heparan sulphate glycosaminoglycans (Barnett et al., 2002; Tanaka et al., 
2002). RET is activated upon binding of a GDNF dimer to GFRα1 linked to the plasma 
membrane via a glycosyl phosphatidylinositol (GPI) anchor. Dimerization of RET triggers its 
autophosphorylation, thus initiating several downstream signalling molecules, prominently 
extracellular signal-regulated kinase (ERK)1/2 (Kaplan and Miller 2000), that regulate cell 
survival, proliferation, differentiation, neurite outgrowth, synaptic plasticity and 
morphogenesis (Airakasinen and Saarma 2002) (Fig. 2.3 A). However, the ability of GDNF to 
protect DA neurons cannot be explained solely in terms of its influence on ERK1/2, since one 
study revealed maximal increase in ERK1/2 phosphorylation already at 0.45µg but GDNF 
started its protective activity at a concentration of 4.5µg (Lindgren et al., 2008). 
Phosphatidylinositol 3-kinase (PI3K)/Akt signalling maintains viability through antiapoptotic 
effects and it mediates effects on axonal caliber, branching and regeneration (Brunet et al., 
2001; Markus et al., 2002; Namikawa et al., 2000). In neurons, Akt activation has been 
identified in response to treatment with IGF-1 (Dudek et al., 1997), NGF (Soltoff et al., 1992) 
and GDNF (Creedon et al., 1997). AAV Myr-Akt (constitutively active form) pronounces 
trophic effects on DA neurons of adult and aged mice and the transduction in the SNpc 
conferred almost complete protection against apoptotic cell death in the 6-OHDA Parkinson 
model (Ries et al., 2006). Thus the PIK3/Akt signalling pathway could be associated with the 
neuroprotective effects of GDNF (Lindgren et al., 2008).  
The Met918Thr mutation leads to constitutive activity of RET, causing the cancer syndrome 
called multiple endocrine neoplasia type B (MEN2B). Constitutive RET activity in knock-in 
MEN2B mice induces a profound elevation of brain DA concentration via enhanced synthesis 
and increases the number of TH-positive cells in the SN (Mijatovic et al., 2007). However, 
two recent studies surprisingly demonstrated that conditional ablation of RET using Cre 
recombinase under control of the dopamine transporter (DAT)-Cre did not disturb the 
development of the nigrostriatal dopaminergic pathway (Jain et al., 2006; Kramer et al., 
2007). While in one study there was no degeneration of the nigrostriatal pathway up to 12 
months of age (Jain et al., 2006) the other study reported a loss of TH-positive neurons in the 
SNpc and TH-positive terminals in the striatum starting at 12 months and progressing 
thereafter (Kramer et al., 2007). Tissue selective ablation of the RET receptor in DA neurons 
does not modulate the MPTP-induced degeneration of SNpc DA neurons and their terminals 
in the striatum in 3-4 months old mice but RET is required for the regeneration of DA axon 
terminals. Thus GDNF/RET signalling has an important impact on the regenerative capacity 
INTRODUCTION 
  26 
of the nigrostriatal system (Kowsky et al., 2007). In most studies examining its 
neuroprotective potential, high concentrations of GDNF (10µg or more) were used (Salvatore 
et al., 2004; Winkler et al., 1996; Lapchak 1996; Kearns and Gash et al., 1995; Tomac et al., 
1995; Hoffer et al., 1994). This seems inconsistent with in vitro experiments showing high-
affinity binding of GDNF to GFRα1/RET to be in the nanomolar to picomolar range (Trupp et 
al., 1998; Sanicola et al., 1997; Jing et al., 1996; Treanor et al., 1996).  
GDNF may also signal indepently of RET but involve the same receptor GFRα1. In RET-
deficient cells GDNF may act through the Src family kinases, inducing sustained activation of 
the Ras/ERK and PI3K/Akt pathways (Tupp et al., 1999). In the absence of RET, Src-
mediated cellular events may also promote survival and neurite outgrowth (Sariola and 
Saarma 2003). NCAM has been proposed as an alternative signalling receptor for GDNF 
(Paratcha et al., 2003). In the absence of GFRα1, GFL associates with NCAM with low 
affinity. In turn in the presence of GFRα1, GDNF may bind to the p140-NCAM and activate 
cytoplasmic Src-like Fyn and FAK kinases (Paratcha et al., 2003) (Fig. 1.3 B). Interestingly, 
in rats both in vivo and in vitro effects of GDNF, such as DA neuron survival, neurite 
outgrowth, DA turnover and locomotor activity were inhibited by anti-NCAM antibodies (Chao 
et al., 2003). Also interesting is an in vitro study revealing that neurons express GFRα1 and 
RET, whereas astrocytes express not only but predominantly GFRα1, suggesting that they 
might utilize separate pathways to mediate autocrine and paracrine effects of GDNF (Sandhu 
et al., 2009). 
Other findings suggest that integrin β1, another adhesion molecule, is also involved in GDNF 
signalling (Cao et al., 2008). Negatively acting players on GDNF signalling are for example 
the transmembrane protein Lrig1 and Gas1, which show high structural similarity to GFRα 
(Ledda et al., 2008; Lopez-Ramirez et al., 2008; Cabrera et al., 2006; Schueler-Furman et 
al., 2006). 
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2.5.4 GDNF in PD Models 
In culture, GDNF is a survival factor for primary mesencephalic DA neurons and protects 
them against a number of toxic insults (Krieglstein 2004). In vivo, the protective effects of 
GDNF against 6-OHDA-induced loss of DA nigrostriatal neurons are undisputed (Lindgren et 
al., 2008; Smith and Cass 2007; Shevtsova et al., 2006; Eslamboli et al., 2005; Bilang-Bleuel 
et al., 1997; Mandel 1997 et al., 1997; Choi-Lundberg et al., 1997). In addition, many 
(Elsworth et al., 2008; Chen et al., 2008; Luan et al., 2008; Schober et al., 2007; Gao et al., 
2003; Palfi et al., 2002; Costa et al., 2001; Kordower et al., 2000; Date et al., 1998; Zhang et 
al., 1997;  Kojima et al., 1997; Gash et al., 1996; Tomac et al., 1995) but not all reports 
(Dietz et al., 2006; Eberhardt et al., 2000) using either virus-mediated GDNF expression or 
direct intraparenchymal GDNF delivery showed protective and regenerative effects against 
MPTP toxicity in animal models (Tab 2.1). 
Importantly, the effect of GDNF is dependent on the route of delivery, because GDNF 
released into the SN is unable to protect axons and axon terminals in the striatum against 
striatal 6-OHDA but is highly efficient in protecting nigral cell bodies (Winkler et al., 1996). 
However, GDNF applied to the striatum preserves the entire nigrostriatal pathway and the 
animals retain their performance in motor tests (Kirik et al., 2004 and 2000). 
Furthermore, the type of cells transduced plays a role and astrocytes, which perform many 
functions critical for neuronal survival, are very promising canditates for GDNF delivery 
Fig. 2.3: GDNF receptor interaction.  (A) A dimer of GDNF brings together two molecules of GFRα1. 
This complex dimerizes two molecules of RET leading to transphosphorylation of their tyrosine 
domains. (B) NCAM interacts with a GDNF-GFRα1 dimer leading to activation of Fyn, a SRC-like 
kinase (image taken from Sariola and Saarma 2003).   
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(Sandhu et al., 2009; Jakobsson et al., 2004; Byrd et al., 2004; Dringen and Hirrlinger 2003; 
Wilson 1997). Interestingly, regarding astroglial expression levels of GDNF in the murine 
striatum using the GFAP promoter (LV-GFAP GDNF) a threefold increase can be detected 
after intrastriatal lesion (Jakobsson et al., 2004). Up-regulation of GFAP is well documented 
in several animal models and pathological states in the human brain (Eng et al., 2000). The 
regulation of a transgene with a GFAP promoter in a viral vector give rise to high transgenic 
expression in the lesioned brain and a less pronounced in the intact brain, thus providing an 
option of regulating expression by using the machinery of the host cell instead of depending 
on recombinant regulatory proteins (Jakobsson et al., 2004). Furthermore, in vitro 
overexpression and long term secretion of GDNF does not alter astrocytic morphology or 
their proliferation rate; although astrocytes transduced with a cytomegalovirus (CMV) 
promoter secrete ~ 10-fold higher concentrations of GDNF in comparison to cells transduced 
with the GFAP promoter (already 35-fold increase to background level), a concomitant 
increase in neuroprotection against 6-OHDA cannot be observed (Sandhu et al., 2009). This 
indicates that higher amounts of GDNF are not always beneficial and might account for side 
effects (Arvidsson et al., 2003; Gill et al., 2003; Zurn et al., 2001; Kordower et al., 1999). 
However, there also seems to exist a threshold under which GDNF is also no longer 
protective (Costa et al., 2001, Zhang et al., 1997). This concentration-dependent effect of 
GDNF can be partly explained by opposite effects of low and high striatal GDNF levels on 
the TH expression in DA neurons (Georgievska et al., 2002 a and b; Kordower et al., 2000). 
In conclusion, the effect of GDNF is dependent on protein levels, degree and pattern of 
receptor expression on cells in the damaged area, route of GDNF delivery, type of cells 
transduced and GDNF actions on neuronal transmission at the site of delivery (Kirik et al., 
2004; Arvidsson et al., 2003). 
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Table 2.1: GDNF in PD models. The table represents a selection of references. 
Model system GDNF application Effect Reference 
6-OHDA, cell culture 460pg GDNF/ml LV-
CMV GDNF; 36pg 
GDNF/ml LV-GFAP 
GDNF 
neuroprotection  Sandhu et al., 2009 
6-OHDA, mice 4.5µg hr GDNF, 
striatum 
protection of striatal  
DA terminals  
Lindgren et al., 2008 
6-OHDA, rat 5µg  hr GDNF, striatum reduced oxidative 
stress and protection 
against loss of 
striatal and nigral DA 
Smith and Cass 2007 
6-OHDA, rat AAV-2 hSyn1 GDNF, 
SN 
neuroprotection Shevtsova et al., 2006 
6-OHDA, primates AAV-2 chicken β-actin 
(CBA) GDNF 
~40pg/mg, striatum 
prevention of 
nigrostriatal 
degeneration, loss of 
striatal DA and motor 
dysfunction 
Eslamboli et al., 2005 
6-OHDA, rat 25µg GDNF, SN;  
25µg GDNF, striatum 
neuroprotection but 
deleterious effects on 
striatal fibre density 
and motor function; 
prevention of 
nigrostriatal 
degeneration and  
motor dysfunction 
Kirik et al., 2000 
6-OHDA, rat AdV-Rous Sarcoma 
Virus (RSV) GDNF, 
striatum 
protection of SN DA 
neurons and motor 
function 
Bilang-Bleuel et al., 
1997 
6-OHDA, rat AAV-CMV GDNF, SN; 
AdV- GDNF, SN; 10µg 
GDNF/day, SN 
neuroprotection Mandel et al., 1997; 
Choi-Lundberg et al., 
1997; Winkler et al., 
1996 
MPTP, primates AAV–2 GDNF, striatum protection of 
implanted fetal DA 
neurons 
Elsworth et al., 2008 
MPTP, mice AAV – GDNF, striatum prevention of striatal 
loss of DA 
Chen et al., 2008 
MPTP, primates 22.5µg GDNF/day, 
putamen 
preservation of motor 
function 
Luan et al., 2008 
MPTP, mice 5µg hr GDNF, striatum prevention of 
nigrostriatal 
degeneration and 
loss of striatal DA 
Schober et al., 2007  
MPTP, mice Tat-GDNF no neuroprotection Dietz et al., 2006 
MPTP, mice AdV-GDNF prevention of loss of 
striatal DA 
Gao et al., 2003; 
Kojima et al., 1997 
MPTP, primates LV-GDNF, caudate 
nucleus, putamen, SN  
increase in striatal 
DA neurons 
Palfi et al., 2002 
MPTP, mice AdV-CMV GDNF ~ 
1ng/ml, striatum 
no neuroprotection, 
preservation of loss 
of striatal DA  
Eberhardt et al., 2000 
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MPTP, primates starting from 100-
500µg GDNF 9 and 13 
weeks post MPTP, 
intraventricular; 
starting from 100-
1000µg GDNF/4 weeks, 
intracerebroventricular 
preservation of motor 
function 
Costa et al., 2001 
Zhang et al., 1997 
MPTP, primates LV-GDNF ~ 3.5ng/mg, 
putamen 
prevention of 
nigrostriatal 
degeneration and 
motor dysfunction 
Kordower et al., 2000 
MPTP, mice 
 
10µg GDNF, striatum  striatal recovery  Date et al., 1998 
MPTP, primates 150µg SN, 450µg 
intracerebral/4 weeks 
prevention of 
nigrostriatal 
degeneration 
Gash et al., 1996 
MPTP, mice 10µg hr GDNF, 
striatum and SN 
prevention of 
nigrostriatal 
degeneration and  
motor dysfunction 
Tomac et al., 1995  
 
 
2.5.5 GDNF in clinical trials 
Because of its potential to maintain function and survival of DA neurons, GDNF application 
has been evaluated for its effects in several clinical trials. In a first trial intracerebroventricular 
injections of GDNF in humans did not result in any symptomatic benefit or slowing of disease 
progression, likely because of limited intraparenchymal diffusion of GDNF (Kordower et al., 
1999 (500-4000µg rh GDNF/month)). Unilateral or bilateral putamenal infusions led to 
substantial beneficial effects in three phase I open-label safety trials (Slevin et al., 2007 (30 
µg recombinant human (rh) GDNF per day) and 2005 (3-30µg rh GDNF/day); Gill et al., 2003 
(14.4µg rh GDNF/day)). However, a similar paradigm but using an intraputaminal catheter 
with a slightly larger outside diameter was not successful in 34 Parkinson’s disease patients 
in a double-blinded placebo controlled study (Lang et al., 2006 (15µg rh GDNF/day)). A 
major question relates to the distribution of GDNF in the putamen by the different infusion 
techniques. Not only methodological questions remain to be resolved (Sherer et al., 2006), 
but also the molecular and signalling effects of GDNF to better characterize and dissect its 
protective and/or regenerative potential for DA neurons. The uncertainties surrounding the 
trials of intraputamenal infusion of GDNF, in which no toxicity was attributable to GDNF, 
should not end the research for therapeutic benefit from neurotrophic factors (Peterson and 
Nutt 2008), but some of the investigators involved the clinical studies have recently stated 
that gene transfer would probable be a potentially better alternative delivery method for 
GDNF (Peterson and Nutt 2008). 
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3 Objectives 
3.1 Astrocytic versus neuronal expression of GDNF: implications for gene therapy 
Since GDNF has been identified in preclinical experiments as an important differentiation and 
survival factor for DA neurons of the midbrain but clinical trials have shown inconsistent 
efficacy for this study it was proposed to study and better characterize the effects of GDNF in 
an in vivo model of PD.   
In this study it will be analyzed if cell-specific GDNF expression, directed to either selective 
astrocytic or neuronal GDNF production, delivers a safe and efficient supply of the 
nigrostriatal system with GDNF in PD-like experimental paradigms. It is hypothesized that 
GDNF produced by astrocytes might be as effective as neuronal GDNF, since, although 
neurons being the physiological cellular basis of striatal GDNF expression during 
development of the brain, astrocytes become the predominant source of GDNF in the adult 
brain upon injury. Furthermore, it is thought that GDNF production by astrocytes might 
circumvent side-effects, seen in clinical trials. This assumption is based on the fact that 
vector-mediated GDNF overexpression in the brain, once neurons are transduced, leads to 
the release of GDNF in all terminal projection areas of that neuron with uncontrollable 
effects. In contrast, astrocytic production of GDNF would be limited to the target area. As 
vector-mediated GDNF gene therapy in PD patients would last the rest of a patient’s life this 
safety issue is of great importance. 
In a first step the requirement for a system allowing to distinguish between production of 
GDNF from astrocytes and neurons by using cell specific viral constructs will be realized. 
Since gene therapy vectors based on recombinant AAVs have become widely accepted for 
transduction of genes into the brain, showing no inherent vector toxicity in combination with a 
short viral production time and long-lasting transgene expression, it was decided in favour of 
AAVs. Furthermore, AAV-5 expressing a transgene under the control of the GFAP or SYN  
promoter guarantees an expression exclusively in astrocytes or neurons with a broad spatial 
distribution. One of the major problems of the inconsistent outcome of GDNF in clinical trials 
was suggested as being related to the insufficient distribution of GDNF in the putamen by 
different infusion techniques. 
In a next step a model has to be established in which virus-mediated production of GDNF 
leads to a robust protection against a nigrostriatal lesion. In this connection, it was decided in 
favour of the subchronic MPTP model in mice, given that MPTP produces an irreversible and 
severe Parkinsonian syndrome that replicates many PD features. Furthermore, regarding the 
question about the site of GDNF administration (SN versus striatum), it is choosen the 
striatum. The benefit of GDNF delivery to the striatum is widely accepted; in contrast, 
functional restoration after SN administration is discussed controversially.  
OBJECTIVES 
  32 
After establishing a model using high viral titres in a first step (described above), it is planned 
to also test low viral titres in order to find the safest and most effective conditions, while still 
receiving protective effects of GDNF in the model.  
This study will provide information derived from the subchronic MPTP mouse model about (i) 
optimized safety and efficacy for GDNF delivery to damaged DA neurons of the nigrostriatal 
system and (ii) protective and regenerative effects of GDNF to that system, thus partaking in 
the achievement of the goal to use neurotrophic factors in PD gene therapy. 
 
Questions: 
1) Is it possible to express GFP and GDNF specifically in astrocytes and neurons in the 
murine striatum by using 2x108 AAV-5 GFAP GFP, AAV-5 GFAP GDNF and AAV-5 
SYN GFP, AAV-5 SYN GDNF? Does a reduction of the viral titre to 2x107 transducing 
units lead to any changes regarding expression level, distribution or cell specifity? 
2) How much GDNF can be produced in the ipsilateral and contralateral striatum and SN 
by injecting 2x108 and 2x107 AAV-5 GFAP GDNF and AAV-5 SYN GDNF? Can we 
detect differences depending on the cellular source of GDNF? 
3) Does the injection of 2x108 AAV-5 expressing a transgene lead to inflammatory tissue 
reactions? Would such a reaction be dependent on the cellular source of transgene 
expression or would it change over time? Does a reduction of the viral titre to 2x107 
transducing units ameliorate the situation? 
4) Is it possible to detect any GDNF-mediated protective or regenerative effects in the 
nirgo-striatal system after MPTP intoxication and unilateral, striatal stereotaxic 
injection of 2x108 AAV-5 GFAP GDNF and AAV-5 syn GDNF?  Can even after a 
reduction of the viral titre to 2x107 transducing units the same effect be achieved? 
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3.2 RET signalling: the basic requirement for GDNF-mediated protection against MPTP 
toxicity 
GDNF classically signals through a two-component receptor complex consisting of RET and 
GFRα. It has already been observed in this laboratory that endogenous GDNF-mediated 
RET signalling has no influence on the survival of DA neurons in the MPTP model of PD, but 
rather facilitates the regeneration of DA axon terminals in the striatum in longitudinal studies. 
Following these results endogenous GDNF does not provide protective but only restorative 
effects by inducing a sprouting response. The predictive value of these previous results is 
limited by their dependence on physiological GDNF concentrations, whereas under treatment 
conditions several times higher concentrations may be achieved. Furthermore, it has been 
claimed that GDNF at higher concentrations may also signal through others than the 
classical RET and GFRα receptors. To address these possibilities mice with a tissue-
selective ablation of the gene encoding Ret (DAT-Retlx/lx mice) as well as DAT-Cre, Ret lx 
control mice and AAV-mediated GDNF overexpression in the striatum will be used, thus 
investigating the effects of GDNF in a MPTP mouse model that is independent of RET-
mediated signalling. In order to distinguish between acute and long-term effects of GDNF on 
the MPTP-induced damage to the nigrostriatal system, animals will be analyzed at two 
weeks and three months after MPTP intoxication.  
Furthermore the experiments will be performed using 2x108 transducing units of AAV-5 
GFAP GDNF in order to primarily guarantee for ipsilateral restricted transgene expression, 
thus making it possible to use the contralateral side as clear internal control. Secondly, the 
very high amount of GDNF will prevent the miss of any signalling pathway, being initially 
activated in the presence of high amount GDNF. This strategy will answer the question if the 
presence of the RET receptor is mandatory for GDNF-mediated protection of the nigrostriatal 
system or if also other signalling pathways might play a role. 
 
Questions: 
5) Are GFP and GDNF after unilateral, striatal stereotaxic injection of 2x108 AAV-5 
GFAP GFP and AAV-5 GFAP GDNF equally expressed among the genotypes DAT-
Retlx/lx, DAT-Cre and Ret lx? 
6) Is it possible to detect any GDNF-mediated protective or regenerative effect in the 
nirgo-striatal system after MPTP intoxication, if the classical GDNF receptor RET is 
not present? 
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4. Methods 
4.1 Molecular biology 
Recombinant DNA techniques were performed according to the protocols described in 
Molecular Cloning Laboratory Manual, 2nd edition (Sambrook et al., 1989). Restriction 
endonucleases and DNA-modifying enzymes were used according to the manufacturer’s 
instructions. Materials including chemicals, buffers, solutions, antibodies and primers are 
listed in chapter 4.9. 
 
4.1.1 Propagation and preparation of plasmid DNA 
 
Buffers and Media for bacterial culture 
LB-medium: 10g/l tryptone, 5g/l yeast extract, 5g/l NaCl. 
LB-plate: LB-medium, 2% (m/v) Agar. 
SOC: 20g/l trypton, 5g/l yeast extract, 10mM NaCl, 10mM MgCl2, 10mM MgSO4, 20mM 
glucose 
 
Plasmids were propagated in DH-5α maximum efficiency (Invitrogen GmbH, Karlsruhe) and 
SURE 2 super chemicompetent (Stratagene, La Jolla, USA) E.coli bacteria. 
 
4.1.1.1 Bacteria culture conditions 
All E. coli strains were cultured in LB-Amp liquid or solid (LB-Amp agar plates) medium, at 
37ºC. For liquid culture, bacteria were incubated by shaking at 200-300rpm overnight.  
Glycerolstocks for longterm storage were prepared by adding 800µl glycerol (80%) to 800µl 
overnight culture in a 2ml screw-cap vial. The vial was vortexed vigorously to ensure an even 
mixing of the bacterial culture and the glycerol, frozen in liquid nitrogen and stored at -80°C. 
 
4.1.1.2 Heat shock transformation 
Heat shock transformations of DH-5α maximum efficiency were performed according to the 
manufacturer’s instructions. Briefly, after thawing 50µl bacteria suspension on ice, an 
appropriate amount of DNA (1-50ng purified plasmid DNA, 5-10µl of a ligation reaction) was 
added. Next, cells were gently mixed by finger tapping and incubated on ice for 30 minutes. 
After heat shocking in a water bath at 42°C for 45s ec, cells were placed on ice for 2min. Next 
cells were supplemented with 450µl of SOC medium and incubated at 37°C for 60min while 
shaking at 300rpm. 250µl of the suspension were then spread on LB-amp selective plates 
and incubated at 37°C overnight. SURE 2 Supercompet ent were transformed in a similar 
manner: 40µl of bacteria suspension were pretreated by adding 0.8µl β-mercaptoethanol 
followed by 10min incubation on ice. An appropriate amount of DNA (1-50ng purified plasmid 
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DNA, 5-10µl of a ligation reaction) was added, the heat shock was carried out at 42°C for 
30sec. Cells were supplemented with 360µl SOC medium then 250µl of this suspension 
spread on LB-amp plates. The resulting single colonies were analyzed via colony PCR or 
used to inoculate LB-Amp liquid cultures. 
 
4.1.1.3 Plasmid mini preparation 
 
Buffers for plasmid mini preparation 
Resuspension buffer: 50mM Tris-HCl; 10mM EDTA; 100µg/ml RNaseA; pH 8.0 
Lysis buffer: 200mM NaOH; 1% SDS 
Neutralization buffer: 3.0M potassium acetate, pH 5.5 
 
An alkaline lysis method (modified according to Sambrook and Russel 2001) was used to 
extract the plasmid DNA from transformed cells by using the QIAprep Spin Miniprep Kit 
according to manufacturer’s instructions. Five ml of LB-amp medium were inoculated with a 
single colony picked from a freshly streaked selective LB-Amp agar plate and incubated by 
shaking at 200-300rpm at 37°C. One ml overnight cul ture was centrifuged (13.000rpm, 5min, 
4°C) in a micro centrifuge and the supernatant was discarded. Pelleted bacterial cells were 
dissolved completely in 300µl resuspension buffer (P1). 300µl lysis buffer (P2) were added, 
followed by inverting the tube 4-6 times and incubating for 5min at RT. After adding chilled 
300µl neutralization buffer (P3), the lysate was mixed by inverting the tube 4-6 times and 
centrifuged (13.000rpm, 10min, 4°C). The supernatan t was transfered to a fresh tube 
containing 600 µl room-temperature isopropanol, mixed and centrifuged immediately 
(13.000rpm, 30min, 4°C). The supernatant was decant ed carefully and the DNA pellet 
washed with 500µl of 70% EtOH and centrifuged again (13.000rpm, 10min, 4°C). The 
supernatant was decanted and the pellet air dried for 5-10min then resuspended in 20µl TE 
buffer or sterile ddH20. 
 
4.1.1.4 Plasmid Midi, Maxi and Mega preparations 
To obtain large amounts of plasmid DNA, bacteria cultures were grown in 2x LB-Amp 
medium and midi, maxi and mega preparations were performed using QIAfilter® Plasmid Kits 
according to manufacturer’s instructions. A preculture of 1.5ml was used to inoculate 1.5l of 
2x LB-Amp medium to produce ~ 1.0mg plasmid DNA required for the preparation of viral 
vectors.  
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4.1.2 Isolation of genomic DNA from mouse tail biopsies 
 
TENS buffer for isolation of genomic DNA 
TENS buffer: 100mM Tris-HCl, 5mM EDTA, 200mM NaCl, 0.2% SDS, pH 8.5 
 
Mouse tail biopsies of 0.5cm were placed in 1.5ml reaction tubes and incubated overnight in 
a thermomixer at 650rpm and 56°C in 0.5ml TENS buff er containing 0.5mg/ml Proteinase K. 
Samples were then shifted to 90°C to inactivate the  Proteinase K. Samples were centrifuged 
(13.000rpm, 5min, 10°C), then 400µl of the supernat ant transfered to a fresh tube containing 
500µl room-temperature isopropanol, then mixed and centrifuged immediately (13.000rpm, 5 
min, 10°C). The supernatant was decanted carefully.  The DNA pellet was washed with 100µl 
of 70% EtOH and centrifuged again (13.000rpm, 5min, 10°C). The supernatant was 
discarded completely; the pellet was dried for 15-20min at 42°C then resuspended in 50µl TE 
buffer. 
 
4.1.3 DNA precipitation 
If increased purity and/or the concentration of DNA in the final solution were required, a 
precipitation step was included after the DNA extraction procedures. The samples were 
mixed with 100% isopropanol (70% of the original volumes) and 3M Na-acetate (10% of the 
original volumes). The samples were centrifuged for 20min at 4ºC, then the supernatant 
discarded. The DNA pellets were rinsed with 70% EtOH and centrifuged again. EtOH was 
carefully removed and the precipitates were air-dried at RT for 5-10min. The DNA pellet was 
resuspended in desired volume of ddH2O or TE buffer. 
 
4.1.4 PCR 
PCR (polymerase chain reaction) was used to test plasmids for cDNA insertion and to add 
restriction sites, necessary for cloning of DNA fragments into respective plasmids, as well as 
epitope sequences to the cDNA by using corresponding primers. Prior to the amplification of 
the DNA sequences of interest, optimal PCR conditions were selected by varying the 
concentration of MgCl2, the amount of template DNA, annealing temperatures (50-60°C) and 
the use of additives (DMSO or glycerol). A standard PCR reaction mix typically contained: 
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reagent (stock concentration) volume (final concentration) 
template (cDNA/plasmid or genomic DNA)  variable (20-200ng) 
10x PCR buffer 2.5µl 
dNTP mix (10mM) 0.5µl  
forward primer (10µM) 1.0µl  
reverse primer (10µM) 1.0µl  
Taq-polymerase (5U/µl) 0.25µl 
ddH2O ad 25µl 
 
The amplification was performed in Mastercycler Gradient (Eppendorf) or DNA engine PTC-
200 (MJ Research) thermocyclers using the following cycling conditions: 
 
step temperature duration number of cycles 
initial denaturation 95°C 5min 1 
denaturation 95°C 45sec 
30 primer annealing 55°C 1min 
elongation 72°C 1min 
final elongation 72°C 10min 1 
 
The amplification products were analyzed on 1% agarose gel by DNA electrophoresis. 
Amplified fragments designed to be inserted into plasmids were purified from the gel using a 
gel extraction kit. 
 
4.1.5 DNA restriction, electrophoresis, gel extraction 
 
Buffers and solutions for agarose gelelectrophoresis 
TAE buffer : 40mM Tris/Acetat; 1mM EDTA; pH 8.0 
6x TAE loading dye: 30% (v/v) glycerol, 0.25% (w/v) Bromophenol blue, 0.25% (w/v) 
xylenol cyanol 
Agarose gel: 0.5% - 2% Agarose in TAE, 0.001% Ethidiumbromide 
 
Preparative restriction digests of 5-10µg of plasmid DNA were used to either obtain 
linearized plasmid vectors or to release cDNA fragments from plasmids. Analytic digests to 
test newly generated plasmid constructs were performed with 100-200ng plasmid DNA. 
Appropriate endonucleases in corresponding buffers (Fermentas) were mixed with DNA and 
left overnight at the temperature specified for each enzyme in the instruction manual of 
Fermentas. Analysis of the DNA size and purification of DNA fragments were performed by 
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agarose gel electrophoresis. DNA samples were mixed with 6x DNA loading buffer and 
ddH2O to reach a final volume of 15-20µl and separated on an agarose gel in 1x TAE buffer 
at 100V. A DNA ladder (Fermentas) of appropriate range was used as size standard. The 
DNA bands were visualized in UV-light using a BIO-VISION™ fluorescence documentation 
system. DNA extraction after gel electrophoresis was performed following the QIAquick Gel 
Extraction Kit protocol. The concentration of DNA in the final solution was measured with a 
Nanodrop spectrophotometer at 260nm. 
  
4.1.6 Cycle sequencing of PCR-amplified DNA 
Cycle sequencing was performed using the services of StarSEQ GENterprise GmbH. 
50-700ng of template (cDNA/plasmid DNA) and 1µl of an appropriate 10µM primer solution 
were sent to StarSEQ for sequencing with an ABI 3730 capillary sequencer based on the 
chain termination method developed by Frederick Sanger. Sequence analysis and alignment 
with reference cDNA were performed using Sequencer software. 
 
4.1.7 Quantitative real-time PCR (qPCR) 
qPCR was performed using the intercalating fluorescent dye SYBR® Green. In a first step 
total RNA was isolated out of mouse tissue using the “RNeasy Mini Kit” (Qiagen) according 
to manufacturer’s instructions. RNA concentration was determined with a Nanodrop 
spectrophotometer (Nanotech). RNA was digested by RQ1 RNase Free DNase (Promega) 
and protected against RNases by adding 20U of RNase Inhibitor RNasin (Promega). 2.5ug of 
total RNA was used for reverse transcriptase PCR (M-LV; Promega). cDNA was diluted 1:5. 
HPLC grade water was used for all reactions including template dilutions. qPCR reactions 
were prepared using “ABsolute™ QPCR SYBR® Green ROX Mix” (ABgene). Primers are 
listed in the material section. 
 
reagent (stock concentration) volume (final concentration) 
template (cDNA derived from RNA) 2.0µl 
SYBR® Green ROX Mix 12.5µl 
forward primer (5µM) 0.35µl (70nM) 
reverse primer (5µM) 0.35µl (70nM) 
HPLC-grade H2O 9.8µl 
 
qPCR was performed in a Stratagene Mx3000P Realtime device (Stratagene) using the 
following cycling conditions: 
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step temperature duration number of cycles 
enzyme 
activation 
95°C 15min 
1 
denaturation 95°C 15sec 
40 
primer 
annealing 
primer Tm 30sec 
extension 72°C 30sec 
melting curve 
95°C 30sec 
1 60°C 30sec 
60-95°C in 0.5°C steps 
 
Fluorescence is detected and measured in real time, and its geometric increase 
corresponding to exponential increase of the product is used to determine the threshold cycle 
(CT) in each reaction. The CT value is characterized as the cycle in which the increasing 
fluorescence is significantly higher than the background fluorescence for the first time. 
Mouse Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was chosen as reference 
gene. Quantitative real time PCR analysis was carried out using the 2-∆∆Ct method. 
 
4.1.8 Plasmid construction: Cloning into AAV-plasmid 
Construction of AAV vectors has been described previously (Kügler, et al., 2003). The pAAV-
human-ß-actin-EWB, pAAV-no promoter-TB-EWB, pAAV-GFAP-EWB, pAAV-hsyn1-EWB 
and pAAV-hsyn1-GDNF-WB plasmids were kindly provided by Dr. Sebastian Kügler. In order 
to produce the pAAV-GFAP-GDNF-WB vector the pAAV-hsyn1-GDNF-WB plasmid was used 
as backbone. The hsyn1 promoter cDNA was substituted for the GFAP promoter cDNA 
coming from the pAAV-GFAP-EWB donor plasmid. The donor plasmid pAAV-GFAP-EWB 
was subjected to MluI/AgeI restriction digest to release the GFAP promoter cDNA. The 
hsyn1 cDNA fragment was also removed from pAAV-hsyn1-GDNF-WB via MluI/AgeI 
restriction digest. After a DNA precipitation step the MluI/AgeI restriction sites were ligated at 
a 1:3 molar ratio (16°C over night).  
 
reagent (stock concentration) volume (final concentration) 
vector (4.7kb) 1.0µl (= 100ng) 
insert (2.3kb) 12.0µl (= 300ng) 
10x ligase buffer (Fermentas) 2.0µl 
Ligase (Fermentas) 1U/µl 1µl 
ddH2O 4µl 
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In order to produce the pAAV-no promoter-TB3-EWB control vector expressing nothing, two 
transcription blocking elements (TB) were inserted into the pAAV-no promoter-TB-EWB 
backbone plasmid. The donor plasmid pAAV-no promoter-TB-EWB was subjected to XbaI 
restriction digest to release the TB cDNA and independently to a NheI restriction digest to 
linearize the backbone plasmid. After dephosphorylation of the linearized backbone plasmid 
(calf intestine alkaline phosphatase 1U (Fermentas), 30min at 37°C) the compatible 
XbaI/NheI restriction sites were ligated at a 1:3 molar ratio (16°C over night) to inhibit 
religation and stop the reaction by DNA precipitation. 
 
reagent (stock concentration) volume (final concentration) 
vector (5.0kb) 2.5µl (1:10 dilution= 100ng) 
insert (0.2kb) 12.0µl (= 300 ng) 
10x ligase buffer (Fermentas) 2.0µl 
Ligase (Fermentas) 1U/µl 0.5µl 
ddH2O 3µl 
 
SURE 2 Supercompetent E. coli cells were heat-shock transformed with the reaction mix (5-
10µl of ligation mix) and spread on LB-Amp agar plates. Colonies were picked and screened 
for the presence of the insert via mini-preparation and different restriction digests. 
 
4.2 Cell culture  
The primary cortical rat culture was used to measure GDNF in the supernatant by ELISA 
after infection with AAV-5 GFAP GFP and AAV-5 GFAP GDNF and the human embryonic 
kidney 293 FT (HEK293FT) cells to check for protein expression after transfection of different 
plasmids by Western Blot. 
 
4.2.1 Preparation of rat cortical neurons  
To obtain primary cortical culture, cortexes were dissected from Wistar rats at E 18 
(embryonic day 18) and further processed for establishing dissociated cell cultures as 
previously described (de Hoop et al. 1993). This primary culture consisted of a mixture of 
neurons and astrocytes and was kindly provided by Dr. Sebastian Kügler. 
 
4.2.2 Culture conditions, transient transfection 
HEK293FT cells were cultured in 75cm2 cell culture flasks in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C 
in a humidified atmosphere of 95% air and 5% CO2 in a cell culture incubator. Cells were 
passaged at 90% confluence one to two times per week: Under sterile conditions, cell culture 
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medium was removed and cells were washed with PBS, before 1ml of trypsin/EDTA solution 
was added. Cells were incubated at 37°C until they could be easily detached by tapping the 
flasks. The cells were thoroughly resuspended in 9ml cell culture medium to obtain a single 
cell suspension. 1ml of the suspension was transferred to a new flask containing 9ml of fresh 
medium. With this 1:10 dilution cells reached confluence after 4-6 days. The cell number was 
determined via light microscopy in a counting chamber. To perform cell culture experiments 
cells were plated at an appropriate density in 6-well or 12-well cell culture plates. Transient 
transfection of HEK293FT cells with 1µg of the target vector was carried out in 6-well plates 
using Metafectene transfection reagent (4µl) according to manufacturer’s instructions. 
 
4.2.3 Viral infection 
For AAV infections 250,000 rat cortical neurons were plated in a 24-well plate. One week 
later the volume of medium was reduced from 750µl to 250µl and AAV in concentrations 
1x108 to 8 x108 infectious virus particles was added to the cells. 24 hours later the volume of 
medium per well was increased again to 750µl. 3 days post infection the cells received fresh 
medium and 1 week post infection cells expressed the transgene (controlled by GFP control 
expression) in a sufficient amount to collect the cells and supernatant for further experiments 
(ELISA, Immuno Blot).  
 
4.3 Protein biochemistry 
This section describes all protein biochemistry related work performed in this study. 
 
4.3.1. Preparation of cell culture lysates 
 
RIPA Buffer for protein extraction 
RIPA buffer: 50mM Tris, pH 8.0, 0.15M NaCl, 0.1% SDS, 1.0% NP-40, 0.5% Na-
Deoxycholate, 2mM EDTA, Complete™ Protease Inhibitors, pH 7.4 
 
Medium was aspired from culture dishes and cells were washed with PBS. Cells were 
scraped in PBS and, in order to decrease the volume, cells were centrifuged for 8min at 6000 
rpm on 4°C. The resulting pellet was resuspended in  an appropriate volume of Ripa lysis 
buffer containing Complete protease inhibitor cocktail and left on ice for 30min for lysis to 
occur. After centrifugation for 10min at 13000rpm at 4°C, the supernatant was taken and the 
pellet containing insoluble cell debris was discarded. For preservation of proteins over a 
longer period of time aliquots were frozen and kept at -20°C. 
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4.3.2 Preparation of tissue lysates 
After PBS-perfusion, murine tissue was rapidly dissected and kept in 1.5ml reaction tubes on 
dry ice until Ripa buffer was added or until addition of RLT buffer (RNeasy Mini Kit) in the 
case of RNA and protein extraction out of the same sample. Cells were lysed using a 
Precellys 24 homogenisator. The lysates were cleared twice from cell debris by 
centrifugation (10min, 13.000rpm at 4°C). 
If RNA and protein were wanted to be extracted out of the same sample, total protein was 
isolated via aceton precipitation from the RLT buffer lysates using the RNeasy Mini Kit and 
following the manufacturer´s instructions. Total protein was resuspended in 0.23M Tris-HCl 
pH 6.8, 50% glycerol and 5% SDS.  
 
4.3.3 Determination of protein concentration 
Protein concentration was determined using the coomassie blue G-based Bio-Rad Protein 
Assay. A 1:5 dilution of the assay reagent stock solution was prepared in ddH2O. A standard 
curve was prepared using bovine serum albumine (BSA) with concentrations ranging from 
0-12µg/µl in ddH2O. Triplets of known protein concentrations were added into 96-well plates 
(50µl) together with samples of unknown concentrations (49µl of ddH2O and 1µl of protein 
lysate). The assay reagent was added to the final volume of 200µl. After incubating for 5min 
at RT, protein concentrations were assayed by measuring absorbance at 595nm using a 
Mithras LB 940 plate reader, equipped with Mikro Win software 2000. If RNA and protein 
were wanted to be extracted out of the same sample protein concentration was measured 
and calculated using the DC Protein Assay (BIO-RAD), tolerating a high SDS concentration 
and according to manufacturer’s instructions. 
 
4.3.4 SDS-PAGE 
 
Buffers for protein separation on SDS polyacrylamide gels 
5x Laemmli buffer: 10% Glycerol, 20% SDS (10% (w/v)), 12.5% 0.5M Tris-Cl, pH 6.8, 5% 
β-Mercaptoethanol, 5% Bromphenol blue (1% (w/v)) 
10x Running Buffer: 250mM Tris/HCl; 1.92M Glycine; 2% SDS, pH 8.3 
 
For SDS-PAGE the “Protean III mini-gel system” (Bio-Rad) was used. Gel components were 
mixed at the required percentage of acryl amide according to the tables for running and 
stacking gel. Samples in 5 x Lämmli buffer containing 20-50µg of protein were boiled for 
5min on 95°C and cooled down on ice immediately aft er incubation on 95°C, thus preventing 
renaturation of proteins. After brief centrifugation samples were subjected to gel 
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electrophoresis at 120V constant voltage in running buffer. A prestained marker was used as 
a protein size standard. 
  
Running gel (all volumes in ml) 
 10% 12% 
30% Acrylamide 1.7 2 
4x running gel 
buffer 
1.3 1.3 
10% APS 0.025 0.025 
TEMED 0.025 0.025 
H2O 2.1 1.75 
 
 
Stacking gel (all volumes in ml) 
 7.5% 
30% Acrylamide 0.625 
4x stacking gel buffer 0.625 
10% APS 0.013 
TEMED 0.013 
H2O 1.25 
 
4.3.5 Immuno blot 
 
Buffers and Solution for protein transfer 
Transfer buffer: 25mM Tris, 192mM Glycine, 20% methanol, pH 8.3 
Ponceau solution: 0.1% Ponceau-S in 5% Acetic acid 
TBS: 10mM Tris/HCl, 150mM NaCl, pH 7.5 
TBS-T: TBS with 0.1% (v/v) Tween20 
Blocking solution: 5% (w/v) skim milk in TBS 
Stripping buffer: 0.2M Glycine, 0.5M NaCl, pH 2.8 
 
Separated proteins on SDS-PAGE were transferred to a Hybond nitrocellulose membrane 
(Amersham). Nitrocellulose membrane, Whatmann paper and foam pads were first soaked in 
1x Transfer buffer. A sandwich was built up on the cathode containing 1xfoam pad, 1x3 mm 
paper, gel, PVDF membrane, 1x3mm paper, 1 x foam pad. The anode was fitted and the 
transfer performed for 1h at constant voltage (100V). The transfer was checked by dying a 
membrane with Ponceau-S solution (0.1% Ponceau-s in 5% Acetic acid). 
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The transfer membrane was placed for 1h in blocking solution (TBS; 5% (w/v) skim milk) at 
room temperature. Subsequently the membrane was incubated with the primary antibody, 
appropriately diluted in 1% skim milk in TBS at 4°C  over night. The next day, the membrane 
was washed 3x10min with TBS-T and incubated with an adequate HRP-coupled secondary 
antibody, appropriately diluted in TBS, for 1h at room temperature. Membrane was washed 
again 3x10min prior to incubation with the Chemiglow chemiluminescent substrate (Alpha 
Innotech) for 1min. Bound proteins were visualized using the AlphaImager video imaging 
device equipped with Fluor Chem 8900 software (Alpha Innotech), which was also used for 
signal quantification. 
 
4.4 Adeno-associated virus production 
AAV-5s were produced by Dr. Sebastian Kügler according to standard protocols of the 
CMPB viral vector service platform (Diss Manuel Joaquim Marques Garrido 2008). Briefly, 
vectors were propagated in AAV-293 cells (Stratagene) using pDG2 as helper plasmid. 
Viruses were concentrated and purified by an iodixanol step gradient procedure. Each virus 
was further purified and concentrated by collecting the “peak” elution phase on Äkta-FPLC 
(Amersham) system using HiTrapTM Heparin HP 1 columns (GE Healthcare). Further 
concentration and purification of rAAV-5 particles was performed by dialysis using Slide-A-
Lyzer (molecular weight cut-off = 10,000). The final virus solution was subjected to real-time 
PCR (RT-PCR) quantification of the rAAV-vector genome particle titre. Purity of the vectors 
was determined by SDS-gel electrophoresis and infectious titre by transduction of cultured 
primary cortical neurons. The genome particles to transducing units (TU) ratio typically was 
25:1 - 35:1 and was calculated as 30:1. The AAV vectors were aliquoted and stored at -80°C 
until used. During all procedures with AAV vectors, 0.5% SDS solution in water was used for 
disinfection. The transducing titres of AAVs used in this study were 3x108/µl for AAV-5 no-
promoter-TB3 GFP, 5x108/µl for AAV-5 GFAP GFP, 0.9x108/µl for AAV-5 SYN GFP, 
1.9x108/µl for AAV-5 GFAP GDNF, 1.2x108/µl for AAV-5 SYN GDNF.  
 
4.5 Animal work 
This section describes all animal work performed in this study. 
 
4.5.1 Animal housing and strains 
Animal experiments were carried out on mice, in accordance with the German Animal 
Welfare Act (TierSchG) and approved by Regierungspräsidium Hannover. Male and female 
mice were obtained from Charles River or were breed in the animal facilities of the Universitiy 
of Goettingen and the Centre for Molecular Neurobiology Hamburg (ZMNH). Mice were 
maintained in a temperature/humidity-controlled environment under a 12hr light/dark cycle 
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with free access to food and water. The following mouse strains were used: C57Bl/6-J, Ret lx, 
DAT-Cre and DAT/Ret lx/lx
.  
To selectively disrupt the gene encoding for Ret in DA neurons 
Kramers group used mice with floxed allele of Ret (Ret lx) in combination with DAT-Cre mice, 
resulting in Ret deficiency in DA neurons (DAT/Ret lx/lx) (Kramer et al., 2007).  
 
4.5.1.1 Genotyping 
Genotyping of transgenic and knock-out mice was performed by PCR using genomic DNA 
extracted from tail biopsies as template with appropriate primer pairs by Dr. Edgar Kramer at 
the ZMNH. 
 
4.5.2 Surgery: stereotaxical injections 
Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine solution (100 or 
5 mg/kg bodyweight, respectively) and placed with flat skull position in a stereotaxic frame 
(WPI). Murine eyes were protected from dehydration by Bepanthen creme (Bayer). A mineral 
oil-sealed glass capillary was fitted into a Nanoliter2000 microinjector and filled with the 
required volume of virus preparation. After slitting the scalp with a scalpel, a hole of 1 mm 
diameter was drilled into the skull to insert the tip of the capillary to the respective 
coordinates relative to bregma. Injections were made as two deposits along the needle tract 
at the coordinates listed below.  
 
Structure 
(total inject. vol) 
anterior 
 
lateral (right) 
 
ventral  
(from skull surface) 
Striatum 2µl = 
2x108 
+0.0mm 
+0.9mm 
-2.2mm 
-1.5mm 
3.0; 4.0mm 
 
After two minutes injection was started with a rate of 250nl/min. The capillary was left in 
place for additional 2min before moving to the deeper coordinates in the same needle tract 
and 5min before withdrawal. 
As post-operative treatment, mice were kept warm with a heating pad and received 
subcutaneously a 1ml deposit of a 1:1 mixture of glucose (5% Braun) and NaCl (0.9% Diaco) 
and were provided with wet mashed food. The wound was closed using Histoacryl (Braun). 
As pain therapy the mice received Novaminsulfon (Ratiopharm) in the drinking water in a 
concentration of 3.2mg/ml. 
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4.5.3 Subchronic MPTP treatment 
Two weeks after unilateral AAV delivery to the striatum, mice were treated either with NaCl 
or MPTP hydrochloride. MPTP was administered at a dose of 30mg/kg free base solved in 
NaCl intraperitoneally at 24h intervals for five doses. 
 
4.5.4 Tissue preparation and processing 
 
10x Stock Solution of PBS buffer 
10x PBS: 1.37M NaCl, 82mM Na2HPO4, 15mM KH2PO4, 2 mM KCl, pH 7.4 
 
Mice were sacrificed using CO2. In order to remove blood from the brain mice were 
transcardially perfused with PBS and in a second step with 4% paraformaldehyde (PFA)/ 
PBS using gravitational force, thus starting the tissue fixation process. The brains were 
removed rapidly, immersion fixed in 4% PFA/PBS overnight and cryoprotected in 30% 
sucrose until tissue was heavier than the fluid at 4°C. In a next step the brains were rapidly 
frozen in isopentane on dry ice. Complete sets of serial coronal sections were cut through 
striatum and SNpc at 30µm on a cryomicrotome and collected in 24 well plates in PBS with 
0.1% Na-Azide. 
 
4.5.5 Behavior 
Animal behavior regarding locomotor function, as a further important analysis point, was 
followed by open field, rotarod and rotation performance and the tight rope test. 
 
4.5.5.1 Open Field 
The locomotor activity of the AAV-injected and control cohorts was examined by monitoring 
their horizontal and vertical movements in an open field to determine whether there was a 
difference between untreated control animals and the two MPTP and AAV-injected groups 
(GFP/GDNF). The motor activity of mice was increased by amphetamine to elucidate more 
clear differences. Animals were surveyed in a 50 x 50cm arena by using the “Videomot2” 
video tracking system (TSE Systems) during the whole experiment. Rearing was detected by 
infrared beams. The tracking arena was divided into a “center” and a “border” zone using the 
Vidoemot2 software. Eleven to fourteen days after MPTP injection, mice were placed 
separately once into the arena after having received the amphetamine injection 
intraperitoneally (5mg/kg body weight). During a tracking period of 60min, the time, distance, 
number of visits, latency, number of rearing and rear time in each area was recorded. At the 
end of the experiments, mice were returned to their housing cages. 
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4.5.5.2 Rotarod 
A rotarod test was used to assess the effect of MPTP and AAV injection on motor 
performance and coordination of the mice  using a gradually accelerating rotarod apparatus 
(47600 ROTA-Rod for Mice, UGO BASILE) set to accelerate from 10 to 40rpm over 180s. 
Two training sessions were performed at a constant speed of 10rpm on two different days 
before starting the measurements. Before and after MPTP administration the animals 
performed 3 times on the gradually accelerating rotarod within one day. The data from the 
rotarod experiments are expressed as the sum of seconds the animals were able to remain 
on the rotarod before falling (latency to fall). The performance was aborted at the latest time 
point of 400s (starting from 180s stable at 40rpm). 
 
4.5.5.3 Tight rope 
A tight rope test was used to further analyze the motor performance of the mice before and 
after MPTP and AAV injection in comparison to untreated animals. During a training period 
the mice had to climb from a central position between two platforms, positioned 30cm above 
the ground on a 60cm long tight rope to one of these platforms in a reasonable time period. 
For animals that performed well enough in these training sessions, the time they needed to 
reach one of the platforms in six rounds of performance was recorded one day before and 
after NaCl / MPTP treatment.  
 
4.5.5.4 Rotation 
In order to reveal side preferences regarding motor performance of animals treated 
systemically with MPTP and unilateral with AAV compared to control groups, animals 
performed the rotation test. In each trial 4 mice were placed for ten minutes in 4 buckets 
(height: 30cm; radius: 13cm) in order to let them adapt to the new environment. After having 
injected amphetamine (5mg/kg body weight) intraperitoneally to induce the rotating behavior, 
left and right turns were counted manually every 5min for 1min over a time period of 30min. 
In order to ascertain individual side preferences the mice were measured once before MPTP 
treatment and one and two weeks afterwards. The data from the rotating experiments are 
expressed as quotient of left to right turns after calibration to the pre MPTP data.  
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4.5.6 Histology 
Immunohistochemistry of 30µm cryosections was performed free-floating.  
 
4.5.6.1 Nissl staining 
Nissl staining solution:  
buffer solution: sodium acetate 7g, glacial acetic acid (100%) 2ml in 1000ml aqua bidest. 
stock stain solution: thionin acetate 1g in 100ml aqua bidest. 
working stain solution: stock solution 45ml and 455ml buffer solution 
 
The Nissl method uses basic aniline to stain RNA blue, and is used to highlight important 
structural features of neurons. The Nissl substance appears dark blue due to the staining of 
ribosomal RNA, giving the cytoplasm a mottled appearance. Following the 3,3'-
Diaminobenzidine (DAB) immunohistochemical staining, sections were rinsed in ddH2O, 
stained in a solution containing 0.1% thionin, pH 5.5 for 7 minutes, rinsed in ddH2O, pre-
dehydrated in 70% and 90% ethanol (2 minutes each) and differentiated in 96% ethanol for 5 
minutes, dehydrated in 100% isopropanol (5min), cleared in xylene (3x 5min) and mounted 
with xylene-based medium (DPX Mountant for histology, Fluka). 
 
4.5.6.2 Immunohistochemistry  
 
Buffers for histology stainings 
Acetate imidazole buffer: 1ml sodium acetate 1M, 1ml imidazole 0.2M to 18ml aqua bidest.                                      
PBS:  137mM NaCl, 8.2mM Na2HPO4, 1.5mM KH2PO4, 2.7mM KCl, pH 7.4 
TBS:  0.1M Tris, 150mM NaCl, pH 7.4 
Dilution Media (DM): 4.1g NaCl, 5.2g Trizma, 350µl Triton X-100 in 700ml aqua bidest. 
Mowiol-mounting medium: 24% w/v Glycerol, 0.1M Tris-base pH 8.5, 9.6% w/v Mowiol 4.88 
and 2.5% w/v DABCO 
Sodium periodate: 2.13g sodium periodate in 100ml TBS 
 
Antibodies and their dilutions are listed in the appendix section. All immunohistochemical 
stains were performed according to the following general protocol: After washing 3x 5 min 
with washing buffer, sections were pretreated with a 10% Methanol, 1-3% H2O2 TBS solution 
for endogenous peroxidase quenching, if necessary, washed again and incubated in blocking 
solution for 1h at room temperature. Incubation with the primary antibody 24-48h was 
followed by 1-2h incubation with the secondary antibody, washing and mounting. 
For fluorescent (multiple) labeling fluorochrome-conjugated secondary antibodies were used 
or in order to further increase the signal biotinylated secondary antibodies combined with an 
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avidin–biotin complex (ABC) Vector kit and the TSATM Plus System (PerkinElmer) based on 
tyramide amplification reagent. TSA can be easily integrated after the addition of horseradish 
peroxidase (HRP), which is used to catalyze the deposition and covalent binding of 
fluorescent labeled tyramide. For light microscopy the antibody reaction was visualized by 
DAB using ABC Vector kit. Detailed protocols are listed below (Table 4.1).  
 
 
Table 4.1: Protocols for light and fluorescent microscopy. 
Light 
microscopy 
   Fluorescent 
microscopy 
 
Staining 
type 
DAB for 
SNpc 
DAB for 
striatum 
GDNF 
staining 
without signal 
amplification 
signal 
amplification 
Wash 3x 5 min in TBS 
3x 10 min in 
TBS 
3x 5 min in 
DM 
        3x 10 min in 
TBS 
Pre- 
treatment 
Quenching 
endogen 
peroxidase 
(5min 3% 
H2O2/10% 
methanol) 
Quenching 
endogen 
peroxidase 
(15min 1% 
H2O2/40% 
methanol) 
Quenching 
endogen 
peroxidase 
(20min 
sodium 
periodat) 
 Quenching 
endogen 
peroxidase 
(15min 1% 
H2O2/40% 
methanol) 
Wash 
see above see above 3x 10 min in 
DM 
3x 5 min in 
0,3% Triton-
X100 in PBS 
see above 
Block 
5% NGS in 
TBS 
10% NGS, 
3% BSA, 
0,1% Triton 
X-100 in 
PBS 
3.3 % NHS, 
2% BSA in 
DM 
10% NGS, 
0,3% Triton X-
100  in PBS 
10% NGS, 3% 
BSA, 0,1% 
Triton X-100 in 
PBS 
1st Ab 
diluted in 
TBS / 2% 
NGS 
48hs/4°C 
diluted in 
10% NGS, 
3% BSA, 
0,1% Triton 
X-100 in 
PBS 
48hs/4°C 
1% NHS, 1% 
BSA, 0,4% 
Triton X-100 
in PBS 
48hs/4°C 
diluted in 1% 
NGS, 0,3% 
Triton X-100  in 
PBS  
24hs/4°C 
diluted in 10% 
NGS, 3% BSA, 
0,1% Triton X-
100 in PBS 
48hs/4°C 
Wash 
see above see above 6x 10 min in 
DM 
3x 5 min in 
0,3% Triton-
X100 in PBS 
see above 
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2nd Ab 
biotin-
conjugated, 
diluted in 
TBS 2% 
NGS 
1h/room 
temperature 
biotin-
conjugated, 
diluted in 
10% NGS, 
3% BSA, 
0,1% Triton 
X-100 in 
PBS 
2hs/room 
temperature 
biotin-
conjugated, 
diluted in 1% 
NHS, 1% 
BSA in DM 
1h/room 
temperature 
fluorochrome-
conjugated, 
diluted in 1% 
NGS, 0,3% 
Triton X-100  in 
PBS  
1h/room 
temperature 
biotin-
conjugated, 
diluted in 10% 
NGS, 3% BSA, 
0,1% Triton X-
100 in PBS 
2hs/room 
temperature 
Wash 
see above see above see above 3x5 min in 
0,3% Triton-
X100 in PBS 
see above 
Detection 
ABC-Kit 
standard 
(1h)/DAB 
(15min) 
ABC-Kit 
elite 
(2hs)/DAB 
(10min) 
ABC-Kit 
standard (30 
min)/  DAB 
(10min) 
fluorescence ABC-Kit elite 
(2hs)/ TSATM 
Plus System 
(10min) 
Wash 
see above see above 3x 10 min 
acetate 
imidazole  
 see above 
Mounting 
DPX mount 
after Nissl 
staining 
DPX mount 
after 
dehydration 
DPX mount Mowiol/DABCO Mowiol/DABCO 
 
 
4.6 Microscopy 
Fluorescent images were acquired using by an inverted fluorescence microscope (Leica 
DMI6000B) equipped with 2.5x, 10x, 20x, 40x, 63x dry and 63x water objectives, Leica  
FX350 (black/white) and FX450 (color) digital cameras digital cameras and the Leica 
Advanced Flurorescence Software. Transmitted light images were acquired by an Axioskop 2 
(Zeiss) equipped with 2.5x, 10x, 20x, 40x dry and a 63xoil-immersion objective, a MicroFire 
camera (Optronics) and the StereoInvestigator software. 
 
4.7 Quantifications 
All quantifications were performed blinded for treatment. 
 
4.7.1 Stereology 
Stereological counts were carried out with the optical fractionator method 
(StereoInvestigator, MBF Bioscience, Magdeburg). The criterion for counting an individual 
cell was its presence either within the counting frame, or touching the right or top frame lines 
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(green), but not touching the left or bottom lines (red). The total number of cells was then 
determined by the StereoInvestigator program. The number of SNpc dopaminergic neurons 
was determined by counting Nissl-positive and TH-immunoreactive neurons using an oil-
immersion 63x objective (Axioskop 2, Zeiss) a counting frame of 50x50 µm and a grid size of 
100x100 µm, while the region of interest was confined to the SNpc. 
 
4.7.2 Optical density  
To quantify TH-IR terminals in the striatum, five coronal sections between bregma +1.10 and 
−0.10mm throughout the striatum were stained for TH with DAB and ABC Elite kit as 
described above. For every section, three pictures were acquired. To automatically delineate 
the fibres and to increase the signal-to-noise ratio, the images were first thresholded, 
binarized and the optical density of photographs evaluated with ImageJ software. Striatal 
values were normalized by subtracting the background staining, measured in the cortex of 
the same section. For the GDNF-Ret signaling study the TH- and DAT-positive fibre density 
in the striatum will be analyzed by Dr. Edgar Kramer as previously described (Kowsky et al. 
2007). 
 
4.7.3 High performance liquid chromatography (HPLC)  
For the measurement of catecholamines by HPLC the mice were sacrificed 14 and 90 days 
after the last MPTP injection by fast cervical dislocation, because of the instability of 
catecholamines after death. The striata were rapidly dissected, frozen, and stored at −80°C. 
Tissue samples were mechanically crushed (Precellys 24) in 50µl of 0.1M perchloric acid per 
milligram of striatal tissue. After centrifugation (15,000×g for 10min at 4°C), 20µl of 
supernatant was injected onto a C18 reverse-phase HR-80 catecholamine column (ESA, 
Bedford, MA). DOPAC and HVA were quantified by HPLC with electrochemical detection 
(Dionex Ultimate 3000 machine, Dionex). The mobile phase (pH 4,3) consisted of 57mM 
citric acid, 43mM sodium acetate, 0.1mM EDTA, 1mM octane sulfonic acid and 20% 
methanol. The samples were first separated on a chromatographic column (Dionex Acclaim 
C 18, 5µm, 2.1 x 150mm column, at 25˚C) and then electrochemically detected on a graphite 
electrode (Dionex ED50 elektrochemicaldetector with the following conditions: disposal 
carbon electrode at 0.8V, flow rate 0.2ml/min. DA, HVA and DOPAC (Sigma-Aldrich) 
standards of 1.5, 0.3 and 0.15µM were included in each HPLC run for creation of a standard 
curve. Data were collected and processed using the Chromeleon 6.60 software. 
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4.8 Statistics 
Data are expressed as means ± SD. Statistical analysis was performed by ANOVA, followed 
by Tukey’s post hoc test to compare group means with GraphPad Prism 4.0 (GraphPad 
Software). Significance levels were set at *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
4.9 Materials 
The listed instruments, consumables, chemicals, media, supplements and buffers for cell 
culture, enzymes, pharmaca, narcotics, kits, antibodies, bacterial strains, cell lines and 
mouse lines, primer and vector maps have been used in the submitted thesis. All supplier 
companies listed below are located in Germany, if not otherwise stated. 
 
4.9.1 Instruments 
Autoclave  
Systec 5075 ELV Systec GmbH, Wettenberg 
Bead grinder homogenizer  
Precellys 24 Peqlab, Biotechnologie, Erlangen 
Cell-counting chamber  
Neubauer cell chamber 
Glaswarenfabrik Hecht GmbH, 
Sondheim/Rhön 
Centrifuges  
Sigma 1-15K 
Sigma 6K 15 
Sigma-Aldrich Chemie GmbH, Taufkirchen 
Centrifuge 5415D Eppendorf Deutschland, Hamburg 
Developing machine  
FMP 800 A Fujifilm Europe, Düsseldorf 
ECL-camera system  
AlphaImager EC 
Alpha Innotec Corporation, San Leandro, 
USA 
Electrophoresis chambers for agarose gels  
Mini Sub Cell GT Bio-Rad Laboratories GmbH, München 
Gel documentation  
BioVision Video documentation system Peqlab Biotechnologie, Erlangen 
Heat blocks  
Thermofixer comfort Eppendorf Deutschland, Hamburg 
HPLC  
UltiMate 3000 Dionex, Idstein 
Incubators  
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Sanyo CO2-Inkubator MCO 18AIC  MS Laborgeräte, Wiesloch 
Luminometer  
Mithras LB 940 plate reader Berthold Technologies, Bad Wildbad 
Microinjector  
Nanoliter2000 microinjector 
Micro4 smart controller unit 
WPI (World Precision Instruments), Berlin 
Microtomes  
Cryostat  LEICA CM3050S Leica Microsystems, Bensheim 
Microscopes  
Axioskop 2 Zeiss, Göttingen 
Leica DMI6000B Leica Microsystems, Bensheim 
pH meter  
CG843/14pH Schott Instruments GmbH,  
Pipets  
Biohit mLine (10, 20, 200, 1000 µl) Biohit Deutschland GmbH, Rosbach v. d. 
Höhe  
Gilson Pipetman (10, 20, 200, 1000 µl) Gilson International B.V., Limburg-Offheim   
Eppendorf Reference (10, 20, 200, 1000 µl) Eppendorf Deutschland, Hamburg 
Photometers  
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific, Dreieich 
Power supplies  
Power-Pac 300 Bio-Rad Laboratories GmbH, München 
Power-Pac 3000 Bio-Rad Laboratories GmbH, München 
Rotarod  
47600 Rota-Rod for mice UGO Basile, Comerio VA - Italy 
SDS-PAGE- and Blotting-Apparatus  
Mini-PROTEAN® II-Electrophoresis-System Bio-Rad Laboratories GmbH, München 
PROTEAN® II xi-Electrophoresis-System Bio-Rad Laboratories GmbH, München 
Shakers  
Incubation shaker Unitron Infors HT, Einsbach 
Roller Shaker "Assistent" RM5 
Glaswarenfabrik Hecht GmbH, 
Sondheim/Rhön 
Orbital platform shaker Rotamax 120 
Heidolph Instruments GmbH & Co.KG, 
Schwabach 
Vortex-Genie 2 
neoLab Migge Laborbedarf GmbH, 
Heidelberg 
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Sterile bench  
HeraSafe HSP Thermo Fisher Scientific, Dreieich 
stereotaxic frame WPI (World Precision Instruments), Berlin 
Scales  
EW4200-2NM Kern & Sohn GmbH, Balingen 
ALC-210-4 Acculab, Bradford, USA 
Thermocycler  
Mastercycler Gradient  Eppendorf Deutschland, Hamburg 
MX3000PTM   Real time PCR system Stratagene, La Jolla, USA 
 
4.9.2 Consumables 
Gel blotting paper 
 
Type GB3000 Whatman GmbH, Dassel 
Nitrocellulose membranes 
 
PROTRAN® Nitrocellulose transfer membrane Whatman GmbH, Dassel 
Cell culture plastic 
 
BD Falcon 6-/24-/48-/96-well cell culture 
plates 
BD Biosciences, Heidelberg 
Costar® cell culture bottles, 75 cm2 Corning GmbH, Life Sciences, Wiesbaden 
Nunclon Surface 96-well cell culture plate, flat 
bottom 
Nunc, Langenselbold 
Histology  
SuperfrostPlus® glass slides Menzel-Gläser, Braunschweig 
Surgery  
sterile scalpel blades, syringes, canules B. Braun Melsungen AG, Melsungen 
 
4.9.3 Chemicals and biochemicals 
     Acetic acid      Carl Roth GmbH, Karlsruhe 
     Acetone      Carl Roth GmbH, Karlsruhe 
     Acrylamide 2K-Solution          
     (30%, Mix Acrylamide:Bisacrylamide; 37,5:1) 
     AppliChem, Darmstadt 
     Agarose      Peqlab, Biotechnologie, Erlangen 
     Ammonuim chloride      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Ammonium persulfate (APS)      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Ammonium sulfate      Merck, Darmstadt 
     Ampicillin      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     BenchMark® Prestained Protein Ladder      Invitrogen, Karlsruhe 
     Bovine serum albumin (BSA)      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Bromphenol blue      Merck, Darmstadt 
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     Chemiglow chemiluminescent substrate      Alpha Innotec, San Leandro, USA 
     Hydrochloric acid      Carl Roth GmbH, Karlsruhe 
     Citric acid monohydrate      Fluka, Neu-Ulm 
     Complete® Proteases-Inhibitor-Cocktail      Roche Diagnostics GmbH, Mannheim 
     DAB      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     DABCO      Sigma-Aldrich Chemie GmbH, Taufkirchen 
 Desoxynucleosid-5’-triphosphate (dNTPs)       Invitrogen GmbH, Karlsruhe 
     Dimethyl sulfoxide (DMSO)      Sigma-Aldrich Chemie GmbH, Taufkirchen 
B   Dopac      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Dopamine      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     DPX mounting medium      Fluka, Neu-Ulm 
     EDTA      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Ethanol, absolute extra pure      Merck, Darmstadt 
     Ethidium bromide      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     GeneRuler® 1 kb-DNA-Ladder      Fermentas Life Sciences, St. Leon-Rot 
     GeneRuler® 100 bp-DNA-Ladder       Fermentas Life Sciences, St. Leon-Rot 
     Glucose      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Glucose oxidase      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Glycine      AppliChem, Darmstadt 
     Glycerol      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Guanidine isothiocyanate      Mobitec Molecular Biotechnology, 
Göttingen 
     Histoacryl      B. Braun, Melsungen 
     Homovanillic acid      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Hydrogen peroxide (30%)      Merck KGaA, Darmstadt 
     Immersion oil      Merck KGaA, Darmstadt 
     Imidazole      Fluka, Neu-Ulm 
     Isopropanol (molecular grade)      Sigma-Aldrich Chemie GmbH, Taufkirchen 
  LB Agar      Invitrogen GmbH, Karlsruhe 
     LB Broth      Invitrogen GmbH, Karlsruhe 
     Magnesium chloride       Fluka (Sigma-Aldrich) 
     Magnesium sulfate      Fluka (Sigma-Aldrich) 
     Metafectene transfection reagent      Biontex Laboratories, Martinsried 
     Methanol      Carl Roth GmbH, Karlsruhe 
     2-Methyl-butane      Carl Roth GmbH, Karlsruhe 
     Mineral oil      Fluka, Neu-Ulm 
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     Mowiol 4.88      Calbiochem, Darmstadt 
     New born goat serum      Invitrogen GmbH, Karlsruhe 
     New born horse serum      Invitrogen GmbH, Karlsruhe 
     N,N,N’,N’-Tetramethylethylendiamin (TEMED)     Carl Roth GmbH, Karlsruhe 
     NaCl solution (0.9%, steril, for injection)      B. Braun Melsungen AG, Melsungen 
     Naturaflor® Milk powder      Töpfer GmbH, Dietmannsried 
     Nickel ammonium sulfate      Fluka (Sigma-Aldrich) 
     NP-40      Sigma-Aldrich Chemie GmbH, Taufkirchen 
O.C.T. compound      Sakura, Staufen 
     Paraformaldehyde (PFA)      Riedel-deHaën, Seelze 
     Ponceau S     Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Potassium chloride      Merck KGaA, Darmstadt 
     Potassium dihydrogen phosphate      Merck KGaA, Darmstadt 
     Prestained SDS-PAGE Standard (Broad 
Range) 
     Bio-Rad, München 
     Saccharose      Carl Roth GmbH, Karlsruhe 
     Sodium acetate Carl Roth GmbH, Karlsruhe 
     Sodium azide Carl Roth GmbH, Karlsruhe 
     Sodium bicarbonate      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Sodium carbonate      Sigma-Aldrich Chemie GmbH, Taufkirchen 
S   Sodium chloride      Carl Roth GmbH, Karlsruhe 
     Sodium deoxycholate      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Sodium dodecyl sulphate (SDS)      AppliChem GmbH, Darmstadt 
     Sodium hydrogen phosphate       Carl Roth GmbH, Karlsruhe 
     Sodium hydroxide      Carl Roth GmbH, Karlsruhe 
     Sodium 1-octanesulfonate monohydrate      Fluka (Sigma-Aldrich) 
     Sodium periodate      Fluka (Sigma-Aldrich) 
     Sodium vanadate      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     ß-Mercaptoethanol      Fluka (Sigma-Aldrich) 
  Temed      AppliChem, Darmstadt 
     Thionine acetate      Sigma-Aldrich Chemie GmbH, Taufkirchen 
     Trichloracetic acid      Merck KGaA, Darmstadt 
     Triton X-100      Sigma-Aldrich Chemie GmbH, Taufkirchen 
      Tris      Carl Roth GmbH, Karlsruhe 
     Tris-HCl      Carl Roth GmbH, Karlsruhe 
     Trizma      Fluka (Sigma-Aldrich) 
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     Tween® 20 Carl Roth GmbH, Karlsruhe 
X   Xylenole cyanole Carl Roth GmbH, Karlsruhe 
Xylol Carl Roth GmbH, Karlsruhe 
 
 
4.9.4 Media, supplements and buffers for cell culture 
Dulbecco’s Modified Eagle Medium (DMEM) PAN-Biotech, Aidenbach 
Dulbecco’s Phosphate Buffered Saline 
(DPBS),      Invitrogen GmbH, Karlsruhe 
Fetale Calf  Serum (FCS)      Invitrogen GmbH, Karlsruhe 
Penicillin/Streptomycin      PAN Biotech, Aidenbach 
 
 
4.9.5 Enzymes 
     Absolute™ QPCR SYBR® Green Rox Mix      Abgene, Epsom, UK 
     Complete™ protease inhibitors      Roche Diagnostics GmbH, Mannheim 
     DNase      Promega, Mannheim 
     Proteinase K (PCR grade)      Roche Diagnostics GmbH, Mannheim 
     Restriction endonucleases      Fermentas Life Sciences, St. Leon-Rot 
     M-MLV reverse transcriptase      Promega, Mannheim 
     RNasin ribonuclease inhibitor      Promega, Mannheim 
     T4 ligase      Fermentas Life Sciences, St. Leon-Rot 
     Taq Polymerase  Fermentas Life Sciences, St. Leon-Rot 
     Trypsin/EDTA      Invitrogen GmbH, Karlsruhe 
 
4.9.6 Pharmaca and narcotics 
     Bepanthen eye and nose ointment  Bayer, Leverkusen 
     D-Amphetaminesulfate 
Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
     Ketamine solution Ketanest-S Pfizer Pharma GmbH, Berlin 
     MPTP 
Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
     Novaminsulfonratiopharm Ratiopharm, Ulm 
     Xylazine  Riemser, Greifswald 
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4.9.7 Kits 
     Vectastain® ABC Kit Vector Laboratories Inc., Burlingham, 
USA 
     Biorad Protein Assay      Bio-Rad Laboratories GmbH, München 
     QIAfilter® Plasmid purification Kits Qiagen GmbH, Hilden 
     QIAquick®  Gel extraction Kit      Qiagen GmbH, Hilden 
     QIAquick®  PCR purification Kit      Qiagen GmbH, Hilden 
     GDNF Emax® ImmunoAssay System      Promega, Mannheim 
     RNeasy Mini Kit      Qiagen GmbH, Hilden 
     TSA Plus Fluorescence System      PerkinElmer, Rodgau-Juegesheim 
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4.9.8 Antibodies 
     Primary antibodies  
GDNF, polyclonal biotinylated goat, #  BAF212, 
1:250 
R&DSystems, Wiesbaden 
Iba-1, polyclonal rabbit, #  019-19741, 1:300 Wako, Neuss 
pERK, monoclonal 1,2 phospho p44/42/MAPK,   
rabbit, #  4376S, 1:1000 
Cell signaling Technology, Frankfurt am 
Main 
pAkt, monoclonal 1,2 phospho-Akt , rabbit, #  
3787S, 1:100 
Cell signaling Technology, Frankfurt am 
Main 
E   GFP, polyclonal rabbit, #  SC-8334 
      (WB: 1:3000; IHC: 1:500) 
Santa Cruz Inc. Santa Cruz, USA 
     FLAG, monoclonal  mouse, # 200471, 1:2000       Stratagene, La Jolla, USA 
     GFAP, polyclonal rabbit, #  Z0334, 1:500      Dako Deutschland GmbH, Hamburg 
     NeuN, monoclonal mouse # MAB377, 1:500 Chemicon Temecula,  USA 
     synphilin-1, polyclonal rabbit, #  S5946, 1:200      Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
     synphilin-1, polyclonal rabbit, # 1007, 1:1000      provided by C. O’Farrell, Jacksonville, 
USA 
     TH, polyclonal rabbit, # AB152, 1:1000      Chemicon Temecula,  USA 
     β-Actin, monoclonal mouse, # A-5441, 1:10000 Sigma-Aldrich Chemie GmbH, 
Taufkirchen 
 
     secondary antibodies  
HRP-sheep anti-mouse Ig, #NXA931, 1:10000 Amersham Pharmacia Biotech, USA 
HRP-donkey anti-rabbit IgG,  #NA934V, 
1:10000 
     Amersham Pharmacia Biotech, USA 
     Alexa555 goat anti-rabbit IgG, (red), 1:1000      Invitrogen GmbH, Karlsruhe 
     Alexa555 goat anti-mouse IgG, (red), 1:1000      Invitrogen GmbH, Karlsruhe 
     Biotin goat anti-rabbit IgG, 1:200, # BA-1000 Vector Laboratories, Loerrach 
     Biotin horse anti-goat IgG, 1:200, # BA-9500 Vector Laboratories, Loerrach  
 
4.9.9 Bacterial strains 
       SURE 2 super chemicompetent         Stratagene, La Jolla, USA 
       DH-5α maximum efficiency        Invitrogen GmbH, Karlsruhe 
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4.9.10 Cell lines 
       HEK293FT        Invitrogen GmbH, Karlsruhe 
 
4.9.11 Mouse lines 
       C57Bl/6-J 
       C57Bl/6-J, Ret lx 
       C57Bl/6-J, DAT-Cre 
       C57Bl/6-J, DAT/Ret lx/lx 
 
 
4.9.12 Real time PCR primer 
Name  Sequence 
TH sense 5′-GGTATACGCCACGCTGAAGG-3′ 
TH antisense 5′-TAGCCACAGTACCGTTCCAGA-3′  
GAPDH sense 5′-TGGCAAAGTGGAGATTGTTGCC-3′ 
GAPDH antisense 5′-AAGATGGTGATGGGCTTCCCG-3′ 
 
 
4.9.13 Vector maps 
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Fig. 4.1: pAAV-GFAP-EWB 
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Fig: 4.2: pAAV-GFAP-GDNF-WB 
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Fig. 4.3: pAAV-hsyn1-EWB 
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Fig. 4.4: pAAV-hsyn1-GDNF-WB 
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Fig. 4.5: pAAV-no promoter-TB3-EWB 
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5 Results 
5.1 Astrocytic versus neuronal expression of GDNF 
5.1.1 Properties of AAV-5 vectors driving transgene expression from GFAP or 
SYNapsin promoters 
The injection of 2x108 AAV-5 GFAP GFP and AAV-5 SYN GFP into the striatum of C57BL-
6/J male mice resulted in a broad spatial distribution of transduced cells all-over the entire 
striatum and parts of the cortex two weeks and three months after the injection (Fig 5.1 and 
5.2 A-B). The injection of 2x107 transducing units resulted in a definite minor GFP expression 
per cell with less dense distribution of transduced cells two weeks and three months after 
injection (Fig 5.1 and 5.2 C-D). While AAV-5 GFAP GFP injection resulted in GFP expression 
exclusively in astrocytes (Fig. 5.1, 5.2 A and C, Fig. 5.3 A), AAV-5 SYN GFP injection 
resulted in neurons expressing the transgene (Fig. 5.1, 5.2 B and D, Fig. 5.3 B) for both viral 
titres.                  
GFAP GFP                                       2w syn GFP                                         2w
2x
10
 
8
2x
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7
GFPA
C GFP
GFPB
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100µm 100µm
 
Fig. 5.1: Striatal GFP expression two weeks (2w) after AAV-5-mediated gene transfer. 
Overview pictures of coronal sections showing striatal GFP expression two weeks after AAV-
5 infection, expressing GFP under the control of the astrocyte-specific GFAP promoter (A 
and C) and under the control of the neuron-specific SYN promoter (B and D) for 2x108 
transducing units (A-B) and 2x107 transducing units (C-D). Close-up of coronal sections for 
2x107 transducing units of AAV-5 GFAP GFP (C) and AAV-5 SYN GFP (D) –infected animals 
showing detailed GFP expression in the striatum. 
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Fig. 5.2: Striatal GFP expression three months (3m) after AAV-5-mediated gene 
transfer. Overview pictures of coronal sections showing striatal GFP expression three 
months after AAV-5 infection, expressing GFP under the control of the GFAP promoter (A 
and C) and under the control of the SYN promoter (B and D) for 2x108 (A-B) and 2x107 
transducing units (C-D). Close-up of coronal sections for 2x107 transducing units of AAV-5 
GFAP GFP (C) and AAV-5 SYN GFP (D) –infected animals showing detailed GFP 
expression in the striatum. 
 
The striatal injection of 2x108 AAV-5 GFAP GDNF and AAV-5 SYN GDNF resulted in a broad 
spatial distribution of GDNF throughout the entire striatum and parts of the cortex two weeks 
and three months after infection (Fig. 5.4 C-F). GDNF detection was based on ABC/DAB 
amplification. Striatal slices from AAV-5 GFAP GFP and AAV-5 SYN GFP-infected mice 
served as negative control (Fig. 5.4 A-B). The results in the SNpc are completely different, 
because the transport of GDNF from the striatum to the ipsilateral SNpc is more efficient 
after infection of neurons (Fig. 5.4 G-J). Furthermore, GDNF expressed by neurons was also 
detected in areas outside the pars compacta, e.g. the pars reticulata (Fig. 5.4 H and J). 
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The injection of 2x107 transducing units resulted in a definite minor striatal distribution of 
GDNF two weeks and three months after infection for both viruses (Fig 5.5 A-D). The 
situation in the SNpc is comparable to the high titre dosage, with the difference that, due to a 
minor signal, GDNF is not longer detectable for animals infected with AAV-5 GFAP GDNF 
(Fig. 5.5 E-H). 
In order to quantify the GDNF amount in the injected and non-injected striatum (CPu) and 
SN, a GDNF ELISA (Promega) was used. Samples were prepared two weeks after viral 
injection and have been diluted within a range of 1:5 up to 1:10.000 to find individually 
optimal ODs. Samples were tested in duplicates in three independent ELISA measurements. 
The ELISA revealed only small differences in the ipsilateral striatal amount of GDNF upon 
injection of high viral titres and no differences upon injection of low ones when comparing 
astrocytic and neuronal produced GDNF (Fig. 5.6). After neuronal infection (2x108 AAV-5 
SYN GDNF) more GDNF is transported to the ipsilateral SN (13% of the striatal amount) in 
comparison to the infection of astrocytes with 2x108 AAV-5 GFAP GDNF (1.3% of the striatal 
amount). These results are in line with the immunohistology data for GDNF (Fig. 5.4). 
Although not detectable in immunohistology, the amount of GDNF was not only increased in 
the ipsilateral striatum and SN but also in the contralateral structures. 
Fig. 5.3: Cell-specific GFP expression after AAV-5-mediated gene transfer (2x108 
infectious particles, two weeks after infection). Close-up of the striatum showing AAV-5 
GFP expression exclusively in astrocytes defined by colocalization with GFAP (astrocytic 
marker, red) -positive cells if controlled by the GFAP promoter (A) and exclusively in 
neurons defined by colocalization with NeuN (neuronal marker, red) -positive cells if 
controlled by the SYN promoter (B). 
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Fig. 5.4: GDNF overexpression in the striatum and SNpc of infected mice for 2x108 
transducing units. Overview pictures of coronal sections showing GDNF overexpression 
two weeks (A-D and G-H) and three months (E-F and I-J) after unilateral AAV-5 GFAP GFP 
or AAV-5 SYN GFP (A-B) and AAV-5 GFAP GDNF or AAV-5 SYN GDNF (C, E, G, I; D, F, H 
J) infection. Pictures are shown with the injected striatum (A-F) and SNpc (G-J) on the left.  
 
The 8-fold higher amount of GDNF found in the contralateral striatum after infection with 
AAV-5 SYN GDNF (25-fold increase over baseline) compared to infection with AAV-5 GFAP 
GDNF (3-fold increase over baseline) shows a tendency to a more efficient transport to the 
contralateral striatum after neuronal infection. Such a tendency could not be detected for the 
contralateral SN (Fig. 5.6).  
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After infection with 2x107 transducing units astrocytes and neurons produce the same 
amount of GDNF (p > 0.05) but both produced considerable less amount of GDNF in 
comparison to the high titre dosage in the ipsilateral striatum (Fig. 5.6). Again, after neuronal 
infection a higher amount of GDNF is transported to the ipsilateral SN (39% of the striatal 
amount) in comparison to the infection of astrocytes (3.6% of the striatal amount) (p < 0.001) 
(Fig. 5.6). These results are again in line with the immunohistology data for GDNF (Fig. 5.5).  
Although having used 10-fold less virus, the percentage of GDNF transported from the 
striatum to the contralateral SN is higher for both neuronal and astrocytic GDNF production 
(Fig. 5.6). In contrast to the high titre dosage, the contralateral striatum or SN did not show 
increased GDNF amounts (Fig. 5.6).  
Comparing the ELISA results to the immunohistology for GDNF, in this study the detection 
limit for GDNF on slices can be defined at ~ 1100pg GDNF/mg tissue (Fig. 5.4, 5.5, 5.6). 
 
Fig. 5.5: GDNF overexpression in the striatum and SNpc of infected mice for 2x107 
transducing units. Overview pictures of coronal sections showing GDNF overexpression 
two weeks (A-B and E-F) and three months (C-D and G-H) after unilateral AAV-5 GFAP 
GDNF or AAV-5 SYN GDNF (A, C, E, G; B, D, F, H) infection. Pictures are shown with the 
injected striatum (A-D) and SNpc (E-H) on the left. 
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Fig. 5.6: Quantification of GDNF in the striatum (CPu) and SN in mice after high and 
low titre infection by ELISA. Red values represent mean pg GDNF/mg CPu or SN, blue 
values mark the fold-increase to background levels and green values demonstrate the 
fraction of the GDNF amount in the injected site, which is transported to the ipsilateral SN. 
Pictures on the top of each titre condition demonstrate the CPu and the SN on the bottom. 
Animals were sacrificed two weeks after unilateral infection (n=3).  
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5.1.2 Tissue reactions to astrocytic or neuronal transgene expression 
All stereotaxic injections provoked a glial response as evaluated by up-regulation of the 
astrocytic marker GFAP and detected by immunohistochemistry. Interestingly, this is also 
evident – though to a lesser extent after sodium chloride or empty AAV-5 (expressing no 
transgene at all) injection (data not shown).  
At two weeks after injection of 2x108 transducing units AAV-5 GFAP GFP and AAV-5 SYN 
GFP an astrogliosis in the striatum could be detected for both of them (Fig. 5.7 A-B). For the 
low titre dosage (2x107 transducing units) the GFAP immunoreactivity was reduced (Fig. 5.7 
C-D). The two weeks time point after AAV-5 GFAP GDNF and AAV-5 SYN GDNF injection 
shows the same pattern but only a slight reduction of astrogliosis in the presence of low titre 
dosages (Fig. 5.8).  
At three months after stereotaxic injection astrogliosis has clearly faded for both AAV-5 
GFAP GFP and AAV-5 SYN GFP for the high titre dosage and disappeared for the low titre 
dosage (Fig. 5.9). The three months time point after AAV-5 GFAP GDNF and AAV-5 SYN 
GDNF injection shows the same but more differentiated pattern (Fig. 5.10).  
Evaluating microglial response to cell type-specific transgene expression, astrocytic GFP and 
GDNF expression at the high titre dosage were the only paradigms that provoked a mild 
increase in ionized calcium binding adaptor molecule-1 (Iba-1) immunoreactivity (Fig. 5.11 A, 
5.12 A). This increase in Iba-1 immunoreactivity was no longer detected at three months 
after stereotaxic injection (data not shown). Injection of AAV-5 SYN GFP and AAV-5 SYN 
GDNF for both viral titres (Fig. 5.11 B and D, 5.12 B and D) and injection of AAV-5 GFAP 
GFP and AAV-5 GFAP GDNF only for the low titre dosage (Fig. 5.11 C, 5.12 C) did not result 
in any activation of microglial markers.  
(i) The AAV-5 serotype efficiently transduces both neurons and astrocytes, but transcriptional 
control is able to completely restrict transgene expression to either neurons or astrocytes using 
2x108 and 2x107 transducing units. 
(ii) Neuronal and astrocytic expression of GFP and GDNF in the striatum is detectable without 
differences regarding distribution or expression level for both time points but transport of 
GDNF to the ipsilateral SN is much more efficient if GDNF is produced by neurons. 
(iii) In addition to the transport of GDNF from the ipsilateral striatum to the ipsilateral SNpc, 
also other tracks from the ipsilateral to the contralateral striatum and SN or from the SN via 
anterograd transport to the striatum might also be in use in the presence of high GDNF 
amounts. 
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Fig. 5.7: Reaction of astrocytes two weeks (2w) after unilateral injection of AAV-5 GFP 
in the striatum. Close-up of coronal sections stained for the astrocytic marker GFAP, 
showing the same reaction of astrocytes after stereotaxic injection of AAV-5 GFAP GFP (A) 
compared to AAV-5 SYN GFP (B) for the high titre dosage (2x108 transducing units). For the 
low titre dosage (2x107 transducing units) the GFAP immunoreactivity was reduced for both 
AAV-5 GFAP GFP (C) and AAV-5 SYN GFP (D) -infected animals. A2 shows GFAP 
immunoreactivity of an uninjected control slide. 
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Fig. 5.8: Reaction of astrocytes two weeks (2w) after unilateral injection of AAV-5 
GDNF in the striatum. Close-up of coronal sections stained for the astrocytic marker GFAP, 
showing the same reaction of astrocytes after stereotaxic injection of AAV-5 GFAP GDNF (A) 
compared to AAV-5 SYN GDNF (B) for the high titre dosage (2x108 transducing units). For 
the low titre dosage (2x107 transducing units) the GFAP reactivity was only slightly reduced 
after both AAV-5 GFAP GDNF (C) and AAV-5 SYN GDNF (D) infection. A2 shows GFAP 
immunoreactivity of an uninjected control slide. 
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Fig. 5.9: Reaction of astrocytes three months (3m) after unilateral injection of AAV-5 
GFP in the striatum. Close-up of coronal sections stained for the astrocytic marker GFAP, 
showing a mild reaction of astrocytes three months after stereotaxic injection of both AAV-5 
GFAP GFP (A) and AAV-5 SYN GFP-infected animals (B) for the high titre dosage (2x108 
transducing units). For the low titre dosage (2x107 transducing units) an increased GFAP 
reactivity in comparison to negative controls was not detected in either AAV-5 GFAP GFP 
(C) or AAV-5 SYN GFP (D) -infected animals. 
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 Fig. 5.10: Reaction of astrocytes three months (3m) after unilateral injection of AAV-5 
GFP in the striatum. Close-up of coronal sections stained for the astrocytic marker GFAP, 
showing a reaction of astrocytes three months after stereotaxic injection of both AAV-5 
GFAP GFP (A) and AAV-5 SYN GFP-infected animals (B) for the high titre dosage (2x108 
transducing units). For the low titre dosage (2x107 transducing units) the GFAP 
immunoreactivity is clearly reduced but still detectable. 
 
 
 
RESULTS 
  74 
                  
GFAP GFP                                       2w syn GFP                                         2w
2x
10
 
8
2x
10
 
7
A Iba-1
Iba-1C
B Iba-1
D Iba-1
50µm
 
 Fig. 5.11: Reaction of microglia two weeks (2w) after unilateral injection of AAV-5 GFP 
in the striatum. Close-up of coronal sections stained for the microglial marker Iba-1, 
showing a very mild reaction of microglia only after stereotaxic injection of AAV-5 GFAP GFP 
(A) for the high titre dosage (2x108 transducing units). For AAV-5 SYN GFP (B) at the high 
titre dosage and both AAV-5 GFAP GFP (C) and AAV-5 SYN GFP (D) at the low titre dosage 
of 2x107 transducing units no increased microglial immunoreactivity was detected.  
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Fig. 5.12: Reaction of microglia two weeks (2w) after unilateral injection of AAV-5 
GDNF in the striatum. Close-up of coronal sections stained for the microglial marker Iba-1, 
showing a reaction of microglia only after stereotaxic injection of AAV-5 GFAP GDNF (A) for 
the high titre dosage (2x108 transducing units). For AAV-5 SYN GDNF (B) at high titre 
dosage and both AAV-5 GFAP GDNF (C) and AAV-5 SYN GDNF (D) at low titre dosage of 
2x107 transducing units no increased microglial immunoreactivity was detected.  
             
 
 
 
 
 
 
 
 
 
 
 
(i) Stereotaxic injection itself induces astrogliosis; the presence of an AAV-5 and the 
overexpression of the transgenes GFP and GDNF potentiate it.  
(ii) The same level of astrogliosis was detected for astrocytic and neuronal transgene 
expression at high and low titre dosages.  
(iii) The recovery from astrogliosis argues against chronic activation of astrocytes. 
(iv) Evaluating microglial response to cell type-specific transgene expression, astrocytic GFP 
and GDNF expression at high titre dosage were the only paradigms to provoke a mild and 
short-term microgliosis. 
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5.1.3 GDNF-mediated neuroprotection in the subchronic MPTP model of PD 
GDNF or GFP expressing AAV-5 vectors were unilaterally injected into the striatum of two-
three month old Bl-6/J male wildtype mice and after two weeks MPTP was administered 
subchronically. Unilateral virus injection had the advantage of using the contralateral side as 
internal control for each animal. GDNF-mediated neuroprotection against MPTP toxicity was 
assessed by several means either two weeks or three months after MPTP applications, 
making it possible to distinguish between acute and regenerative effects of GDNF: 
stereological quantification of nigral DA neurons, quantitative assessment of TH positive 
striatal fibre density, determination of striatal levels of DA and its metabolites DOPAC and 
HVA and functional analysis of motor control by rotarod. The experiments were performed 
using 2x108 and 2x107 transducing units as viral titres in order to find out, which cell type-
specific GDNF expression is leads to the most protective and regenerative effects: astrocytic 
(AAV-5 GFAP GDNF) or neuronal GDNF (AAV-5 GFAP GDNF) expression.  
 
5.1.3.1 Stereological quantification of nigral DA neurons 
Stereological quantification was accomplished by counting both TH and Nissl-positive cells in 
the SNpc. Nissl stain served as a TH-independent neuronal marker. The counting revealed 
that expression of GFP in either astrocytes or neurons had no effect in comparison to the 
contralateral SN for the high titre dosage, true for both time points (Fig. 5.13 B-E and Fig. 
5.14 A,B). At two weeks after MPTP administration neuronal expression of GDNF resulted in 
a moderate but significant neuroprotection against MPTP toxicity in both the ipsilateral and 
the contralateral SNpc (Fig. 5.13 G and Fig. 5.14 A).  
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Fig. 5.13: DA SNpc neurons two weeks and three months after MPTP treatment for 
2x108 transducing units. Overviews of coronal sections stained for DA neurons of the SNpc 
by TH/DAB and Nissl. The MPTP-induced loss of SNpc neurons in the AAV-5 GFAP GFP 
and AAV-5 SYN GFP-injected control groups (B-E) can be prevented unilaterally in the AAV-
5 GFAP GDNF (F, H) and bilaterally in the AAV-5 SYN GDNF-treated animals (G, I) for both 
timepoints. Animals injected intraperitoneally with sodium chloride (NaCl) served as control 
(A) for the MPTP-treated animals (B, I). left: virus-injected side; right: control side 
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Fig. 5.14: Stereological counts for TH and Nissl-positive cells in the SNpc two weeks 
(A) and three months (B) after MPTP treatment for 2x108 transducing units. Animals 
injected intraperitoneally with sodium chloride (NaCl) served as control (A) for the MPTP-
treated animals. Bars represent mean ± SD; n = 4-5 animals for each group. Comparisons 
were made by ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001;  
left bar: virus-injected side; right bar: control side 
 
In contrast, astrocytic GDNF expression presented a complete preservation of DA SNpc 
neurons in the ipsilateral side, but no protection in the contralateral SNpc (Fig. 5.13 F and 
Fig. 5.14 A).  
At three months after MPTP administration and neuronal GDNF expression now almost pre-
lesion numbers of SNpc DA neurons in both brain hemispheres were counted (Fig. 5.13 I 
and Fig. 5.14 B). Although this increase in cell numbers showed only a tendency to 
significance, it indicates a certain recovery from MPTP toxicity – probably due to a short-term 
downregulation of TH in a fraction of DA neurons of the SNpc. Again, astrocytic GDNF 
expression exclusively resulted in an almost complete ipsilateral protection of DA neurons 
(Fig. 5.13 H and Fig. 5.14 B). 
Neither did stereology of nigral DA neurons show any effect compared to the contralateral 
control side for the low titre dosage and both time points for AAV-5 GFAP GFP and AAV-5 
SYN GFP treated animals (Fig. 5.15 B-E and Fig. 5.16 A, B). Two weeks after MPTP 
administration neuronal and astrocytic expression of GDNF resulted in an almost complete 
ipsilateral, but in no protection in the contralateral SNpc (Fig. 5.15 F, G and Fig. 5.16 A). 
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Three months after MPTP administration neuronal and astrocytic expression of GDNF still 
protects the ipsilateral SNpc (Fig. 5.15 H and Fig. 5.16 B). In AAV-5 SYN GDNF treated 
animals an additional but just rudimental protection of the contralateral SNpc was detected 
(Fig. 5.15 I and Fig. 5.16 B). Correlating the stereology results to the GDNF ELISA data, 
244pg GDNF/mg SNpc are enough to be long-term protective to the ipsilateral injection side, 
whereas 220pg GDNF/mg SNpc are not sufficient to protect the contralateral SNpc (Fig. 5.6, 
5.14 and 5.16). Thus, other factors in addition to the GDNF amount itself, can possibly make 
a crucial difference. One of these factors might be the anatomical position and connection to 
the injected tissue, resulting in alterations of signalling pathways and cellular responses. 
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Fig. 5.15: DA SNpc neurons two weeks and three months after MPTP treatment for 
2x107 transducing units. Overview of coronal sections stained for DA neurons of the SNpc 
by TH/DAB and Nissl. The MPTP-induced loss of SNpc neurons in the AAV-5 GFAP GFP 
and AAV-5 SYN GFP-injected control groups (B-E) can be prevented unilaterally in the AAV-
5 GFAP GDNF-treated animals for both time points (F, H) and in the AAV-5 SYN GDNF-
treated animals unilaterally for the two weeks (G) and rudimental bilaterally for the three 
months time point (I). Animals injected intraperitoneally with sodium chloride (NaCl) served 
as control (A) for the MPTP-treated animals (B, I).  left: virus-injected side; right: control side 
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Fig. 5.16: Stereological counts for TH and Nissl-positive cells in the SNpc two weeks 
(A) and three months (B) after MPTP treatment for 2x107 transducing units. Animals 
injected intraperitoneally with sodium chloride (NaCl) served as control for the MPTP-treated 
animals. Bars represent mean ± SD; n = 4-5 animals for each group. Comparisons were 
made by ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001;  left 
bar: virus-injected side; right bar: control side 
 
5.1.3.2 Assessment of striatal fibre density 
A rapidly progressive degeneration of DA nigrostriatal projections, affecting about 80% in the 
striatum, was detected by TH/DAB immunoreactivity two weeks after MPTP administration 
(Fig. 5.17 B-E and Fig. 5.19 A). The quantification of the striatal fibre density revealed that 
GFP expression in either astrocytes or neurons had no effect compared to the contralateral 
side regarding both time points (Fig. 5.17 B-E; Fig. 5.18 B-E and Fig. 5.19 A, B). In 
congruence with the stereology it was found that two weeks after MPTP administration 
unilateral neuronal GDNF expression protected DA fibres in both the ipsi- and contralateral 
striatum (Fig. 5.17 H-I and Fig. 5.19 A). Again, astrocytic GDNF expression resulted in 
almost complete but ipsilaterally restricted protection of DA projections (Fig. 5.17 F-G and 
Fig. 5.19 A). Three months after MPTP administration the protective effect is still ipsilaterally 
limited (Fig. 5.18 F-G and Fig. 5.19 B). Animals, which have been treated with AAV-5 SYN 
GDNF show ipsi- and contralateral protection (Fig. 5.18 H-I and Fig. 5.19 B). 
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Fig. 5.17: TH fibre density in the striatum two weeks after MPTP treatment for 2x108 
transducing units. Close-up of coronal sections stained for DA fibres of the striatum by 
TH/DAB. The MPTP-induced loss of TH-positive fibres in the AAV-5 GFAP GFP and AAV-5 
SYN GFP-injected control groups can be prevented unilaterally in the AAV-5 GFAP GDNF 
and bilaterally in the AAV-5 SYN GDNF-treated animals. Animals injected intraperitoneally 
with sodium chloride (NaCl) served as control (A) for the MPTP-treated animals (B, I) i.: 
virus-injected side n.i.: control side 
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Fig. 5.18: TH fibre density in the striatum three months after MPTP treatment for 2x108 
transducing units. Close-up of coronal sections stained for DA fibres of the striatum by 
TH/DAB. The MPTP-induced loss of TH-positive fibres detected in the AAV-5 GFAP GFP 
and AAV-5 SYN GFP-injected control groups is prevented unilaterally in the AAV-5 GFAP 
GDNF and bilaterally in the AAV-5 SYN GDNF-treated animals. Animals injected 
intraperitoneally with sodium chloride (NaCl) served as control (A) for the MPTP-treated 
animals (B, I);  i.: virus-injected side n.i.: control side 
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Fig. 5.19: Quantification of TH fibre density in the striatum two weeks (A) and three 
months (B) after MPTP treatment for 2x108 transducing units. Animals injected 
intraperitoneally with sodium chloride (NaCl) served as control for the MPTP-treated animals. 
Bars represent mean ± SD; n = 3-4 animals for each group. Comparisons were made by 
ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001;  left bar: virus- 
injected side; right bar: control side 
 
Furthermore, a comparison between contralateral control sides two weeks and three months 
after MPTP treatment reveals a moderate recovery of striatal DA innervation in AAV-5 GFAP 
GFP, AAV-5 SYN GFP and AAV-5 GFAP GDNF-treated animals (Fig. 5.20). Because at the 
two weeks time point for neuronal expression of GDNF also the contralateral side was 
protected, no regeneration was observed three months after MPTP treatment for this 
condition.  
The TH fibre density for the low titre dosage-treated animals has not been determined, 
because due to restricted animal numbers it was decided to use their striatum for the 
sensitive HPLC measurement of catecholamines (chapter 5.1.3.3). 
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Fig. 5.20:  Regeneration of TH fibre density in the striatum for 2x108 transducing units. 
A comparison between two weeks (first bar) and three months (second bar) fibre density of 
non-injected control sides shows a significant recovery in AAV-5 GFAP GFP, AAV-5 SYN 
GFP and AAV-5 GFAP GDNF-treated animals. Bars represent mean ± SD; n = 3-4 animals 
for each group. Comparisons were made by ANOVA followed by Tukey’s post hoc test. p* < 
0.05, p** < 0.01; left bar: virus-injected side; right bar: control side 
 
5.1.3.3 Measurement of striatal catecholamine levels 
The results revealed by fibre density analysis of the striatum for the high titre dosage were 
supported by the measurement of DA and its metabolites DOPAC and HVA as functional 
outcome. MPTP induced two weeks after injection a substantial depletion of DA. In addition, 
the amount of the DA metabolites DOPAC and HVA were decreased (Fig. 5.21 A, C, E). The 
astrocytic GDNF expression prevented DA, DOPAC and HVA depletion ipsilateral and 
neuronal GDNF in both hemispheres, although to a significantly higher extent in the 
ipsilateral striatum for HVA (Fig. 5.21 A, C, E).  
The degradation of DA to DOPAC and HVA is significantly enhanced in the ipsilateral side of 
AAV-5 GFAP GDNF-treated animals compared to control levels (DOPAC p < 0.01; HVA p < 
0,001). Neuronal GDNF induced only a heightened HVA level in comparison to the control 
group but for both the ipsi- and contralateral injection side (ipsilateral p < 0.001; contralateral 
p < 0.01) (Fig. 5.21 A, C, E). 
In contrast to the fibre density analysis three months after MPTP lesion the striatal 
concentrations of DA, DOPAC and HVA did not recover significantly in comparison to the two 
week level (Fig. 5.21). The unilateral prevention of astrocytic GDNF against DA, DOPAC and 
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HVA depletion was still present (Fig. 5.21 B, D, F). Furthermore, neuronal GDNF still 
protected both hemispheres to the same extent (Fig. 5.21 B, D, F). The primarily increased 
degradation of DA to DOPAC and HVA was reduced to control level for DOPAC but still 
significantly enhanced for HVA in the ipsilateral side of AAV-5 GFAP GDNF-treated animals 
and in both sides for AAV-5 SYN GDNF-treated animals (AAV-5 GFAP GDNF ipsilateral p < 
0.001; AAV-5 SYN GDNF ipsilateral p < 0.001; AAV-5 SYN GDNF contralateral p < 0.01) 
(Fig. 5.21 B, D, F).  
The analysis of striatal catecholamine concentrations for the low titre dosage again revealed 
a depletion of DA and its metabolites two weeks after MPTP treatment (Fig. 5.22 A, C, E). In 
contrast to the high titre dosage the astrocytic and neuronal GDNF expression prevented DA 
depletion exclusively ipsilateral (Fig. 5.22 A, C, E). In AAV-5 SYN GDNF-treated animals 
only DOPAC and HVA levels of the contralateral side were significantly higher compared to 
the contralateral side of AAV-5 GFAP GDNF-injected animals (Fig. 5.22 A, C, E). In contrast 
to the situation after high titre treatment exclusively HVA levels are significantly enhanced in 
the ipsilateral side and only for AAV-5 SYN GDNF-treated animals compared to control 
levels (p < 0.01) (Fig. 5.22 A, C, E).  
Three months after MPTP lesion striatal concentrations of DA, DOPAC and HVA for the low 
titre experiment did not recover in comparison to two week levels (Fig. 5.22). The ipsilateral 
prevention of astrocytic GDNF against DA, DOPAC and HVA depletion is still present. 
Neuronal GDNF went back to baseline levels for both hemispheres with a significantly higher 
extent in the ipsilateral striatum only for HVA (Fig. 5.22 B, D, F). Thus, the long-lasting 
bilateral protective effect of neuronal GDNF, which has been observed for the animals in the 
high titre experiment, was again established. Since this regeneration of catecholamine levels 
in the contralateral side of AAV-5 SYN GDNF animals could not be observed in the 
contralateral side of astrocytic GDNF expression, it could not have been due to normal 
striatal regenerative capacity, but seems rather to have been dependent on neuronally 
produced GDNF. The initially increased level of HVA in the AAV-5 SYN GDNF animals was 
still present three months after MPTP injection in comparison to the control group (p < 0.01) 
(Fig. 5.22 B, D, F).  
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Fig. 5.21: 2x108 transducing units: striatal catecholamine concentrations two weeks 
(A, C, E) and three months (B, D, F) after MPTP treatment. Bars represent mean ± SD; n 
= 4-5 animals for each group. Comparisons were made by ANOVA followed by Tukey’s post 
hoc test. p* < 0.05, p** < 0.01, p***< 0.001;  left bar: virus-injected side; right bar: control side 
 
Correlating the results of the fibre density analysis and catecholamine concentration 
measurement in the striatum to the ELISA results for GDNF, 812pg GDNF/mg striatum 
seems to be sufficient to deliver a structural and functional protection, whereas 124pg seems 
not to be a sufficient amount (Fig. 5.6, 5.19, 5.21). 
 
RESULTS 
  87 
  
0
1
2
3
4
5
6
7
8
9
10
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
0
1
2
3
4
5
6
7
8
9
10
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
***
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
0
0,5
1
1,5
2
2,5
3
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
***
***
**
*** **
***
***
**
***
**
**
***
***
***
**
***
***
**
***
******
***
***
***
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
***
*** ***
***
***
***
***
*
***
0
0,5
1
1,5
2
2,5
3
GFAP GFP GFAP GDNF syn GFP syn GDNF NaCl
***
***
******
******
**
**
n
g 
do
pa
m
in
e
 
/ m
g 
tis
s
u
e
n
g 
HV
A 
/ m
g 
tis
su
e
n
g 
D
O
PA
C 
/ m
g 
tis
su
e
A
FE
DC
B
 
Fig. 5.22: 2x107 transducing units: striatal catecholamine concentrations two weeks 
(A, C, E) and three months (B, D, F) after MPTP treatment. Bars represent mean ± SD; n 
= 4-5 animals for each group. Comparisons were made by ANOVA followed by Tukey’s post 
hoc test. p* < 0.05, p** < 0.01, p***< 0.001;  left bar: virus-injected side; right bar: control side 
 
5.1.3.4 Functional motor impairments 
Because MPTP application in mice leads to degeneration of DA neurons in the SNpc to only 
about 50% compared with 90% in the 6’OHDA Parkinson model, functional motor 
impairments are not easy to detect. It was tried to establish differences between 
experimental groups by performing behavior tests like Open Field, Rotation and Tight rope, 
without success. No effect of MPTP compared to sodium chloride vehicle i.p. injection was 
detected as a basis for any further data evaluation (data not shown). The same problem was 
present during the first Rotarod test with mice under high titre treatment (data not shown). 
However, finally a significant effect of MPTP for the accelerated rotarod performance of low 
titre treated mice could be observed (Fig. 5.23). The MPTP-induced impairment of 
performance in the AAV-5 GFAP GFP and AAV-5 SYN GFP-treated control groups is stable 
over the period of the experiment for three months. The AAV-5 GFAP GDNF-injected animal 
groups also worsen in performance directly after MPTP administration but improve over time 
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and return to baseline level. Animals with neuronal GDNF expression behave in a same way 
with the exception of being impaired shortly after MPTP treatment merely by trend (Fig. 
5.23). A measurement of untreated control animals in parallel to the differently treated 
groups, showed no alteration in performance (data not shown). 
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Fig. 5.23: Behavior on rotarod: 2x107 transducing units. Bars represent mean seconds on 
rotarod ± SD; n = 12 animals for each group (6 animals for the three months time point). 
Comparisons were made by ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, 
p***< 0.001;  first bar: pre MPTP treatment; second bar: one week after MPTP treatment; 
third bar: two weeks after MPTP treatment; fourth bar: three months after MPTP treatment. 
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(i) Long-term neuronal and astrocytic GDNF expression protected ipsilateral DA SNpc neurons 
to almost 100% from MPTP toxicity, even under conditions of low dosage GDNF.  
(ii) Only high amounts of neuronally produced GDNF also protect the contralateral SNpc, 
arguing for a neuron-specific mechanism activated only by a threshold amount of GDNF. 
(iii) Under conditions of high dosage GDNF the MPTP-induced loss of TH-positive fibres in the 
AAV-5 GFP injected control groups was prevented unilaterally through astrocytic and 
bilaterally through neuronal GDNF expression. 
(iv) Three months after MPTP treatment a moderate recovery of striatal DA innervation was  
detected. 
(v) Long-term neuronal and astrocytic GDNF expression provided ipsilateral protection from 
DA, HVA, DOPAC depletion in the striatum, even under conditions of low dosage GDNF. 
(vi) Both high and low amounts of neuronally produced GDNF also protected the contralateral 
levels of DA, DOPAC and HVA from depletion in a long-term view. 
(vii) Three months after MPTP lesion the striatal concentrations of DA, DOPAC and HVA did 
not recover significantly, independently of the GDNF concentration. 
(viii) Overexpression of GDNF induces an increased metabolism of DA to DOPAC and HVA. 
(ix) Regarding rotarod performance, mice were impaired after MPTP treatment and both 
astrocytic and neuronal produced GDNF protected from that disability with comparable 
efficiency. 
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5.2 RET signalling: the basic requirement for GDNF-mediated protection against MPTP 
toxicity 
5.2.1 Astrocytic GFP and GDNF short- and long-term expression in DAT-Cre, Ret lx 
and DAT Ret lx/lx  mice  
The striatal injection of 2x108 AAV-5 GFAP GFP resulted in a broad spatial GFP expression 
without differences between genotypes DAT-Cre, Ret lx and DAT Ret lx/lx  for both time points 
(Fig 5.24 and 5.25). The transduced areas encompass the entire striatum and parts of the 
cortex, sparing of the corpus callosum. GFP expression was exclusively observed in 
astrocytes for all three genotypes DAT-Cre, Ret lx and DAT Ret lx/lx (Fig. 5.26). 
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Fig. 5.24: Striatal GFP expression two weeks after AAV-5-mediated gene transfer. 
Overview pictures of coronal sections showing anterior (A-C) and posterior (D-F) striatal GFP 
expression two weeks after AAV-5 infection, expressing GFP under the control of the GFAP 
promoter for 2x108 transducing units in DAT-Cre (A, D), Ret lx (B, E) and DAT Ret lx/lx (C, F) 
animals. For both the anterior and posterior striatal GFP expression no differences regarding 
genotypes are observable. 
RESULTS 
  91 
       
A
AV
 
G
FA
P 
G
FP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
m
o
n
th
s
R
DAT-Cre DAT Ret lx/lxRet lx
A
FED
CB
 
 
 
Fig. 5.25: Striatal GFP expression three months after AAV-5-mediated gene transfer. 
Overview pictures of coronal sections showing anterior (A-C) and posterior (D-F) striatal 
GFP expression three months after AAV-5 infection, expressing GFP under the control of 
the GFAP promoter for 2x108 transducing units in DAT-Cre (A, D), Ret lx (B, E) and DAT 
Ret lx/lx animals (C, F). For both the anterior and posterior striatal GFP expression no 
differences in comparison to the two weeks expression level and between genotypes are 
observable. 
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The striatal injection of 2x108 AAV-5 GFAP GDNF resulted in the same broad spatial GDNF 
expression without differences between genotypes DAT-Cre, Ret lx and DAT Ret lx/lx for both 
time points (Fig. 5.27 M-X). Striatal slices from AAV-5 GFAP GFP-infected mice served as 
negative control (Fig. 5.27 A-L).  
In the SNpc retrograde transport of GDNF from the striatum is restricted to the ipsilateral side 
and remains stable over time without differences between genotypes (Fig. 5.28 M-X). SNpc 
slices from AAV-5 GFAP GFP-infected mice served as negative control (Fig. 5.28 A-L). 
 
Fig. 5.26: Cell-specific GFP expression after AAV-5-mediated gene transfer (2x108 
infectious particles, two weeks after infection). Close-up of the striatum showing AAV-5 
GFAP GFP expression exclusively in astrocytes defined by colocalization with GFAP-positive 
cells (astrocytic marker) for the three genotypes DAT-Cre (A), Ret lx (B) and DAT Ret lx/lx (C). 
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Fig. 5.27: GDNF expression in the striatum of infected mice. Overview pictures of coronal 
sections showing GDNF immunoreactivity by DAB staining two weeks (A-F; M-O, S-U) and 
three months (G-L; P-R, V-X) after unilateral AAV-5 GFAP GFP (A-L) and AAV-5 GFAP 
GDNF (M-X) infection. Pictures are shown with the injected side of the anterior (A-C, G-I; M-
R) and posterior striatum (D-F, J-L; S-U, V-X) on the left for 2x108 transducing units. No 
differences regarding the negative outcome for GFP-expressing animals and the ipsilateral 
restricted positive signal for GDNF-expressing animals can be detected between time points 
and the three genotypes DAT-Cre (A, D, M, S; G, J, P, V), Ret lx (B, E, N, T; H, K, Q, W) and 
DAT Ret lx/lx (C, F, O, U; I, L, R, X). 
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Fig. 5.28: GDNF expression in the SNpc of infected mice. Overview pictures of coronal 
sections showing GDNF immunoreactivity by DAB staining two weeks (A-F; M-O, S-U) and 
three months (G-L; P-R, V-X) after unilateral AAV-5 GFAP GFP (A-L) and AAV-5 GFAP 
GDNF (M-X) infection. Pictures are shown with the injected side of the anterior (A-C, G-I; M-
R) and posterior SNpc (D-F, J-L; S-X) on the left for 2x108 transducing units. No differences 
regarding the negative outcome for GFP-expressing animals and the ipsilateral restricted 
positive signal for GDNF-expressing animals can be detected between time points and the 
three genotypes DAT-Cre (A, D, M, S; G, J, P, V), Ret lx (B, E, N, T; H, K, O, W) and DAT 
Ret lx/lx (C, F, Q, U; I, L, R, X). 
 
 
 
 
 
 
 
 
 
 (i) AAV-5 GFAP GFP and AAV-5 GFAP GDNF injection assured long-term astrocytic 
transgene expression restricted to the injected side of the striatum and an ipsilateral retrograde 
transport of GDNF to the SNpc without differences between the genotypes DAT-Cre, Ret lx 
and DAT Ret lx/lx. 
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5.2.2 GDNF-mediated protection of the nigro-sriatal system against MPTP toxicity in 
the presence and absence of the RET receptor 
AAV-5 GFAP GFP and AAV-5 GFAP GDNF were unilaterally injected into the striatum of 
two-three month old DAT-Cre, Ret lx and DAT Ret lx/lx mice and two weeks later MPTP was 
administered subchronically. The unilateral injection of the virus offered the usage of the 
contralateral side as internal control for each animal. GDNF-mediated neuroprotection 
against MPTP toxicity was assessed by several means either two weeks or three months 
after MPTP applications in order to be capable to differentiate between acute and 
regenerative effects of GDNF: stereological quantification of DA SNpc neurons, quantitative 
determination of TH positive striatal fibre density (cooperation partner Dr. Edgar Kramer, 
Center for Molecular Neurobiology Hamburg (ZMNH)) and identification of striatal levels of 
DA and its metabolites DOPAC and HVA.  
 
5.2.2.1 Quantification of DA SNpc neurons by stereology 
Stereological quantification of nigral DA neurons revealed that expression of GFP in 
astrocytes had no effect compared with the contralateral side for both time points and all 
genotypes (Fig. 5.29 D-F, Fig. 5.30 D-F and Fig. 5.31). Two weeks after MPTP 
administration astrocytic expression of GDNF in DAT-Cre and Ret lx mice resulted in a 
significant ipsilateral neuroprotection, but there was no protection in the contralateral SNpc 
(Fig. 5.29 G-H and Fig. 5.31 A). In contrast, GDNF did not show any protective effect to the 
SNpc DA neurons of DAT Ret lx/lx mice, in which the RET receptor is missing (Fig. 5.29 I and 
Fig. 5.31 A).   
At three months after MPTP administration again only the SNpc of DAT-Cre and Ret lx 
control mice was ipsilateral protected by astrocytic GDNF expression (Fig. 5.30 G-H and Fig. 
5.31 B). DAT Ret lx/lx mice were completely hit by MPTP toxicity with no difference between 
them and the AAV-5 GFAP GFP- treated animals (Fig. 5.30 I and Fig. 5.31 B).  
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Fig. 5.29: DA SNpc neurons two weeks after MPTP treatment. Overview of coronal 
sections stained for DA neurons of the SNpc by TH/DAB and Nissl. The MPTP-induced loss 
of SNpc neurons in all three AAV-5 GFAP GFP-injected control groups (D-F) can be 
prevented ipsilaterally in the AAV-5 GFAP GDNF (G-I) -treated DAT-Cre (G) and Ret lx (H) 
animals but not for the DAT Ret lx/lx (I) group. Animals injected intraperitoneally with sodium 
chloride (NaCl) served as control (A-C) for the MPTP-treated animals (D, I). left: virus- 
injected side for 2x108 transducing units; right: control side 
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Fig. 5.30: DA SNpc neurons three months after MPTP treatment. Overview of coronal 
sections stained for DA neurons of the SNpc by TH/DAB and Nissl. The MPTP-induced 
stable loss of SNpc neurons in all three AAV-5 GFAP GFP-injected control groups (D-F) can 
be prevented long-term ipsilaterally in the AAV-5 GFAP GDNF (G-I) -treated DAT-Cre (G) 
and Ret lx (H) animals but not in the DAT Ret lx/lx (I) group. Animals injected intraperitoneally 
with sodium chloride (NaCl) served as control (A-C) for the MPTP-treated animals (D, I). left: 
virus-injected side for 2x108 transducing units; right: control side 
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Fig. 5.31: Stereological cell counts for TH and Nissl-positive cells in the SNpc two 
weeks (A) and three months (B) after MPTP treatment. Animals injected intraperitoneally 
with sodium chloride (NaCl) served as control for the MPTP-treated animals. Bars represent 
mean ± SD; n = 3-6 animals for each group. Comparisons were made by ANOVA followed by 
Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001; GFP: AAV-5 GFAP GFP-injected 
animals (2x108 transducing units); GDNF: AAV-5 GFAP GDNF-injected animals (2x108 
transducing units); left bar: virus-injected side; right bar: control side 
 
5.2.2.2 Quantification of striatal catecholamine concentrations by HPLC 
Two weeks after MPTP treatment HPLC analysis revealed a substantial depletion of DA and 
its metabolites DOPAC and HVA without differences between genotypes (Fig. 5.32). 
Astrocytic GDNF expression prevented DA, DOPAC and HVA depletion ipsilateral in DAT-
Cre and Ret lx control mice but not in DAT Ret lx/lx mice (Fig. 5.32). The degradation of DA to 
DOPAC and HVA was significantly enhanced in the ipsilateral side of AAV-5 GFAP GDNF- 
treated DAT-Cre and Ret lx animals compared to control levels. This increased DA 
metabolism rate was not detected in the DAT Ret lx/lx animals (Fig. 5.32 B, C).  
Three months after MPTP lesion the striatal concentration of DA, DOPAC, and HVA 
recovered in comparison to the two week level in DAT-Cre and Ret lx animals (Fig. 5.33 and 
5.34). The ipsilateral protection of DOPAC and HVA levels in both control strains as well as 
the increased metabolism rate could still be observed. Reproducing already published data, 
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striatal catecholamine levels of DAT Ret lx/lx animals did not recover at all (Fig. 5.33 and 5.34) 
(Kowsky et al., 2007). 
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Fig. 5.32: Striatal catecholamine concentrations two weeks after MPTP treatment. Bars 
represent mean ± SD; n = 3-6 animals for each group. Comparisons were made by ANOVA 
followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001; GFP: AAV-5 GFAP 
GFP-injected animals (2x108 transducing units); GDNF: AAV-5 GFAP GDNF-injected 
animals (2x108 transducing units); left bar: virus-injected side; right bar: control side 
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Fig. 5.33: Striatal catecholamine concentrations three months after MPTP treatment. 
Bars represent mean ± SD; n = 3-6 animals for each group. Comparisons were made by 
ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** < 0.01, p***< 0.001; GFP: AAV-5 
GFAP GFP-injected animals (2x108 transducing units); GDNF: AAV-5 GFAP GDNF-injected 
animals (2x108 transducing units);  left bar: virus-injected side; right bar: control side 
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Fig. 5.34: Regeneration of striatal catecholamine concentrations. A comparison between 
two weeks (first bar) and three months (second bar) striatal catecholamine concentrations of 
non-injected control sides is shown. Bars represent mean ± SD; n = 3-6 animals for each 
group. Comparisons were made by ANOVA followed by Tukey’s post hoc test. p* < 0.05, p** 
< 0.01; GFP: AAV-5 GFAP GFP-injected animals (2x108 transducing units); GDNF: AAV-5 
GFAP GDNF-injected animals (2x108 transducing units); left bar: virus-injected side; right 
bar: control side 
 
 
 
 
 
 
 
 
 
 
 
 
 (i) Astrocytic GDNF expression mediates short- and long-term protection of DA SNpc neurons 
from MPTP toxicity if they express the RET receptor.  
(ii) Astrocytic GDNF expression prevented DA, DOPAC and HVA depletion after MPTP 
intoxication ipsilateral in DAT-Cre and Ret lx control mice but not in DAT Ret lx/lx mice. 
(iii) Three months after MPTP lesion the striatal concentration of DA, DOPAC, and HVA 
recovered in DAT-Cre and Ret lx animals but not in DAT Ret lx/lx mice. 
 
There is no alternative to an intact GDNF-RET mediated signalling in the nigrostriatal 
sytem, this being a prerequisite for the protective potential of GDNF and the natural 
regenerative capacity of the striatum after MPTP lesion in mice. 
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6. Discussion 
6.1 Astrocytes or neurons as source for GDNF-mediated protection of the nigrostriatal 
system against MPTP toxicity mice 
 
6.1.1 Transduction properties of the AAV-5 serotype 
Wild-type (wt) AAV is not known to be associated with any disease in humans or mammals 
and shows no inherent vector toxicity. A short viral production time and long-lasting 
transgene expression from the recombinant genome are further benefits of these vector 
systems (Shevtsova et al., 2005; Kügler et al., 2003; Peel and Klein, 2000). Thus, 
recombinant AAV vectors are considered to have one of the highest biosafety rankings 
among viral vectors (Mandel et al., 2008). The most extensively studied serotypes are AAV-
2, the only AAV serotype in active clinical trials, and AAV-5 (Hildinger and Auricchio 2004). 
This strategy has been challenged recently by the failure of AAV-2 based vectors to escape 
human immune responses in patients with pre-existing immunity to AAV-2 (Hasbrouck and 
High et al., 2008). It is currently unknown if such pre-existing immunity, which is present in 
the majority of humans, might impact on trials delivering the vector into the immuno-
specialized brain. It is also unknown if failure of the GDNF-relative neurturin expressed from 
an AAV-2 vector in the brain of PD patients was due to immune related problems or to an 
inefficiency of the protein (Bartus 2009, Scientific Symposium 113: Late stage industry 
clinical trials). In any case, of all known AAV serotypes the serotype-5 capsid is the least 
homologous to AAV-2 and pre-clinical studies have already demonstrated that AAV-5 can be 
re-delivered into rodent CNS in animals pre-immunized against AAV-2 (Peden et al., 2004). It 
appears that cells transduced via AAV-2 present capsid peptides for a much longer period 
than other serotypes (Lowenstein et al., 2007; Thomas et al., 2009). Indeed, there is 
apparently little to no brain immune response to the AAV-5 capsid (Manfredsson et al., 
2009). Thus, AAV-5 based vectors may hold great promise for clinical applicability. In this 
study the AAV-5 capsid provoked an astroglial reaction (detected via GFAP staining), which 
could be reduced to a weak, short-lasting effect by decreasing the viral titre (Fig. 5.7-5.10). 
GFAP is the principal intermediate filament in mature astrocytes of the CNS and a member 
of the cytoskeletal protein family. It is thought to be important in modulating astrocyte motility 
and shape by providing structural stability to astrocytic processes. In the CNS of higher 
vertebrates, following an injury astrocytes become reactive and respond with astrogliosis, 
characterized by a rapid synthesis of GFAP (Eng et al., 2000). The observed recovery from 
astrogliosis three months after stereotaxic injection argues against chronic activation of 
astrocytes (Fig. 5.9-5.10). Since simply the stereotaxic injection of sodium chloride caused 
astrogliosis, only slightly enhanced in the presence of a non-expressing AAV-5, the effect of 
AAV-5 itself on astrogliosis has to be ranked as cumulative but non-initiative.  
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Activation of microglia due to inflammation can be detected by staining against Iba-1, which 
is specifically expressed in microglia. The detection of Iba-1 upregulation makes it possible to 
discriminate between resting and activated microglia. Upregulation of Iba-1 could be 
selectively but weakly and only detected in the acute phase after GFP and GDNF expression 
in astrocytes. No such reaction was detectable after neuronal transgene expression or after 
transduction with a vector not expressing a transgene. Since both EGFP and GDNF 
expression provoked micgroglial activation, no potentially beneficial or detrimental effect of 
this activation could have influenced the outcome of this study (Fig. 5.11-5.12).  
One of the major causes of the inconsistend outcome of GDNF in clinical trials has been 
suggested to relate to the distribution of GDNF in the putamen by different infusion 
techniques (Manfredsson et al., 2009). Some of the investigators involved in these clinical 
studies have recently stated that gene transfer is likely a potentially better alternative delivery 
method for GDNF (Peterson and Nutt 2008). Since AAV-5 allows for a drastically increased 
spread of the vector compared to AAV-2 (Shevtsova et al., 2005), the application of AAV-5 
might circumvent the problem. Indeed, in this study stereotaxic injection of AAV-5 resulted in 
long-lasting, broad spatial distribution of transduced cells over the entire striatum, even after 
a 10-fold reduction of the viral titre, but with reduced transgene expression per cell and less 
density of transduced cells (Fig. 5.1 and 5.2). 
 
6.1.2 Cell type-specific expression through the control of the GFAP or synapsin 
promoter 
The possibility of implementing a transgene expression exclusively in target cells based on 
cell specific promoters is a further benefit of AAV vector systems (Shevtsova et al., 2005). 
The type of cells transduced can play an important role for the GDNF effect and astrocytes, 
which perform many functions critical for neuronal survival, are very promising candidates for 
GDNF delivery (Sandhu et al., 2009; Jakobsson et al., 2004; Byrd et al., 2004; Dringen and 
Hirrlinger 2003; Wilson et al., 1997).   
The various AAV serotypes differ in structure and bind unique membrane-associated 
receptors, resulting in differences in cell tropism. The AAV-5 vector was found to be able to 
transduce both neurons and astrocytes, being only transcriptionally targeted to either one of 
these cell types in a very efficient way (Shevtsova et al., 2005). The results of this study 
support these data by demonstrating that AAV-5 tropism is not restricted to neurons as in the 
case for the AAV-2 serotype. In contrast, astroglial cells are transduced with a very high 
efficacy given that transgene expression was driven by the GFAP promoter (Fig. 5.3 A). 
Efficient transduction of astrocytes by AAV vectors has been demonstrated only very recently 
but is still hampered by considerable co-expression in neurons (Koerber et al., 2009) and the 
need for either very high vector dosage (Lawlor et al., 2009) or systemic vector application in 
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neonates (Foust et al., 2009). In contrast, the AAV-5 based strategy presented here 
demonstrated very low vector dosages to be still highly efficient in astrocytic transgene 
expression, while high titres were still entirely astrocyte-specific. Neurons are transduced 
specifically and with a very high efficacy given that transgene expression was driven by the 
SYN promoter (Fig 5.3 B), without restrictions for low vector dosages.  
 
6.1.3 Cell type-specific expression of GDNF: impacts on GDNF transport and 
distribution within the brain  
It was hypothesised that GDNF produced by astrocytes might be as effective as neuronal 
GDNF. Although neurons are the physiological cellular basis of striatal GDNF expression 
during development of the brain (Oo et al., 2005), astrocytes become the predominant 
source of GDNF in the adult brain upon injury (Bresjanac and Antauer 2000; Nakagawa and 
Schwartz 2004; Chen et al., 2006).  
GDNF is transported retrogradely from the striatum to the DA cell bodies in the SNpc 
(Barroso-Chinea et al., 2005; Oo et al., 2005; Kordower et al., 2000; Choi-Lundberg and 
Bohn 1995; Tomac et al., 1995). A quantitative GDNF determination by ELISA two weeks 
upon viral injection in the striatum revealed that the transport of GDNF to the ipsilateral SN 
was much more efficient if GDNF was produced by neurons for both high and low viral titres 
(Fig 5.6). In the ipsilateral striatum only little differences in the amount of GDNF were 
detected after high and no differences upon injection of low viral titres (Fig. 5.6).  
AAVs can also be transported retrogradely (Kaspar et al., 2003; Pirozzi et al., 2006). 
However, a comparison of the retrograde transport efficiency between serotypes revealed 
AAV-1 to have the greatest efficiency after intramuscular injection. Serotypes 2-6 showed a 
low efficiency for retrograde transport (Hollis et al., 2008). Thus, in this study the presence of 
GDNF in the SN after striatal virus injection is probably not due to the retrograde transport of 
the AAV-5.  
In the case of high GDNF expression levels contralateral nigrostriatal structures showed 
increased GDNF levels; GDNF produced by neurons showed a tendency to a more efficient 
transport to the contralateral Striatum than GDNF produced by astrocytes, probably due to 
the fact that neurons are able to secrete GDNF not only from their cell bodies but also from 
pre-synaptic sites, which can be found at remote areas, i.e. the contralateral hemisphere.   
Thus, in addition to transport of GDNF from the ipsilateral striatum to the ipsilateral SNpc, 
tracks others than those, namely from the ipsilateral to the contralateral striatum and SN or 
from the SN to the striatum might be in use in the presence of high amounts of GDNF. 
Indeed, anterograde transport of GDNF to the striatum after nigral AAV injection (Arvidsson 
et al., 2003; Kordower et al., 2000) and contralateral effects of high amounts of GDNF were 
described previously (Peterson and Nutt 2008; Slevin et al., 2007; Eslamboli et al., 2005). 
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The explanation of how GDNF reaches all the remote sites in this experimental setup is 
currently a suggestion only. However, GDNF expressed by neurons was detected to a strong 
extent in areas outside the SNpc, e.g. the SNpr (Fig. 5.4 H/J and Fig. 5.5 F/H), an indication 
for an anterograde delivery of GDNF to the midbrain.  
 
6.1.4 Astrocytic versus neuronal GDNF: Which cellular source of GDNF is favourable 
for a PD gene therapy? 
The results of this study suggest that expressing the neurotrophin GDNF by neurons is more 
favourable than expression of GDNF by astrocytes in an established animal model of PD. 
Even under low dosage GDNF a long-term prevention of the MPTP-induced reduction in DA 
neurons of the SNpc, DA positive fibres and catecholamine levels in the striatum was 
effected unilaterally through astrocytic and bilaterally through neuronal GDNF expression 
(Fig. 5.14, 5.16, 5.19, 5.21, 5.22). Possible actions by which GDNF could provide positive 
effects on the nigrostriatal system in the model of this study are 1) promotion of survival for 
remaining neurons; 2) restoration of neuronal function regarding the DA phenotype; 3) 
induction of DA neurogenesis in the SN; or 4) stimulation of the DA system (Peterson and 
Nutt 2008). However, the first hypothesis is most likely the protective effect of GDNF 
(reviewed by Manfredsson et al., 2009). 
Although delivery of bilateral nigrostriatal protection by neuronal expression of GDNF 
appears to be an approach with high therapeutic efficacy, it reveals serious safety concerns.  
Under normal conditions GDNF shows highest expression levels during development and 
greatly reduced expression in the adult brain (Saavedra et al., 2008). Adult 
catecholaminergic neurons crucially depend on GDNF signalling in the adult brain (Pascual 
et al., 2008) and the prototype receptors GFRα and RET are expressed throughout the adult 
brain (Sarabi et al., 2003; Glazner et al., 1998). Furthermore, GDNF has been proposed to 
be able to induce signalling through additional receptor systems like NCAM and integrins 
(Sariola and Saarna 2003).  
The hypothesis that GDNF probably only induces beneficial effects on remaining nigrostriatal 
DA neurons, led to the conclusion regarding the failure of clinical trials that the patients in 
those trials likely had too little of their nigrostriatal dopaminergic tract intact for the GDNF to 
induce therapeutic effects. Performance of future Phase II trials in earlier stage patients or 
higher and effectively distributed GDNF amounts would be a better test of the clinical efficacy 
for GDNF in PD (Manfredsson et al., 2009; Peterson and Nutt 2008). However, currently 
gene therapy is an irreversible process and should the putative need for higher dosages of 
GDNF and the wish to target younger patients in order to develop a successful strategy for 
Parkinson’s patients be realized, serious side effects may be imposed by the dissemination 
of a potent neurotrophic factor to areas outside the affected nigrostriatal system 
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(Manfredsson et al., 2009). The detailed wiring of the human brain has not at all been fully 
elucidated (Guye et al., 2008), and it is unfeasible to predict into which distant CNS nuclei 
caudate and putamenal neurons may project and deliver GDNF after being transduced by a 
neuronal gene therapy vector. Further, the long-term presence of a neurotrophic factor may 
result in an activation of low affinity receptors, in turn inducing unforeseeable signalling 
events. For example, in monkey, cat and mouse the nigro-collicular projection originates in 
the substantia nigra pars reticulata, links the basal ganglia to the sensorimotor layers of the 
superior colliculus and is crucially involved in promotion of orienting behaviour (Kaneda et al., 
2008; Harting et al., 2001; Huerta et al., 1991). The functional capabilities of these neurons 
might eventually be modified if exposed long-term to a potent neurotrophic factor as seen 
after neuronal GDNF expression in the striatum. Also, weight loss, a common side effect in a 
number of clinical trials and currently the best-characterized off-target effect of GDNF, has 
recently been suggested as being caused by the secretion of neuron-expressed GDNF from 
un-myelinated axons in the medial forebrain bundle and activation of hypothalamic 
corticotriopin releasing hormone secreting neurons (Manfredsson et al., 2009). 
In contrast, in no case did striatal astrocyte-derived GDNF exert measurable biological 
effects outside the target structures (ipsilateral striatum and nigra), not even in the case of 
injection of high titre of virus. Astrocyte-derived GDNF could only be transported 
retrogradely, resulting in only 10% of the total striato-nigral GDNF transport as compared to 
neuronal expression. None-the-less, astrocyte-derived GDNF was as efficient as neuron-
derived GDNF in preventing degeneration of nigral DA neurons, their striatal terminals and 
their striatal DA content from MPTP toxicity. Thus, in the ipsilateral nigrostriatal projection the 
astrocytic expression of GDNF provided an essential safety criterion by avoiding remote 
biological effects without any restriction on therapeutic efficacy. While lowering the vector 
titre somewhat improved the safety profile of neuronal GDNF expression, it still resulted in a 
pronounced impact on contralateral neurotransmitter synthesis. At two weeks after MPTP a 
four-fold increase of GDNF over control levels in the contralateral nigra and a two-fold 
increase in the contralateral striatum showed no benefit but were sufficient to fully restore 
striatal DA levels after long-term (three months) expression, demonstrating that some 
biological effects of GDNF may take their time to build up. In contrast, after astrocytic GDNF 
expression, a 13-fold increase of GDNF in the ipsilateral nigra was fully protective (low titre 
group), but the same increase in GDNF levels did not show any biological effect in the 
contralateral nigra (in the high titre group), exemplifying that it is not only the absolute level of 
GDNF which might exert biological effects but also the mode of delivery (Fig. 5.6, 5.14 and 
5.16). Interestingly, retrogradely transported GDNF is widely accepted to have protective 
effects (reviewed by Kirik et al., 2004), while anterogradely transported GDNF does not have 
any protective potenial or is even neurotoxic (Arvidsson et al., 2003; Kordower et al., 2000). 
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This fact leads to the assumption of a modifying mechanism, depending on the mode of 
GDNF transport, which influences the protective capacity of GDNF. 
Three months after MPTP treatment a moderate recovery of striatal DA innervation was 
detected (Fig. 5.20), whereas no such recovery was observed regarding striatal 
concentrations of DA, DOPAC and HVA for all MPTP treated animal groups (Fig. 5.21, Fig. 
5.22). It is known that structural striatal recovery starts earlier than functional recovery of 
catecholamine levels (Mitsumoto et al., 1998). Thus, in this model striatal recovery was 
indeed already initiated but obviously had not enough time to show its full regenerative 
capacity.  
Overexpression of GDNF induced increased levels of DOPAC and HVA (Fig. 21, Fig. 22). 
This GDNF effect on the DA metobilsm to DOPAC and HVA has been also observed in 
another study, starting from certain amounts of GDNF (Eslamboli et al., 2005). 
The results presented in this study are valid for the specific MPTP mouse model, but may 
differ in other models. In the absence of a perfect transgenic mouse model for PD that would 
combine the degeneration of DA synapses and neurons with the cytoplasmatic aggregation 
of insoluble α-synuclein, the MPTP model still appears to be the preferential model for PD 
(Tande et al., 2006; Dawson 2002). However, a study using unilateral, striatal AAV-CBA 
GDNF expression in primates came to similar observations: 14ng GDNF/mg tissue, 
representing about the double amount of GDNF as in the low titre study (Fig. 5.6), led to a 
bilateral increase in TH protein levels and activity, which could be restricted ipsilaterally by 
drastically decreasing the amount of GDNF (Eslamboli et al., 2005). Similarly, unilateral 
GDNF infusions into the intact midbrain led to profound bilateral changes in DA physiology 
and decrease in feeding behavior (Hudson et al., 1995).  
Moreover, in this study 244pg GDNF/mg SNpc (13-fold increase to background level) and 
812pg GDNF/mg striatum (25-fold increase to background level) seemed to be enough to 
deliver a structural and functional protection (Fig. 5.6, 5.16, 5.19, 5.21). Higher amounts of 
GDNF did not provide an increased protective quality (Fig. 5.6, 5.14, 5.19, 5.21). 
Interestingly, in an in vitro study, although astrocytes transduced with a cytomegalovirus 
(CMV) promoter secrete ~ 10-fold higher concentrations of GDNF in comparison to cells 
transduced with the GFAP promoter (already 35-fold increase to background level), a 
concomitant increase in neuroprotection against 6-OHDA was not observed (Sandhu et al., 
2009). This indicates that higher amounts of GDNF are not stringently beneficial since they 
might also account for side effects (Arvidsson et al., 2003; Gill et al., 2003; Zurn et al., 2001; 
Kordower et al., 1999). However, there seems to exist a threshold under which GDNF is no 
longer protective (Lindgren et al., 2008; Costa et al., 2001, Zhang et al., 1997). For example, 
in this study 124pg GDNF/mg striatum seemed to be under that threshold (Fig. 5.6, 5.19, 
5.21). This concentration-dependent effect of GDNF can be partly explained by opposite 
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effects of low and high striatal GDNF levels on the TH expression in DA neurons (Kordower 
et al 2000; Georgievska et al., 2002 a and b).  
 
6.2 The presence of the RET receptor as prerequisite for the protective and 
regenerative capacity of GDNF 
Tyrosine kinases signal through the MAPK and/or the PI3-kinase pathway. For the activation 
of PI3-kinase/Akt higher concentrations are necessary than for the activation of the MAPK 
ERK1/2, and only the higher concentration provides protection against MPTP toxicity 
(Lindgren et al., 2008). GDNF may thus have qualitatively different effects on RET-induced 
signalling at different concentrations. Therefore, it was decided to use the high titre dosage of 
2x108 transducing units producing high amounts of GDNF. Moreover, AAV-5 GFAP GFP or 
AAV-5 GFAP GDNF were unilaterally injected, thus restricting the effects of GDNF to the 
injected brain side and being able to use the contralateral side as clear internal control for 
each mouse. 
A conditional RET-deficient mouse model was used and found that RET-dependent 
signalling mediated through striatal GDNF overexpression protected nigral DA neurons from 
MPTP-induced degeneration and depletion of catecholamines in the striatum. The 
overexpression of GDNF in mice with RET deficiency did not protect against MPTP toxicity 
(Fig. 5.31, 3.32). Furthermore, reproducing the results of a previous study in this lab, the 
recovery of striatal catecholamine levels between two weeks and three months after MPTP 
intoxication was dependent on the presence of RET (Fig. 5.34). One explanation, why no 
such a recovery was seen in this study about astrocytic versus neuronal production of GDNF 
in C57Bl/6J mice (Fig. 5.21, Fig. 5.22) might possibly be that the susceptibility to MPTP 
depends on MAO-B activity and on the capacity to sequester MPP+ into synaptic vesicles via 
the vesicular monoamine transporter (VMAT) as cellular protective mechanism, probably 
based on the ratio of DAT and VMAT (Miller et al., 1999; Takahashi et al., 1997; Liu et al., 
1992). This might be an explanation for mouse strains reacting differently to the toxin. 
Striatal recovery of catecholamine levels can generally be due to (i) neurogenesis of DA 
neurons in the SNpc, outgrowing new axonal connections to the striatum; (ii) recovery of 
axons originating from the somata of injured cells; or (iii) a sprouting response in the terminal 
field of the nigrostriatal pathway by surviving DA axons. To date no evidence for the 
neurogenesis of DA neurons after lesioning of the nigrostriatal pathway exists (Frielingsdorf 
et al., 2004). Further, in a previous study no outgrowth of axons close to the SNpc, but an 
increased DA fibre density in the striatum was shown (Kowsky et al., 2007). Thus the above 
mentioned third mechanism has to be responsible for the observed striatial restoration of 
catecholamine levels. In RET deficient mice the overexpression of GDNF was not able to 
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induce recovery of striatal catecholamine levels three months after MPTP intoxication (Fig. 
5.34).  
These results are unlikely to be influenced by factors that may alter MPTP toxicity because 
the following factors did not differ between genotypes: (i) the basal number of DA neurons, 
the primary density of TH-positive and DAT-positive fibres and the seminal expression of 
DAT; (ii) the conversion of MPTP to MPP+; (iii) the glial response (Kowsky et al., 2007); and 
(iv) the GFP and GDNF expression levels (Fig. 5.24, 5.25, 5.27, 5.28).  
NCAM has been proposed as an alternative signalling receptor for GDNF (Paratcha et al., 
2003) and RET independent GDNF signalling has been already described (Sariola and 
Saarma 2003). The results of this study suggest that besides the classical GDNF-mediated 
activation of RET, no alternative GDNF receptors are involved in the protection and 
regeneration of the nigrostriatal system against MPTP toxicity in mice. This result can be 
possibly explained by the expression pattern of GFRα and RET in different brain regions. In 
many areas of the nervous system, especially in the forebrain, cortex and inner ear GFRα 
receptors are much more widely expressed than RET (Ylikoski et al., 1999; Kokaia et al., 
1999; Trupp et al., 1997), but RET is easily detectable in the murine striatum and SNpc 
(Kramer et al., 2007; Jain et al., 2006) suggesting that GFLs may signal independently of 
RET in collaboration with other transmembrane proteins only in some areas of the brain. 
However, although dispensable for the establishment of the nigrostriatal system, the 
presence of RET is a prerequisite for long-term maintenance and protective/regenerative 
effects of GDNF to the nigrostriatal system after MPTP lesion (Kramer et al., 2007). 
 
6.3 Perspectives 
In this study it was found that GDNF produced by astrocytes is as effective as neuronal 
GDNF in protecting unilaterally the murine nigrostriatal system against MPTP toxicity, even 
by using in low quantity GDNF. In the long-term view, even low amounts of neuronal-
produced GDNF also protected contralateral structures, what supports the hypothesis that 
neurons, once they are transduced, release GDNF in all terminal projection areas with 
uncontrollable effects. In order to further prepare the ground for a gene therapy of PD 
patients by using astrocytic GDNF expression (AAV-5 GFAP GDNF), a repetition of the 
experiment with the modification to inject GDNF after MPTP treatment should be performed. 
Since approximately 60% of the SNpc DA neurons and 80% of their axonal projections in the 
putamen have been already lost at the onset of PD symptoms (Dauer and Przedborski 2003) 
a protection via GDNF after MPTP treatment would much better reflect the situation in PD 
patients. 
In order to further elucidate via which tracks astrocytic and neuronal GDNF is transported in 
the brain AAVs producing fluorescent or mutated GDNF should be injected. These GDNF 
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variants indeed can indeed be distinguished from endogenous GDNF, but might possibly 
influence the biological function of GDNF.  
Since neurons and astrocytes express different GDNF signalling components, the usage of 
separate pathways to mediate autocrine and paracrine effects of GDNF could be an 
explanation for the detected differences in astrocytic or neuronal production of GDNF. Thus, 
it would be interesting to find out which signalling pathways are active in the presence of 
astrocytic or neuronal GDNF. 
Further, it would be fascinating to distinguish between anterogradely and retrogradely 
transported GDNF in order to prove the hypothesis about a missing protective effect of 
anterogradely transported GDNF due to transport-dependent modifications. In this context an 
experimental setup to discriminate between intra- and extracellular GDNF would be useful. 
The measurement of GDNF in the ELISA three months after injection of high and low titres 
dosages would give the opportunity to include long-term GDNF transportation in the 
argumentation for astrocytic GDNF having the advantage over neuronal GDNF regarding 
safety issues for a hypothetical gene therapy in PD patients.  
One potential method to address and avoid potential augmented risks in clinical trials might 
be to utilize a regulated viral vector system, for example the tetracycline (tet)-transcriptional 
regulation system. The advantages of such an external regulable system would be the 
possibility to find individual doses, circumvention of unexpected side-effects and the 
termination of the treatment if no longer effective. In contrast, there is no clinically relevant 
regulatable vector system currently available. Second, the available gene regulation 
schemes represent a potential toxicity issue on their own since in all cases, a portion of the 
regulated system must be constitutively expressed. The third contra-argument is that if no 
GDNF-induced side-effects can be demonstrated even at the highest possible over-
expression levels in pre-clinical toxicology studies, then any requirement to add a potential 
complication such as regulated vector constructs to the experiment would be unwarranted 
(Kordower and Olanow 2009, Manfredsson et al., 2009). 
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The results regarding the RET study revealed that there is no alternative to an intact GDNF-
RET mediated signalling in the nigrostriatal system. RET is a prerequisite for the protective 
potential of GDNF and the natural regenerative capacity of the striatum after MPTP lesion in 
mice. In terms of that study different proof of principle experiments could be performed: 
A MPTP experiment with NCAM-deficient mice (Bukalo et al., 2004; Cremer et al., 1994) in 
combination with AAV-mediated GDNF overexpression should not show disturbances in the 
protective effect of GDNF to the nigrostriatal system and the natural regenerative capacity of 
the striatum. 
Mice with inducible RET expression in the dopaminergic system would provide a tighter 
connection between the presence of RET and the protective effect of GDNF, if restoration of 
GDNF-mediated protection could be observed after induction of RET expression. 
Furthermore, the question, of whether besides the activation of RET signalling by GDNF 
other GFLs might also lead to protective and/or regenerative effects still has to be elucidated. 
A MPTP experiment with GDNF-deficient mice (Pascual et al., 2008; Moore et al., 1996) in 
combination with AAV-mediated overexpression of other GFLs would demonstrate if other 
GFLs are also capable to induce protection in the nigrostriatal system or if they are important 
for the natural regenerative capacity of the striatum.  
REFERENCES 
  112 
Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and 
therapeutic value. Nat Rev Neurosci 3:383-394. 
Aisen P, Cohen G, Kang JO (1990) Iron toxicosis. Int Rev Exp Pathol 31:1-46. 
Allen KL, Almeida A, Bates TE, Clark JB (1995) Changes of respiratory chain activity in 
mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded 
ischaemia. J Neurochem 64:2222-2229. 
Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA (2004) UCH-L1 aggresome formation 
in response to proteasome impairment indicates a role in inclusion formation in 
Parkinson's disease. J Neurochem 90:379-391. 
Arenas E, Trupp M, Akerud P, Ibanez CF (1995) GDNF prevents degeneration and promotes 
the phenotype of brain noradrenergic neurons in vivo. Neuron 15:1465-1473. 
Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O (2003) 
Elevated GDNF levels following viral vector-mediated gene transfer can increase 
neuronal death after stroke in rats. Neurobiol Dis 14:542-556. 
Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Bueler H (2000) Increased 
motoneuron survival and improved neuromuscular function in transgenic ALS mice 
after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol 
Genet 9:803-811. 
Backman CM, Shan L, Zhang YJ, Hoffer BJ, Leonard S, Troncoso JC, Vonsatel P, Tomac 
AC (2006) Gene expression patterns for GDNF and its receptors in the human 
putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol 
252:160-166. 
Baloh RH, Enomoto H, Johnson EM, Jr., Milbrandt J (2000) The GDNF family ligands and 
receptors - implications for neural development. Curr Opin Neurobiol 10:103-110. 
Barnett MW, Fisher CE, Perona-Wright G, Davies JA (2002) Signalling by glial cell line-
derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J 
Cell Sci 115:4495-4503. 
Barroso-Chinea P, Cruz-Muros I, Aymerich MS, Rodriguez-Diaz M, Afonso-Oramas D, 
Lanciego JL, Gonzalez-Hernandez T (2005) Striatal expression of GDNF and 
differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci 21:1815-1827. 
Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M (2007) 
Issues regarding gene therapy products for Parkinson's disease: the development of 
CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord 13 Suppl 
3:S469-477. 
Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334. 
Berman SB, Hastings TG (1997) Inhibition of glutamate transport in synaptosomes by 
dopamine oxidation and reactive oxygen species. J Neurochem 69:1185-1195. 
REFERENCES 
  113 
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain 
dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological 
and neurochemical correlations. J Neurol Sci 20:415-455. 
Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P (1997) 
Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived 
neurotrophic factor prevents dopaminergic neuron degeneration and behavioral 
impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94:8818-
8823. 
Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal 
ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88. 
Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular 
pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution 
to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172. 
Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's 
disease. NeuroRx 2:484-494. 
Bowling AC, Beal MF (1995) Bioenergetic and oxidative stress in neurodegenerative 
diseases. Life Sci 56:1151-1171. 
Braak H, Del Tredici K (2008) Invited Article: Nervous system pathology in sporadic 
Parkinson disease. Neurology 70:1916-1925. 
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of 
brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211. 
Bresjanac M, Antauer G (2000) Reactive astrocytes of the quinolinic acid-lesioned rat 
striatum express GFRalpha1 as well as GDNF in vivo. Exp Neurol 164:53-59. 
Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent 
control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 
11:297-305. 
Bukalo O, Fentrop N, Lee AY, Salmen B, Law JW, Wotjak CT, Schweizer M, Dityatev A, 
Schachner M (2004) Conditional ablation of the neural cell adhesion molecule 
reduces precision of spatial learning, long-term potentiation, and depression in the 
CA1 subfield of mouse hippocampus. J Neurosci 24:1565-1577. 
Byrd AS, Sikorska M, Walker PR, Sandhu JK (2004) Effects of glutathione depletion on the 
viability of human NT2-derived neuronal and astroglial cultures. Neuron Glia Biol 
1:317-326. 
Cabrera JR, Sanchez-Pulido L, Rojas AM, Valencia A, Manes S, Naranjo JR, Mellstrom B 
(2006) Gas1 is related to the glial cell-derived neurotrophic factor family receptors 
alpha and regulates Ret signaling. J Biol Chem 281:14330-14339. 
REFERENCES 
  114 
Cao JP, Yu JK, Li C, Sun Y, Yuan HH, Wang HJ, Gao DS (2008) Integrin beta1 is involved in 
the signaling of glial cell line-derived neurotrophic factor. J Comp Neurol 509:203-
210. 
Chang LK, Putcha GV, Deshmukh M, Johnson EM, Jr. (2002) Mitochondrial involvement in 
the point of no return in neuronal apoptosis. Biochimie 84:223-231. 
Chao CC, Ma YL, Chu KY, Lee EH (2003) Integrin alphav and NCAM mediate the effects of 
GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats. 
Neurobiol Aging 24:105-116. 
Chauhan NB, Siegel GJ, Lee JM (2001) Depletion of glial cell line-derived neurotrophic factor 
in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 21:277-
288. 
Chen LW, Zhang JP, Kwok-Yan Shum D, Chan YS (2006) Localization of nerve growth 
factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-
expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated C57/Bl mice. J Comp Neurol 497:898-909. 
Chen YH, Harvey BK, Hoffman AF, Wang Y, Chiang YH, Lupica CR (2008) MPTP-induced 
deficits in striatal synaptic plasticity are prevented by glial cell line-derived 
neurotrophic factor expressed via an adeno-associated viral vector. Faseb J 22:261-
275. 
Cheng H, Wu JP, Tzeng SF (2002) Neuroprotection of glial cell line-derived neurotrophic 
factor in damaged spinal cords following contusive injury. J Neurosci Res 69:397-405. 
Choi-Lundberg DL, Bohn MC (1995) Ontogeny and distribution of glial cell line-derived 
neurotrophic factor (GDNF) mRNA in rat. Brain Res Dev Brain Res 85:80-88. 
Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn 
MC (1997) Dopaminergic neurons protected from degeneration by GDNF gene 
therapy. Science 275:838-841. 
Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, 
Wright JF, Bankiewicz KS, Aminoff MJ (2009) Safety and tolerability of putaminal 
AADC gene therapy for Parkinson disease. Neurology 73:1662-1669. 
Costa S, Iravani MM, Pearce RK, Jenner P (2001) Glial cell line-derived neurotrophic factor 
concentration dependently improves disability and motor activity in MPTP-treated 
common marmosets. Eur J Pharmacol 412:45-50. 
Cotzias GC, Papavasiliou PS, Gellene R (1968) Experimental treatment of parkinsonism with 
L-Dopa. Neurology 18:276-277. 
Creedon DJ, Tansey MG, Baloh RH, Osborne PA, Lampe PA, Fahrner TJ, Heuckeroth RO, 
Milbrandt J, Johnson EM, Jr. (1997) Neurturin shares receptors and signal 
REFERENCES 
  115 
transduction pathways with glial cell line-derived neurotrophic factor in sympathetic 
neurons. Proc Natl Acad Sci U S A 94:7018-7023. 
Cremer H, Lange R, Christoph A, Plomann M, Vopper G, Roes J, Brown R, Baldwin S, 
Kraemer P, Scheff S, et al. (1994) Inactivation of the N-CAM gene in mice results in 
size reduction of the olfactory bulb and deficits in spatial learning. Nature 367:455-
459. 
Date I, Aoi M, Tomita S, Collins F, Ohmoto T (1998) GDNF administration induces recovery 
of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. 
Neuroreport 9:2365-2369. 
Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 
39:889-909. 
Dawson TM (2000) New animal models for Parkinson's disease. Cell 101:115-118. 
de Hoop MJ, Dotti CG (1993) Membrane traffic in polarized neurons in culture. J Cell Sci 
Suppl 17:85-92. 
de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-
Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and 
Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. 
European Community Concerted Action on the Epidemiology of Parkinson's disease. 
J Neurol Neurosurg Psychiatry 62:10-15. 
Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H (2002) Where does parkinson disease 
pathology begin in the brain? J Neuropathol Exp Neurol 61:413-426. 
Deuschl G, Goddemeier C (1998) Spontaneous and reflex activity of facial muscles in 
dystonia, Parkinson's disease, and in normal subjects. J Neurol Neurosurg Psychiatry 
64:320-324. 
Dietz GP, Valbuena PC, Dietz B, Meuer K, Mueller P, Weishaupt JH, Bahr M (2006) 
Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for 
Parkinson's disease. Brain Res 1082:61-66. 
Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505-516. 
Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF (1998) 
Circular intermediates of recombinant adeno-associated virus have defined structural 
characteristics responsible for long-term episomal persistence in muscle tissue. J 
Virol 72:8568-8577. 
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, 
Greenberg ME (1997) Regulation of neuronal survival by the serine-threonine protein 
kinase Akt. Science 275:661-665. 
Eberhardt O, Coelln RV, Kugler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, 
Isenmann S, Gravel C, Srinivasan A, Bahr M, Weller M, Dichgans J, Schulz JB (2000) 
REFERENCES 
  116 
Protection by synergistic effects of adenovirus-mediated X-chromosome-linked 
inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J 
Neurosci 20:9126-9134. 
Elsworth JD, Redmond DE, Jr., Leranth C, Bjugstad KB, Sladek JR, Jr., Collier TJ, Foti SB, 
Samulski RJ, Vives KP, Roth RH (2008) AAV2-mediated gene transfer of GDNF to 
the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted 
fetal dopamine neurons. Exp Neurol 211:252-258. 
Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res 25:1439-1451. 
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, 
Annett L, Kirik D (2005) Continuous low-level glial cell line-derived neurotrophic factor 
delivery using recombinant adeno-associated viral vectors provides neuroprotection 
and induces behavioral recovery in a primate model of Parkinson's disease. J 
Neurosci 25:769-777. 
Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 
991:1-14. 
Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars 
compacta in comparison with basal ganglia and prefrontal cortex measured with an 
improved dinitrophenylhydrazine assay. J Neurochem 70:268-275. 
Flotte TR, Afione SA, Zeitlin PL (1994) Adeno-associated virus vector gene expression 
occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell 
Mol Biol 11:517-521. 
Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, Carter BJ (1992) Gene expression from 
adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 
7:349-356. 
Follenzi A, Santambrogio L, Annoni A (2007) Immune responses to lentiviral vectors. Curr 
Gene Ther 7:306-315. 
Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, 
Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Sudhof TC 
(2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent 
roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U 
S A 102:3413-3418. 
Forno LS, DeLanney LE, Irwin I, Langston JW (1993) Similarities and differences between 
MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic 
considerations. Adv Neurol 60:600-608. 
REFERENCES 
  117 
Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) 
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat 
Biotechnol 27:59-65. 
Frank E, Novick D, Kupfer DJ (2005) Antidepressants and psychotherapy: a clinical research 
review. Dialogues Clin Neurosci 7:263-272. 
Frielingsdorf H, Schwarz K, Brundin P, Mohapel P (2004) No evidence for new dopaminergic 
neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 
101:10177-10182. 
Gao H, Wang J, Zhang W, Jiang Y, Niu D, Wang X (2003) [Recombinant adenovirus carrying 
glial cell line-derived neurotrophic factor gene protect midbrain dopaminergic neurons 
in mice]. Beijing Da Xue Xue Bao 35:256-260. 
Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak 
PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian 
monkeys treated with GDNF. Nature 380:252-255. 
Georgievska B, Kirik D, Bjorklund A (2002a) Aberrant sprouting and downregulation of 
tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-
lasting overexpression of glial cell line derived neurotrophic factor in the striatum by 
lentiviral gene transfer. Exp Neurol 177:461-474. 
Georgievska B, Kirik D, Rosenblad C, Lundberg C, Bjorklund A (2002b) Neuroprotection in 
the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. 
Neuroreport 13:75-82. 
Ghahremani MH, Keramaris E, Shree T, Xia Z, Davis RJ, Flavell R, Slack RS, Park DS 
(2002) Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of 
embryonic cortical neurons evoked by DNA damage. J Biol Chem 277:35586-35596. 
Gibb WR (1997) Functional neuropathology in Parkinson's disease. Eur Neurol 38 Suppl 
2:21-25. 
Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen 
CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic 
factor in Parkinson disease. Nat Med 9:589-595. 
Glazner GW, Mu X, Springer JE (1998) Localization of glial cell line-derived neurotrophic 
factor receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 
391:42-49. 
Goldberg MS, Lansbury PT, Jr. (2000) Is there a cause-and-effect relationship between 
alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2:E115-119. 
Gupta AK, Bluhm R (2004) Seborrheic dermatitis. J Eur Acad Dermatol Venereol 18:13-26; 
quiz 19-20. 
REFERENCES 
  118 
Guye M, Bartolomei F, Ranjeva JP (2008) Imaging structural and functional connectivity: 
towards a unified definition of human brain organization? Curr Opin Neurol 21:393-
403. 
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 
59:1609-1623. 
Hanna J, Finley D (2007) A proteasome for all occasions. FEBS Lett 581:2854-2861. 
Harting JK, Updyke BV, Van Lieshout DP (2001) The visual-oculomotor striatum of the cat: 
functional relationship to the superior colliculus. Exp Brain Res 136:138-142. 
Hasbrouck NC, High KA (2008) AAV-mediated gene transfer for the treatment of hemophilia 
B: problems and prospects. Gene Ther 15:870-875. 
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, 
Moffet B, Vandlen RA, Simpson LC, et al. (1994) GDNF: a potent survival factor for 
motoneurons present in peripheral nerve and muscle. Science 266:1062-1064. 
Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN (1991) 
Selective retention of MPP+ within the monoaminergic systems of the primate brain 
following MPTP administration: an in vivo autoradiographic study. Neuroscience 
40:133-158. 
Hildinger M, Auricchio A (2004) Advances in AAV-mediated gene transfer for the treatment of 
inherited disorders. Eur J Hum Genet 12:263-271. 
Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA 
(1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to 
midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111. 
Hollis ER, 2nd, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH (2008) Efficient retrograde 
neuronal transduction utilizing self-complementary AAV1. Mol Ther 16:296-301. 
Hornykiewicz O (2002) L-DOPA: from a biologically inactive amino acid to a successful 
therapeutic agent. Amino Acids 23:65-70. 
Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW (1995) An essay on Wilhelm von 
Humboldt and the shaking palsy: first comprehensive description of Parkinson's 
disease by a patient. Neurology 45:565-568. 
Hristova AH, Koller WC (2000) Early Parkinson's disease: what is the best approach to 
treatment. Drugs Aging 17:165-181. 
Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, 
Mackerlova L, Lile JD, Collins F, et al. (1995) Glial cell line-derived neurotrophic 
factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432. 
Huerta MF, Van Lieshout DP, Harting JK (1991) Nigrotectal projections in the primate Galago 
crassicaudatus. Exp Brain Res 87:389-401. 
REFERENCES 
  119 
Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch 
EC (1999) FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in 
vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J 
Neurosci 19:3440-3447. 
Ibanez CF (1998) Emerging themes in structural biology of neurotrophic factors. Trends 
Neurosci 21:438-444. 
Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, Shibasaki H, Noda M, Kinoshita M 
(2003) Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic 
inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 
278:24095-24102. 
Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding 
Parkinson's disease. Acta Neurol Scand 113:211-220. 
Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF (1998) 
Circular intermediates of recombinant adeno-associated virus have defined structural 
characteristics responsible for long-term episomal persistence in muscle tissue. J 
Virol 72:8568-8577. 
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, 
Greenberg ME (1997) Regulation of neuronal survival by the serine-threonine protein 
kinase Akt. Science 275:661-665. 
Eberhardt O, Coelln RV, Kugler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, 
Isenmann S, Gravel C, Srinivasan A, Bahr M, Weller M, Dichgans J, Schulz JB (2000) 
Protection by synergistic effects of adenovirus-mediated X-chromosome-linked 
inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J 
Neurosci 20:9126-9134. 
Elsworth JD, Redmond DE, Jr., Leranth C, Bjugstad KB, Sladek JR, Jr., Collier TJ, Foti SB, 
Samulski RJ, Vives KP, Roth RH (2008) AAV2-mediated gene transfer of GDNF to 
the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted 
fetal dopamine neurons. Exp Neurol 211:252-258. 
Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res 25:1439-1451. 
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, 
Annett L, Kirik D (2005) Continuous low-level glial cell line-derived neurotrophic factor 
delivery using recombinant adeno-associated viral vectors provides neuroprotection 
and induces behavioral recovery in a primate model of Parkinson's disease. J 
Neurosci 25:769-777. 
REFERENCES 
  120 
Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 
991:1-14. 
Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars 
compacta in comparison with basal ganglia and prefrontal cortex measured with an 
improved dinitrophenylhydrazine assay. J Neurochem 70:268-275. 
Flotte TR, Afione SA, Zeitlin PL (1994) Adeno-associated virus vector gene expression 
occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell 
Mol Biol 11:517-521. 
Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, Carter BJ (1992) Gene expression from 
adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 
7:349-356. 
Follenzi A, Santambrogio L, Annoni A (2007) Immune responses to lentiviral vectors. Curr 
Gene Ther 7:306-315. 
Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, 
Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Sudhof TC 
(2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent 
roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U 
S A 102:3413-3418. 
Forno LS, DeLanney LE, Irwin I, Langston JW (1993) Similarities and differences between 
MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic 
considerations. Adv Neurol 60:600-608. 
Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) 
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat 
Biotechnol 27:59-65. 
Frank E, Novick D, Kupfer DJ (2005) Antidepressants and psychotherapy: a clinical research 
review. Dialogues Clin Neurosci 7:263-272. 
Frielingsdorf H, Schwarz K, Brundin P, Mohapel P (2004) No evidence for new dopaminergic 
neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 
101:10177-10182. 
Gao H, Wang J, Zhang W, Jiang Y, Niu D, Wang X (2003) [Recombinant adenovirus carrying 
glial cell line-derived neurotrophic factor gene protect midbrain dopaminergic neurons 
in mice]. Beijing Da Xue Xue Bao 35:256-260. 
Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak 
PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian 
monkeys treated with GDNF. Nature 380:252-255. 
Georgievska B, Kirik D, Bjorklund A (2002a) Aberrant sprouting and downregulation of 
tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-
REFERENCES 
  121 
lasting overexpression of glial cell line derived neurotrophic factor in the striatum by 
lentiviral gene transfer. Exp Neurol 177:461-474. 
Georgievska B, Kirik D, Rosenblad C, Lundberg C, Bjorklund A (2002b) Neuroprotection in 
the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. 
Neuroreport 13:75-82. 
Ghahremani MH, Keramaris E, Shree T, Xia Z, Davis RJ, Flavell R, Slack RS, Park DS 
(2002) Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of 
embryonic cortical neurons evoked by DNA damage. J Biol Chem 277:35586-35596. 
Gibb WR (1997) Functional neuropathology in Parkinson's disease. Eur Neurol 38 Suppl 
2:21-25. 
Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen 
CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic 
factor in Parkinson disease. Nat Med 9:589-595. 
Glazner GW, Mu X, Springer JE (1998) Localization of glial cell line-derived neurotrophic 
factor receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 
391:42-49. 
Goldberg MS, Lansbury PT, Jr. (2000) Is there a cause-and-effect relationship between 
alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2:E115-119. 
Gupta AK, Bluhm R (2004) Seborrheic dermatitis. J Eur Acad Dermatol Venereol 18:13-26; 
quiz 19-20. 
Guye M, Bartolomei F, Ranjeva JP (2008) Imaging structural and functional connectivity: 
towards a unified definition of human brain organization? Curr Opin Neurol 21:393-
403. 
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 
59:1609-1623. 
Hanna J, Finley D (2007) A proteasome for all occasions. FEBS Lett 581:2854-2861. 
Harting JK, Updyke BV, Van Lieshout DP (2001) The visual-oculomotor striatum of the cat: 
functional relationship to the superior colliculus. Exp Brain Res 136:138-142. 
Hasbrouck NC, High KA (2008) AAV-mediated gene transfer for the treatment of hemophilia 
B: problems and prospects. Gene Ther 15:870-875. 
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, 
Moffet B, Vandlen RA, Simpson LC, et al. (1994) GDNF: a potent survival factor for 
motoneurons present in peripheral nerve and muscle. Science 266:1062-1064. 
Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN (1991) 
Selective retention of MPP+ within the monoaminergic systems of the primate brain 
following MPTP administration: an in vivo autoradiographic study. Neuroscience 
40:133-158. 
REFERENCES 
  122 
Hildinger M, Auricchio A (2004) Advances in AAV-mediated gene transfer for the treatment of 
inherited disorders. Eur J Hum Genet 12:263-271. 
Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA 
(1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to 
midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111. 
Hollis ER, 2nd, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH (2008) Efficient retrograde 
neuronal transduction utilizing self-complementary AAV1. Mol Ther 16:296-301. 
Hornykiewicz O (2002) L-DOPA: from a biologically inactive amino acid to a successful 
therapeutic agent. Amino Acids 23:65-70. 
Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW (1995) An essay on Wilhelm von 
Humboldt and the shaking palsy: first comprehensive description of Parkinson's 
disease by a patient. Neurology 45:565-568. 
Hristova AH, Koller WC (2000) Early Parkinson's disease: what is the best approach to 
treatment. Drugs Aging 17:165-181. 
Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, 
Mackerlova L, Lile JD, Collins F, et al. (1995) Glial cell line-derived neurotrophic 
factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432. 
Huerta MF, Van Lieshout DP, Harting JK (1991) Nigrotectal projections in the primate Galago 
crassicaudatus. Exp Brain Res 87:389-401. 
Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch 
EC (1999) FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in 
vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J 
Neurosci 19:3440-3447. 
Ibanez CF (1998) Emerging themes in structural biology of neurotrophic factors. Trends 
Neurosci 21:438-444. 
Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, Shibasaki H, Noda M, Kinoshita M 
(2003) Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic 
inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 
278:24095-24102. 
Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding 
Parkinson's disease. Acta Neurol Scand 113:211-220. 
Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's 
disease. Nat Protoc 2:141-151. 
Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM, Jr., Milbrandt J (2006) RET is 
dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J 
Neurosci 26:11230-11238. 
REFERENCES 
  123 
Jakobsson J, Georgievska B, Ericson C, Lundberg C (2004) Lesion-dependent regulation of 
transgene expression in the rat brain using a human glial fibrillary acidic protein-
lentiviral vector. Eur J Neurosci 19:761-765. 
Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg 
Psychiatry 79:368-376. 
Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor 
complications in patients with Parkinson's disease. CNS Drugs 21:677-692. 
Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural 
Transm 116:1111-1162. 
Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3:S26-36; 
discussion S36-28. 
Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 
44:S72-84. 
Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis 
JC, Hu S, Altrock BW, Fox GM (1996) GDNF-induced activation of the ret protein 
tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 
85:1113-1124. 
Kaneda K, Isa K, Yanagawa Y, Isa T (2008) Nigral inhibition of GABAergic neurons in mouse 
superior colliculus. J Neurosci 28:11071-11078. 
Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr 
Opin Neurobiol 10:381-391. 
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, 
Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with 
an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open 
label, phase I trial. Lancet 369:2097-2105. 
Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of 
IGF-1 prolongs survival in a mouse ALS model. Science 301:839-842. 
Kearns CM, Gash DM (1995) GDNF protects nigral dopamine neurons against 6-
hydroxydopamine in vivo. Brain Res 672:104-111. 
Kermer P, Klocker N, Bahr M (1999) Neuronal death after brain injury. Models, mechanisms, 
and therapeutic strategies in vivo. Cell Tissue Res 298:383-395. 
Kim R (2005) Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res 
Commun 333:336-343. 
Kirik D, Rosenblad C, Bjorklund A (2000) Preservation of a functional nigrostriatal dopamine 
pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of 
administration of the trophic factor. Eur J Neurosci 12:3871-3882. 
REFERENCES 
  124 
Kirik D, Georgievska B, Bjorklund A (2004) Localized striatal delivery of GDNF as a 
treatment for Parkinson disease. Nat Neurosci 7:105-110. 
Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV (2009) Molecular 
evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 
17:2088-2095. 
Kojima H, Abiru Y, Sakajiri K, Watabe K, Ohishi N, Takamori M, Hatanaka H, Yagi K (1997) 
Adenovirus-mediated transduction with human glial cell line-derived neurotrophic 
factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine 
depletion in striatum of mouse brain. Biochem Biophys Res Commun 238:569-573. 
Kokaia Z, Airaksinen MS, Nanobashvili A, Larsson E, Kujamaki E, Lindvall O, Saarma M 
(1999) GDNF family ligands and receptors are differentially regulated after brain 
insults in the rat. Eur J Neurosci 11:1202-1216. 
Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, 
Penn R, Goetz CG, Comella CD (1999) Clinicopathological findings following 
intraventricular glial-derived neurotrophic factor treatment in a patient with 
Parkinson's disease. Ann Neurol 46:419-424. 
Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi 
S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, 
Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by 
lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 
290:767-773. 
Kowsky S, Poppelmeyer C, Kramer ER, Falkenburger BH, Kruse A, Klein R, Schulz JB 
(2007) RET signaling does not modulate MPTP toxicity but is required for 
regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A 104:20049-
20054. 
Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R (2007) 
Absence of Ret signaling in mice causes progressive and late degeneration of the 
nigrostriatal system. PLoS Biol 5:e39. 
Krieglstein K (2004) Factors promoting survival of mesencephalic dopaminergic neurons. 
Cell Tissue Res 318:73-80. 
Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ (2007) Translational principles of deep 
brain stimulation. Nat Rev Neurosci 8:623-635. 
Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M (2003) Differential transgene expression 
in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control 
units. Virology 311:89-95. 
REFERENCES 
  125 
Kuhn DM, Arthur RE, Jr., Thomas DM, Elferink LA (1999) Tyrosine hydroxylase is inactivated 
by catechol-quinones and converted to a redox-cycling quinoprotein: possible 
relevance to Parkinson's disease. J Neurochem 73:1309-1317. 
Lang AE (2007) The progression of Parkinson disease: a hypothesis. Neurology 68:948-952. 
Lang AE, Lozano AM (1998) Parkinson's disease. Second of two parts. N Engl J Med 
339:1130-1143. 
Lang AE et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived 
neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466. 
Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin 
Neuropharmacol 9:485-507. 
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a 
product of meperidine-analog synthesis. Science 219:979-980. 
Lapchak PA (1996) Therapeutic potentials for glial cell line-derived neurotrophic factor 
(GDNF) based upon pharmacological activities in the CNS. Rev Neurosci 7:165-176. 
Larkin M (1999) Parkinson's disease research moves on briskly. Lancet 353:566. 
Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ (2009) Efficient gene delivery and 
selective transduction of glial cells in the mammalian brain by AAV serotypes isolated 
from nonhuman primates. Mol Ther 17:1692-1702. 
Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G (2008) Lrig1 is an endogenous inhibitor 
of Ret receptor tyrosine kinase activation, downstream signaling, and biological 
responses to GDNF. J Neurosci 28:39-49. 
Lei K, Nimnual A, Zong WX, Kennedy NJ, Flavell RA, Thompson CB, Bar-Sagi D, Davis RJ 
(2002) The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal 
transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 22:4929-4942. 
Lepoutre AC, Devos D, Blanchard-Dauphin A, Pardessus V, Maurage CA, Ferriby D, 
Hurtevent JF, Cotten A, Destee A, Defebvre L (2006) A specific clinical pattern of 
camptocormia in Parkinson's disease. J Neurol Neurosurg Psychiatry 77:1229-1234. 
Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson 
VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates 
dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 
5:1403-1409. 
Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW (2004) Pro-regenerative properties 
of cytokine-activated astrocytes. J Neurochem 89:1092-1100. 
Lieberman A (2006) Are dementia and depression in Parkinson's disease related? J Neurol 
Sci 248:138-142. 
Lin LF, Zhang TJ, Collins F, Armes LG (1994) Purification and initial characterization of rat 
B49 glial cell line-derived neurotrophic factor. J Neurochem 63:758-768. 
REFERENCES 
  126 
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived 
neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132. 
Lindgren N, Leak RK, Carlson KM, Smith AD, Zigmond MJ (2008) Activation of the 
extracellular signal-regulated kinases 1 and 2 by glial cell line-derived neurotrophic 
factor and its relation to neuroprotection in a mouse model of Parkinson's disease. J 
Neurosci Res 86:2039-2049. 
Lopez-Ramirez MA, Dominguez-Monzon G, Vergara P, Segovia J (2008) Gas1 reduces Ret 
tyrosine 1062 phosphorylation and alters GDNF-mediated intracellular signaling. Int J 
Dev Neurosci 26:497-503. 
Lorincz MT (2006) Clinical implications of Parkinson's disease genetics. Semin Neurol 
26:492-498. 
Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein 
mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol 
Genet 11:2395-2407. 
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002) Effect of mutant 
alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J 
Biol Chem 277:38884-38894. 
Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ 
(1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of 
diverse type in man, including those of Parkinson's disease, Pick's disease, and 
Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, 
cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 
155:9-15. 
Lowenstein PR, Castro MG (2003) Inflammation and adaptive immune responses to 
adenoviral vectors injected into the brain: peculiarities, mechanisms, and 
consequences. Gene Ther 10:946-954. 
Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG (2007) Immune responses to 
adenovirus and adeno-associated vectors used for gene therapy of brain diseases: 
the role of immunological synapses in understanding the cell biology of neuroimmune 
interactions. Curr Gene Ther 7:347-360. 
Luan L, Ding F, Ai Y, Andersen A, Hardy P, Forman E, Gerhardt GA, Gash DM, Grondin R, 
Zhang Z (2008) Pharmacological MRI (phMRI) monitoring of treatment in 
hemiparkinsonian rhesus monkeys. Cell Transplant 17:417-425. 
Malik JM, Shevtsova Z, Bahr M, Kugler S (2005) Long-term in vivo inhibition of CNS 
neurodegeneration by Bcl-XL gene transfer. Mol Ther 11:373-381. 
Mandel RJ, Burger C, Snyder RO (2008) Viral vectors for in vivo gene transfer in Parkinson's 
disease: properties and clinical grade production. Exp Neurol 209:58-71. 
REFERENCES 
  127 
Mandel RJ, Spratt SK, Snyder RO, Leff SE (1997) Midbrain injection of recombinant adeno-
associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral 
neurons in a progressive 6-hydroxydopamine-induced degeneration model of 
Parkinson's disease in rats. Proc Natl Acad Sci U S A 94:14083-14088. 
Manfredsson FP, Okun MS, Mandel RJ (2009) Gene therapy for neurological disorders: 
challenges and future prospects for the use of growth factors for the treatment of 
Parkinson's disease. Curr Gene Ther 9:375-388. 
Marks WJ, Jr., Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-
Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of 
intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to 
patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet 
Neurol 7:400-408. 
Markus A, Zhong J, Snider WD (2002) Raf and akt mediate distinct aspects of sensory axon 
growth. Neuron 35:65-76. 
McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta 
DA, Di Monte DA (2002) Environmental risk factors and Parkinson's disease: 
selective degeneration of nigral dopaminergic neurons caused by the herbicide 
paraquat. Neurobiol Dis 10:119-127. 
Mijatovic J, Airavaara M, Planken A, Auvinen P, Raasmaja A, Piepponen TP, Costantini F, 
Ahtee L, Saarma M (2007) Constitutive Ret activity in knock-in multiple endocrine 
neoplasia type B mice induces profound elevation of brain dopamine concentration 
via enhanced synthesis and increases the number of TH-positive cells in the 
substantia nigra. J Neurosci 27:4799-4809. 
Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) 
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in 
Parkinson's disease. Exp Neurol 156:138-148. 
Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD 
(2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site 
preferences. PLoS Biol 2:E234. 
Mitsumoto Y, Watanabe A, Mori A, Koga N (1998) Spontaneous regeneration of nigrostriatal 
dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res 
Commun 248:660-663. 
Mochizuki H, Yasuda T, Mouradian MM (2008) Advances in gene therapy for movement 
disorders. Neurotherapeutics 5:260-269. 
Mogi M, Togari A, Kondo T, Mizuno Y, Kogure O, Kuno S, Ichinose H, Nagatsu T (2001) 
Glial cell line-derived neurotrophic factor in the substantia nigra from control and 
parkinsonian brains. Neurosci Lett 300:179-181. 
REFERENCES 
  128 
Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of 
Parkinson's disease. Annu Rev Neurosci 28:57-87. 
Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, 
Carver-Moore K, Rosenthal A (1996) Renal and neuronal abnormalities in mice 
lacking GDNF. Nature 382:76-79. 
Mouradian MM, Chase TN (1997) Gene therapy for Parkinson's disease: an approach to the 
prevention or palliation of levodopa-associated motor complications. Exp Neurol 
144:51-57. 
Muller T, Eising E, Kuhn W, Buttner T, Coenen HH, Przuntek H (1999) Delayed motor 
response correlates with striatal degeneration in Parkinson's disease. Acta Neurol 
Scand 100:227-230. 
Muqit MM, Gandhi S, Wood NW (2006) Mitochondria in Parkinson disease: back in fashion 
with a little help from genetics. Arch Neurol 63:649-654. 
Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T, Clark SA, Ross PJ, Meulenbroek 
RA, Maelandsmo GM, Parks RJ (2004) Helper-dependent adenovirus vectors elicit 
intact innate but attenuated adaptive host immune responses in vivo. J Virol 78:5966-
5972. 
Nakagawa T, Schwartz JP (2004) Gene expression patterns in in vivo normal adult 
astrocytes compared with cultured neonatal and normal adult astrocytes. Neurochem 
Int 45:203-242. 
Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T, Miwa A, Okado H, Kiyama H 
(2000) Akt/protein kinase B prevents injury-induced motoneuron death and 
accelerates axonal regeneration. J Neurosci 20:2875-2886. 
Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type 
B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9:1233-1250. 
Nosrat CA, Tomac A, Hoffer BJ, Olson L (1997) Cellular and developmental patterns of 
expression of Ret and glial cell line-derived neurotrophic factor receptor alpha 
mRNAs. Exp Brain Res 115:410-422. 
Olanow CW, Stocchi F (2004) COMT inhibitors in Parkinson's disease: can they prevent 
and/or reverse levodopa-induced motor complications? Neurology 62:S72-81. 
Olanow CW, Kordower JH (2009) Modeling Parkinson's disease. Ann Neurol 66:432-436. 
Oo TF, Ries V, Cho J, Kholodilov N, Burke RE (2005) Anatomical basis of glial cell line-
derived neurotrophic factor expression in the striatum and related basal ganglia 
during postnatal development of the rat. J Comp Neurol 484:57-67. 
Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH (2008) Accumulation and 
clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J 
Neurochem 106:529-540. 
REFERENCES 
  129 
Ossowska K, Smialowska M, Kuter K, Wieronska J, Zieba B, Wardas J, Nowak P, 
Dabrowska J, Bortel A, Biedka I, Schulze G, Rommelspacher H (2006) Degeneration 
of dopaminergic mesocortical neurons and activation of compensatory processes 
induced by a long-term paraquat administration in rats: implications for Parkinson's 
disease. Neuroscience 141:2155-2165. 
Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, Deglon N, Hantraye P, Aebischer 
P, Kordower JH (2002) Lentivirally delivered glial cell line-derived neurotrophic factor 
increases the number of striatal dopaminergic neurons in primate models of 
nigrostriatal degeneration. J Neurosci 22:4942-4954. 
Pappolla MA (1986) Lewy bodies of Parkinson's disease. Immune electron microscopic 
demonstration of neurofilament antigens in constituent filaments. Arch Pathol Lab 
Med 110:1160-1163. 
Paratcha G, Ledda F, Ibanez CF (2003) The neural cell adhesion molecule NCAM is an 
alternative signaling receptor for GDNF family ligands. Cell 113:867-879. 
Parkinson J (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 
14:223-236; discussion 222. 
Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gomez-Diaz R, Lopez-Barneo J 
(2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. 
Nat Neurosci 11:755-761. 
Peden CS, Burger C, Muzyczka N, Mandel RJ (2004) Circulating anti-wild-type adeno-
associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-
mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344-6359. 
Peel AL, Klein RL (2000) Adeno-associated virus vectors: activity and applications in the 
CNS. J Neurosci Methods 98:95-104. 
Peltekian E, Garcia L, Danos O (2002) Neurotropism and retrograde axonal transport of a 
canine adenoviral vector: a tool for targeting key structures undergoing 
neurodegenerative processes. Mol Ther 5:25-32. 
Perrelet D, Ferri A, MacKenzie AE, Smith GM, Korneluk RG, Liston P, Sagot Y, Terrado J, 
Monnier D, Kato AC (2000) IAP family proteins delay motoneuron cell death in vivo. 
Eur J Neurosci 12:2059-2067. 
Peterson AL, Nutt JG (2008) Treatment of Parkinson's disease with trophic factors. 
Neurotherapeutics 5:270-280. 
Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533. 
Pirozzi M, Quattrini A, Andolfi G, Dina G, Malaguti MC, Auricchio A, Rugarli EI (2006) 
Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of 
hereditary spastic paraplegia. J Clin Invest 116:202-208. 
REFERENCES 
  130 
Pochon NA, Menoud A, Tseng JL, Zurn AD, Aebischer P (1997) Neuronal GDNF expression 
in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 
9:463-471. 
Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of 
Parkinson's disease. J Bioenerg Biomembr 36:375-379. 
Puntel M, Curtin JF, Zirger JM, Muhammad AK, Xiong W, Liu C, Hu J, Kroeger KM, Czer P, 
Sciascia S, Mondkar S, Lowenstein PR, Castro MG (2006) Quantification of high-
capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using 
quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther 17:531-
544. 
Rideout HJ, Stefanis L (2001) Caspase inhibition: a potential therapeutic strategy in 
neurological diseases. Histol Histopathol 16:895-908. 
Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland R, During MJ, Kholodilov N, Burke RE 
(2006) Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's 
disease. Proc Natl Acad Sci U S A 103:18757-18762. 
Saavedra A, Baltazar G, Duarte EP (2008) Driving GDNF expression: the green and the red 
traffic lights. Prog Neurobiol 86:186-215. 
Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, Thomas TC, Haycock JW, Bing G, 
Stanford JA, Gash DM, Gerhardt GA (2004) Striatal GDNF administration increases 
tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J 
Neurochem 90:245-254. 
Sampaio C, Ferreira JJ Parkinson disease: ADAGIO trial hints that rasagiline slows disease 
progression. Nat Rev Neurol 6:126-128. 
Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, 
Tremblay R, Kiuchi K, Sikorska M (2009) Astrocyte-secreted GDNF and glutathione 
antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 
33:405-414. 
Sanicola M, Hession C, Worley D, Carmillo P, Ehrenfels C, Walus L, Robinson S, Jaworski 
G, Wei H, Tizard R, Whitty A, Pepinsky RB, Cate RL (1997) Glial cell line-derived 
neurotrophic factor-dependent RET activation can be mediated by two different cell-
surface accessory proteins. Proc Natl Acad Sci U S A 94:6238-6243. 
Sarabi A, Hoffer BJ, Olson L, Morales M (2003) Glial cell line neurotrophic factor-family 
receptor alpha-1 is present in central neurons with distinct phenotypes. Neuroscience 
116:261-273. 
Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 
116:3855-3862. 
REFERENCES 
  131 
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial 
complex I deficiency in Parkinson's disease. Lancet 1:1269. 
Schmidt ML, Murray J, Lee VM, Hill WD, Wertkin A, Trojanowski JQ (1991) Epitope map of 
neurofilament protein domains in cortical and peripheral nervous system Lewy 
bodies. Am J Pathol 139:53-65. 
Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and 
MPTP. Cell Tissue Res 318:215-224. 
Schober A, Peterziel H, von Bartheld CS, Simon H, Krieglstein K, Unsicker K (2007) GDNF 
applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its 
neuroprotective action. Neurobiol Dis 25:378-391. 
Schueler-Furman O, Glick E, Segovia J, Linial M (2006) Is GAS1 a co-receptor for the GDNF 
family of ligands? Trends Pharmacol Sci 27:72-77. 
Schulz JB (2008) Update on the pathogenesis of Parkinson's disease. J Neurol 255 Suppl 
5:3-7. 
Schulz JB, Falkenburger BH (2004) Neuronal pathology in Parkinson's disease. Cell Tissue 
Res 318:135-147. 
Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP 
susceptibility in the mouse: behavioral, neurochemical, and histological analysis of 
gender and strain differences. Behav Genet 30:171-182. 
Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW (2006) Crossroads in GDNF 
therapy for Parkinson's disease. Mov Disord 21:136-141. 
Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S (2005) Promoters and serotypes: 
targeting of adeno-associated virus vectors for gene transfer in the rat central 
nervous system in vitro and in vivo. Exp Physiol 90:53-59. 
Shevtsova Z, Malik I, Garrido M, Scholl U, Bahr M, Kugler S (2006) Potentiation of in vivo 
neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in 
deafferentiated CNS neurons. Gene Ther 13:1569-1578. 
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, 
Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-
synuclein by parkin from human brain: implications for Parkinson's disease. Science 
293:263-269. 
Sian J, Gerlach M, Youdim MB, Riederer P (1999) Parkinson's disease: a major hypokinetic 
basal ganglia disorder. J Neural Transm 106:443-476. 
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) 
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative 
disorders affecting basal ganglia. Ann Neurol 36:348-355. 
REFERENCES 
  132 
Sinn PL, Sauter SL, McCray PB, Jr. (2005) Gene therapy progress and prospects: 
development of improved lentiviral and retroviral vectors--design, biosafety, and 
production. Gene Ther 12:1089-1098. 
Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of 
bilateral motor functions in patients with Parkinson disease through the unilateral 
intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 
102:216-222. 
Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, 
Young AB (2007) Unilateral intraputamenal glial cell line-derived neurotrophic factor 
in patients with Parkinson disease: response to 1 year of treatment and 1 year of 
withdrawal. J Neurosurg 106:614-620. 
Smith MP, Cass WA (2007) GDNF reduces oxidative stress in a 6-hydroxydopamine model 
of Parkinson's disease. Neurosci Lett 412:259-263. 
Soltoff SP, Rabin SL, Cantley LC, Kaplan DR (1992) Nerve growth factor promotes the 
activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine 
kinase. J Biol Chem 267:17472-17477. 
Soudais C, Boutin S, Hong SS, Chillon M, Danos O, Bergelson JM, Boulanger P, Kremer EJ 
(2000) Canine adenovirus type 2 attachment and internalization: coxsackievirus-
adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 
74:10639-10649. 
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in 
filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with 
lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473. 
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-
synuclein in Lewy bodies. Nature 388:839-840. 
Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative 
disease. Neuropsychiatr Dis Treat 5:597-610. 
Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, 
Provost N, Martin L, Moullier P, Rolling F (2006) Long-term doxycycline-regulated 
transgene expression in the retina of nonhuman primates following subretinal 
injection of recombinant AAV vectors. Mol Ther 13:967-975. 
Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, Hoffer B, Humpel C 
(1993) Glial cell line-derived neurotrophic factor is expressed in the developing but 
not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 
124:401-412. 
Takahashi M (2001) The GDNF/RET signaling pathway and human diseases. Cytokine 
Growth Factor Rev 12:361-373. 
REFERENCES 
  133 
Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski 
S, Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced 
amphetamine-conditioned reward, enhanced amphetamine locomotion, and 
enhanced MPTP toxicity. Proc Natl Acad Sci U S A 94:9938-9943. 
Tanaka M, Xiao H, Kiuchi K (2002) Heparin facilitates glial cell line-derived neurotrophic 
factor signal transduction. Neuroreport 13:1913-1916. 
Tande D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, Francois C (2006) New striatal 
dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not 
neurogenesis. Brain 129:1194-1200. 
Terzioglu M, Galter D (2008) Parkinson's disease: genetic versus toxin-induced rodent 
models. Febs J 275:1384-1391. 
Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16 Spec No. 2:R183-194. 
Thomas DL, Wang L, Niamke J, Liu J, Kang W, Scotti MM, Ye GJ, Veres G, Knop DR (2009) 
Scalable recombinant adeno-associated virus production using recombinant herpes 
simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene 
Ther 20:861-870. 
Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, Wolters EC 
(2001) Loss of olfaction in de novo and treated Parkinson's disease: possible 
implications for early diagnosis. Mov Disord 16:41-46. 
Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995a) Protection 
and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-
339. 
Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ, Olson L (1995b) Retrograde 
axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal 
system suggests a trophic role in the adult. Proc Natl Acad Sci U S A 92:8274-8278. 
Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini 
MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, 
Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A (1996) 
Characterization of a multicomponent receptor for GDNF. Nature 382:80-83. 
Trupp M, Belluardo N, Funakoshi H, Ibanez CF (1997) Complementary and overlapping 
expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, 
and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the 
adult rat CNS. J Neurosci 17:3554-3567. 
Trupp M, Raynoschek C, Belluardo N, Ibanez CF (1998) Multiple GPI-anchored receptors 
control GDNF-dependent and independent activation of the c-Ret receptor tyrosine 
kinase. Mol Cell Neurosci 11:47-63. 
REFERENCES 
  134 
Trupp M, Scott R, Whittemore SR, Ibanez CF (1999) Ret-dependent and -independent 
mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J 
Biol Chem 274:20885-20894. 
Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E, Ibanez CF (1995) 
Peripheral expression and biological activities of GDNF, a new neurotrophic factor for 
avian and mammalian peripheral neurons. J Cell Biol 130:137-148. 
Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-
Grueso E, Pachnis V, Arumae U (1996) Functional receptor for GDNF encoded by 
the c-ret proto-oncogene. Nature 381:785-789. 
van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y (2003) Delivery of ciliary 
neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal 
ganglion cells for an extended period of time. Hum Gene Ther 14:103-115. 
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson 
LM (2003) Incidence of Parkinson's disease: variation by age, gender, and 
race/ethnicity. Am J Epidemiol 157:1015-1022. 
Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine 
designed for controlled proteolysis. Annu Rev Biochem 68:1015-1068. 
von Bohlen Und Halbach O, Krieglstein K, Schober A, Schulz JB (2004) The dopaminergic 
nigrostriatal system: development, physiology, disease. Cell Tissue Res 318:3. 
Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H (2000) 
Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47:521-523. 
Wichmann T, DeLong MR (1993) Pathophysiology of parkinsonian motor abnormalities. Adv 
Neurol 60:53-61. 
Wilson JX (1997) Antioxidant defense of the brain: a role for astrocytes. Can J Physiol 
Pharmacol 75:1149-1163. 
Winkler C, Sauer H, Lee CS, Bjorklund A (1996) Short-term GDNF treatment provides long-
term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's 
disease. J Neurosci 16:7206-7215. 
Wong LF, Ralph GS, Walmsley LE, Bienemann AS, Parham S, Kingsman SM, Uney JB, 
Mazarakis ND (2005) Lentiviral-mediated delivery of Bcl-2 or GDNF protects against 
excitotoxicity in the rat hippocampus. Mol Ther 11:89-95. 
Woo YJ, Zhang JC, Taylor MD, Cohen JE, Hsu VM, Sweeney HL (2005) One year transgene 
expression with adeno-associated virus cardiac gene transfer. Int J Cardiol 100:421-
426. 
Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S 
(2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-
REFERENCES 
  135 
tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100:6145-
6150. 
Xu Z, Cawthon D, McCastlain KA, Slikker W, Jr., Ali SF (2005) Selective alterations of gene 
expression in mice induced by MPTP. Synapse 55:45-51. 
Ylikoski J, Pirvola U, Virkkala J, Suvanto P, Liang XQ, Magal E, Altschuler R, Miller JM, 
Saarma M (1998) Guinea pig auditory neurons are protected by glial cell line-derived 
growth factor from degeneration after noise trauma. Hear Res 124:17-26. 
Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) 
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson 
disease. Proc Natl Acad Sci U S A 93:2696-2701. 
Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM (1997) 
Dose response to intraventricular glial cell line-derived neurotrophic factor 
administration in parkinsonian monkeys. J Pharmacol Exp Ther 282:1396-1401. 
Zurn AD, Widmer HR, Aebischer P (2001) Sustained delivery of GDNF: towards a treatment 
for Parkinson's disease. Brain Res Brain Res Rev 36:222-229. 
 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES AND TABLES 
  136 
Fig. 2.1:  The nigrostriatal DA pathway in the rat brain. 
Fig. 2.2:  The basal ganglia-thalamocortical circuitry under normal conditions and in PD. 
Fig. 2.3: GDNF receptor interaction. 
Table 2.1:  GDNF in PD models. 
Table 4.1:  Protocols for light and fluorescent microscopy. 
Fig. 4.1:  pAAV-GFAP-EWB 
Fig: 4.2:  pAAV-GFAP-GDNF-WB 
Fig. 4.3:  pAAV-hsyn1-EWB 
Fig. 4.4:  pAAV-hsyn1-GDNF-WB 
Fig. 4.5: pAAV-no promoter-TB3-EWB 
Fig. 5.1:  Striatal GFP expression two weeks (2w) after AAV-5-mediated gene transfer. 
Fig. 5.2:  Striatal GFP expression three months (3m) after AAV-5-mediated gene transfer. 
Fig. 5.3: Cell-specific GFP expression after AAV-5-mediated gene transfer (2x108 
infectious particles, two weeks after infection). 
Fig. 5.4:  GDNF overexpression in the striatum and SNpc of infected mice for 2x108 
transducing units. 
Fig. 5.5: GDNF overexpression in the striatum and SNpc of infected mice for 2x107 
transducing units. 
Fig. 5.6:  Quantification of GDNF in the striatum (CPu) and SN in mice after high and low 
titre infection by ELISA. 
Fig. 5.7:  Reaction of astrocytes two weeks (2w) after unilateral injection of AAV-5 GFP in 
the striatum. 
Fig. 5.8:  Reaction of astrocytes two weeks (2w) after unilateral injection of AAV-5 GDNF in 
the striatum.  
Fig. 5.9:  Reaction of astrocytes three months (3m) after unilateral injection of AAV-5 GFP 
in the striatum. 
Fig. 5.10:  Reaction of astrocytes three months (3m) after unilateral injection of AAV-5 GFP 
in the striatum. 
Fig. 5.11:  Reaction of microglia two weeks (2w) after unilateral injection of AAV-5 GFP in 
the striatum. 
Fig. 5.12:  Reaction of microglia two weeks (2w) after unilateral injection of AAV-5 GDNF in 
the striatum. 
Fig. 5.13:  DA SNpc neurons two weeks and three months after MPTP treatment for 2x108 
transducing units. 
Fig. 5.14:  Stereological counts for TH and Nissl-positive cells in the SNpc two weeks (A) 
and three months (B) after MPTP treatment for 2x108 transducing units. 
LIST OF FIGURES AND TABLES 
  137 
Fig. 5.15:  DA SNpc neurons two weeks and three months after MPTP treatment for 2x107 
transducing units. 
Fig. 5.16:  Stereological counts for TH and Nissl-positive cells in the SNpc two weeks (A) 
and three months (B) after MPTP treatment for 2x107 transducing units. 
Fig. 5.17: TH fibre density in the striatum two weeks after MPTP treatment for 2x108 
transducing units. 
Fig. 5.18: TH fibre density in the striatum three months after MPTP treatment for 2x108 
transducing units. 
Fig. 5.19:  Quantification of TH fibre density in the striatum two weeks (A) and three months 
(B) after MPTP treatment for 2x108 transducing units. 
Fig. 5.20:  Regeneration of TH fibre density in the striatum for 2x108 transducing units. 
Fig. 5.21:  2x108 transducing units: striatal catecholamine concentrations two weeks (A, C, 
E) and three months (B, D, F) after MPTP treatment. 
Fig. 5.22:  2x107 transducing units: striatal catecholamine concentrations two weeks (A, C, 
E) and three months (B, D, F) after MPTP treatment. 
Fig. 5.23:  Behavior on rotarod: 2x107 transducing units. 
Fig. 5.24:  Striatal GFP expression two weeks after AAV-5-mediated gene transfer. 
Fig. 5.25:  Striatal GFP expression three months after AAV-5-mediated gene transfer. 
Fig. 5.26:  Cell-specific GFP expression after AAV-5-mediated gene transfer (2x108 
infectious particles, two weeks after infection). 
Fig. 5.27:  GDNF expression in the striatum of infected mice. 
Fig. 5.28:  GDNF expression in the SNpc of infected mice. 
Fig. 5.29:  DA SNpc neurons two weeks after MPTP treatment. 
Fig. 5.30:  DA SNpc neurons three months after MPTP treatment. 
Fig. 5.31:  Stereological cell counts for TH and Nissl-positive cells in the SNpc two weeks 
(A) and three months (B) after MPTP treatment. 
Fig. 5.32:  Striatal catecholamine concentrations two weeks after MPTP treatment. 
Fig. 5.33:  Striatal catecholamine concentrations three months after MPTP treatment. 
Fig. 5.34:  Regeneration of striatal catecholamine concentrations. 
 
 
 
 
 
 
 
PUBLICATIONS 
  138 
 
 
 
 
 
Drinkut A, Tereshchenko Y, Schulz JB, Bähr M, Kügler S (2010) Astrocytic versus neuronal 
expression of GDNF: added safety for gene therapy of Parkinson’s Disease. 
 
submitted to Nature Biotechnology NBT-RA23962 
 
 
Reich A, Spering C, Gertz K, Harms C, Gerhardt E, Kronenberg G, Nave KA, Schwab M, 
Tauber S, Drinkut A, Harms K, Voigt A, Göbbels S, Endres M, Schulz JB (2010) Fas/CD95 
regulatory protein Faim2 is neuroprotective after transient brain ischemia. 
 
submitted to J Neuroscience, JN-RM-2188-10 
 
 
 
 Krenz A, Falkenburger BH, Gerhardt E, Drinkut A, Schulz JB (2009) Aggregate formation 
and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using 
adenoviral vectors. J Neurochemistry 108(1): 139-46 
 
 
 
Kowsky S, Pöppelmeyer C, Kramer ER, Falkenburger BH, Kruse A, Klein R, Schulz JB 
(2007) RET signaling does not modulate MPTP toxicity but is required for regeneration of 
dopaminergic axon terminals. PNAS 104(50): 20049-54 
 
 
CURRICULUM VITAE 
  139 
Personal data 
Name     Dipl. Biol. Anja Drinkut (birth name: Anja Kruse) 
Date and place of birth  15.09.1982 Helmstedt, Germany 
Contact details  Reinhäuser Landstr. 28, 37083 Göttingen, Germany 
phone: 0551 27783992 (private) 01520 4661711 
(mobile), E-mail: akruse@gwdg.de 
Doctoral thesis 
2007-2010 Department of Neurodegeneration and Restorative 
Research (Prof. Dr. med. Schulz), Phd student at the 
Göttinger Graduate School for Neurosciences and 
Molecular Biosciences (GGNB); title: „Neuroprotection 
and Neurorestoration in the MPTP model for Parkinson’s 
Disease” 
Education 
2006 Diploma thesis in the group of Prof. Barré-Sinoussi at 
the Pasteur Institute Paris; title: “Analysis of the impact 
of HIV-1 infection on TGF-beta 1 signaling” (grade: 1.0) 
2002-2006 Biology degree at the Technical University 
Braunschweig, main subject in microbiology; minor 
subjects in cell biology, genetics, biochemistry, 
pharmacology 
2002 “Abitur”, Julianum Helmstedt grammar school (grade: 
1,3) 
Experiences  
- strategy workshop  „Move On“  2010 at The  Boston 
Consulting Group in Düsseldorf 
- active participation in the SPD Göttingen (Jusos, 
working teams for migration/integration and city 
development/environment/traffic (since 2009) 
 - presentation of scientific results at international 
conferences in Göttingen (GGNB 2007), Leipzig (ESN 
2009) and Busan (South Korea, ISN 2009) 
- several stays abroad (New Zealand 2008, France 
2006, Australia 2005, USA 2004) 
- care of handicapped people at the “Lebenshilfe” 
Helmstedt (2003-2006) 
 
